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ABSTRACT 
Non-traditional targets for therapeutic intervention are those proteins that have not evolved to 
bind small molecules, but have instead evolved to bind other macromolecules. Such targets include 
protein–protein interaction sites, protein–RNA interaction sites and protein–DNA interaction sites. 
Modulating these biologically important targets will allow us as a community to develop novel 
therapeutics, but still remains a major challenge. In this thesis, I describe two different computational 
approaches that I have developed: one for identifying small-molecule inhibitors of protein–protein 
interactions, and the other for identifying small-molecule inhibitors of protein–RNA interactions. 
To specifically target protein interaction sites, I have developed a docking method called DARC 
(Docking Approach using Ray-Casting). This method quantitatively measures the complementarity 
between the protein surface and a ligand, by using ray-casting to map and compare their shapes. I have 
applied DARC to carry out a virtual screen against the protein interaction site of the protein Mcl-1, 
allowing us to identify 6 new inhibitors of this exciting target. To specifically target protein-RNA 
interactions, I have developed a mimicry-inspired strategy that extracts a “hotspot pharmacophore” from 
the structure of a protein-RNA complex, and then uses this as a template for ligand-based virtual 
screening. I have applied this strategy to screen for compounds that inhibit the Musashi-1 / NUMB 
mRNA interaction, allowing us to identify a new class of compounds that inhibit this interaction in both 
biochemical and cell-based assays. 
This thesis is outlined as follows. In the first chapter, I will compare the structural features of 
inhibitor-bound complexes of traditional versus non-traditional protein targets. In the second chapter, I 
will present the DARC method and its application to Mcl-1. In the third chapter, I will present various 
enhancements to DARC method that result in both speed and performance improvements. Finally, in the 
Fourth chapter I will present the “hotspot mimicry” approach for targeting protein-RNA interactions and 
application of this approach in identification of inhibitors for Musashi 1 / NUMB mRNA interaction. 
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INTRODUCTION 
 
  
Non-traditional targets for therapeutic intervention: 
 
The most common targets of modern drugs are GPCR's, ion-channels, and enzymes (kinases, 
hydrolases, oxidases, reductases, etc.) (1). Each of these broad protein classes have evolved to bind some 
cognate small-molecule, and most therapeutics disrupt activity by competitively binding to the same 
region of the protein surface as the natural interaction partner. These surface binding pockets are typically 
deep, and present a well-defined shape that often complements the natural substrate (2). In contrast, there 
are also a tantalizing number of well-validated protein targets that are not evolved to bind small-
molecules, but rather are evolved to bind other macromolecules. These include targets involved in 
protein-DNA interactions, protein–RNA interactions, and protein–protein interactions. Developing novel 
therapeutics that modulate these interactions is an important ongoing challenge. Identifying promising 
new targets in these non-traditional target classes and characterizing their interaction surfaces for 
druggability is critical, since most of these targets are unyielding to modern approaches for computational 
or biochemical screening. Indeed, the performance of docking methods used for computational screening 
depends on the target class of protein: performance is typically poor for non-traditional protein targets in 
particular, suggesting that new approaches are needed in this regime. The interaction surfaces of these 
targets are often large and flat, lacking deep pockets typically used for small-molecule binding (2). In my 
thesis, I will describe two different computational approaches that I have developed: one for identifying 
small-molecule inhibitors of protein–protein interactions, and the other for identifying small-molecule 
inhibitors of protein–RNA interactions. 
 
 
Protein-protein interactions: 
 
Protein-protein interactions (PPIs) underlie almost all biological processes, making them 
important therapeutic targets. Targeting a protein interface using traditional approaches have met with 
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limited success, because PPIs are different from traditional enzyme targets (3). Enzymes have deep and 
well-defined active sites to bind their substrates, whereas PPIs usually have large, flat and noncontiguous 
interfaces. Further, PPIs do not have natural small-molecule partners that one might use for investigating 
druggability or as a starting point for designing inhibitors. 
In many cases, protein interfaces undergo conformation changes upon binding of an inhibitor (4); 
hence, for many cases of PPIs the “apo” (unbound) structure is not necessarily suitable for docking, since 
the protein conformation may change upon binding. On the other hand, there are typically few inhibitor 
bound structures available for PPI drug targets, and requiring a prior small-molecule bound structure may 
also limit one to finding hit compounds that are similar to the known (starting) ligand. Some docking 
methods incorporate receptor flexibility, but these are too slow for virtual screening. There are also many 
ligand-based methods available for shape matching, that simply use the shape of the ligand to hop for 
scaffolds (5, 6): the drawback of these methods, however, is that we may miss out on potential inhibitors 
that do not resemble the natural protein partner. 
These shortcomings of existing methods highlight the need for a receptor-based scaffold hopping 
approach for this challenge. To address this need, I have developed DARC, a method that matches the 
surface pockets to complementary small molecules. 
 
Protein-RNA interactions: 
Protein-RNA interactions play key roles in diverse cellular functions through a variety of 
different mechanisms, including  controlling production of target proteins by post-transcriptional 
regulation (7-9). Interactions of proteins with their cognate RNAs are mostly driven by base stacking, 
electrostatic interactions and hydrogen bonding. To date there exist very few classes of compounds that 
target protein-RNA interactions, and the majority of them are nucleoside analogues (10). The goal of this 
study is to develop a robust computational method that can be utilized to design small-molecules that 
selectively inhibit interactions between an RNA binding protein and its cognate RNAs. Here, I will 
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present the "hotspot mimicry" approach for rationally designing such small-molecule inhibitors of RBPs. 
This approach works by identifying the chemical moieties of a given RNA that contribute critical 
interactions to a particular protein-RNA complex, and then identifying small molecules that can mimic 
the geometrical arrangement of these key moieties. 
 
Summary of the thesis: 
Chapter 1 describes the quantitative evaluation of properties that distinguish traditional and non-
traditional class inhibitory complexes. I have systematically compared the existing examples of inhibitors 
of protein–protein interactions to inhibitors of traditional drug targets, and demonstrate that the 
differences in the components of the inhibitory complexes are manifest in the structural features of the 
complexes themselves. I also show results of experiments to study how these differences affect the 
performance of virtual screening tools when applied to protein–protein interaction sites. I demonstrate 
that the modern virtual screening methods are typically less suited for identifying inhibitors of protein 
interactions than for identifying inhibitors of traditional drug targets. 
Chapter 2 introduces a low-resolution docking method that we call DARC (Docking Approach 
using Ray Casting) for targeting protein-protein interactions. I will show results of benchmark 
experiments demonstrating that we can use DARC to identify known inhibitors of Bcl-xL and XIAP from 
a large set of “decoy” compounds. I will then show a specific application of DARC in which we to carry 
out a virtual screen against Mcl-1, an anti-apoptotic member of the Bcl-2 family. We tested the top 21 hits 
in biochemical assays, and found that indeed 6 of these are inhibitors of Mcl-1. 
Chapter 3 presents five key enhancements to the robustness, speed and accuracy of the DARC 
method. First, we use multiple vantage points to more accurately determine protein-ligand surface 
complementarity. Second, we describe a new scheme for rapidly determining optimal weights in the 
DARC scoring function. Third, we incorporate sampling of ligand conformers “on-the-fly” during 
docking. Fourth, we move beyond simple shape complementarity and introduce a term in the scoring 
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function to capture electrostatic complementarity. Finally, we adjust the control flow in our GPU 
implementation of DARC to achieve greater speedup of these calculations. For each enhancement, I will 
describe systematic improvement relative to the original version of DARC using a “pose recapitulation” 
benchmark. 
Finally, Chapter 4 presents the “hotspot pharmacophore” approach for targeting protein-RNA 
interactions. I will describe the automated framework that extracts the pharmacophore features from the 
structure of a protein-RNA complex, and the protocol for using it as a template for ligand-based 
screening. I will describe our application of this approach to Musashi-1, which has led us to a novel class 
of inhibitors that disrupt the RNA-binding activity of this tumor-promoting protein. 
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CHAPTER 1 
 
The structural properties of non-traditional drug targets 
present new challenges for virtual screening 
 
 
 
 
Ragul Gowthaman1, Eric J. Deeds1,2, and John Karanicolas1,2 
 
1 Center for Bioinformatics and 2 Department of Molecular Biosciences, 
University of Kansas, 2030 Becker Dr., Lawrence, KS 66045-7534 
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1.1 Abstract 
Traditional drug targets have historically included signaling proteins that respond to small-
molecules and enzymes that use small-molecules as substrates. Increasing attention is now being directed 
towards other types of protein targets, in particular those that exert their function by interacting with 
nucleic acids or other proteins rather than small-molecule ligands. Here, we systematically compare 
existing examples of inhibitors of protein–protein interactions to inhibitors of traditional drug targets. 
While both sets of inhibitors bind with similar potency, we find that the inhibitors of protein–protein 
interactions typically bury a smaller fraction of their surface area upon binding to their protein targets. 
The fact that an average atom is less buried suggests that more atoms are needed to achieve a given 
potency, explaining the observation that ligand efficiency is typically poor for inhibitors of protein–
protein interactions. We then carried out a series of docking experiments, and found a further 
consequence of these relatively exposed binding modes is that structure-based virtual screening may be 
more difficult: such binding modes do not provide sufficient clues to pick out active compounds from 
decoy compounds. Collectively, these results suggest that the challenges associated with such 
non-traditional drug targets may not lie with identifying compounds that potently bind to the target 
protein surface, but rather with identifying compounds that bind in a sufficiently buried manner to achieve 
good ligand efficiency, and thus good oral bioavailability. While the number of available crystal 
structures of distinct protein interaction sites bound to small-molecule inhibitors is relatively small at 
present (only 21 such complexes were included in this study), these are sufficient to draw conclusions 
based on the current state of the field; as additional data accumulate it will be exciting to refine the 
viewpoint presented here. Even with this limited perspective however, we anticipate that these insights, 
together with new methods for exploring protein conformational fluctuations, may prove useful for 
identifying the “low-hanging fruit” amongst non-traditional targets for therapeutic intervention. 
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1.2 Introduction 
The majority of modern drugs modulate the function of a relatively small number of protein 
targets that include enzymes, G-protein coupled receptors (GPCRs), ion channels, transporters, and 
nuclear hormone receptors (1, 11). With the exception of proteases, each of these broad classes of protein 
have evolved to bind a cognate small-molecule, and most therapeutics disrupt activity by competitively 
binding to the same region of the protein surface as the natural interaction partner. These surface binding 
pockets are typically deep and present a well-defined shape that often complements the natural substrate 
(12). In such cases, mimicry of the natural substrate (or transition state) may serve as an attractive starting 
point for designing new inhibitors (13). Given that new inhibitors often have similar chemical properties 
as endogenous ligands, identification of one or more natural ligands with drug-like physicochemical 
characteristics can also be used to infer the “druggability” of a new protein target (14). 
In contrast to these “traditional” protein targets for therapeutic intervention, there are also a 
tantalizing number of well-validated “non-traditional” potential targets. These proteins have evolved to 
bind not small-molecules but rather other macromolecules, and include targets involved in protein–DNA 
interactions (e.g., (15, 16)), protein–RNA interactions (e.g., (17, 18)), and protein–protein interactions 
(e.g., (19, 20)). The interaction surfaces of these proteins are often large and flat, lacking a deep pocket 
suitable for small-molecule binding (12). Given the size of the natural substrate in these cases, examples 
of mimicry by small molecules leading to potent inhibitors are few (21-26), and even in these successful 
cases the resulting inhibitors tend to be larger than typical orally available drugs (27, 28). 
Structure-based virtual screening methods offer a means to directly identify novel inhibitory 
compounds that complement the target protein surface (29); these methods are not limited by the 
requirement for template compound(s) implicit to ligand-centric (mimicry) approaches (30). In the 
simplest terms, virtual screening requires some method for sequentially positioning each candidate 
compound from a library at its most likely position on the protein surface (i.e., “docking”), followed by a 
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subsequent discrimination step (i.e., “scoring”) to rank each of the resulting complexes based on their 
likelihood of showing the desired activity. 
The historical focus on inhibiting proteins evolved to bind a cognate small-molecule (both 
enzymes and proteins involved in signaling) has led to an understanding of many structural features 
exhibited by such complexes (31). These insights have been facilitated in part by databases such as 
MOAD (32, 33), which have enabled comparisons to reveal subtle differences in enzyme versus non-
enzyme classes of “traditional” drug targets (34). 
The question now arises whether the same structural features apply to inhibitors that bind at 
“non-traditional” sites (i.e., those not evolved for small-molecule binding). To identify any systematic 
differences between these two broad classes of targets is critical, since structure-based virtual screening 
methods absolutely require these insights to appropriately rank docked complexes and select the most 
promising compounds for experimental characterization. Since very few examples of direct inhibitors of 
nucleic acid binding sites have been described, here we instead focus on small-molecule inhibitors of 
protein–protein interactions. While the widespread impression in the field is that small-molecule 
inhibitors of protein–protein interactions tend to be larger and contribute less binding affinity per atom 
than inhibitors of traditional drug targets, this viewpoint is predicated largely on a study that described a 
relatively small number of examples (4). Here we seek to carry out a more thorough quantitative 
evaluation of properties that distinguish each class of inhibitor, then ask how these differences affect the 
performance of virtual screening tools when applied to protein–protein interaction sites. 
1.3 Results 
Extent of ligand burial in inhibitory complexes 
For this study we compiled a set of 21 unique protein–protein interaction sites for which a crystal 
structure has been solved in complex with a small-molecule inhibitor (Table 1), which we will refer to as 
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the “PPI set.” We compared properties of these representative complexes to those of the Astex Diverse 
Set from Gold (35), which contains crystal structures of proteins of pharmaceutical or agrochemical 
interest each bound to a small-molecule inhibitor with drug-like chemical properties. The chemical 
properties of the ligands in the PPI set are comparable to those of the Astex set (the construction and 
composition of both sets are described in the Methods section). 
It has been noted anecdotally that inhibitors of protein–protein interactions bind at flatter regions 
of the protein surface than do inhibitors of “traditional” drug targets (4, 12). To systematically 
characterize whether the ligand is less buried upon binding, we defined a parameter θlig that quantifies the 
fraction of ligand solvent accessible surface area (SASA) (36) that remains exposed upon binding: 
𝜃!"# = 1 −
!"!"!"#$%&'!!"!"!"#$%& !!"!"!"#$%&'
!∗!"!"!"#$%&
     (Eqn. 1) 
where SASAprotein is the SASA of the protein with the ligand removed, SASAligand is the SASA of the 
ligand with the protein removed, and SASAcomplex is the total SASA of the protein–ligand complex. We 
note that SASAprotein and SASAligand are each computed directly from the structures that comprise the 
complex, and not from other unbound crystal structures. 
We computed θlig for each complex in the Astex set and the PPI set; the results of this comparison 
are presented in Figure 1. It is immediately evident that the bound inhibitors at protein interaction sites 
retain more exposed surface area than their counterparts which bind at sites evolved for small-molecule 
binding (high θlig for traditional targets); this observation further holds for other analogous sets of drug-
like complexes (DUD-E (37) and SB2010 (38), Figure S1). Among the members of the Astex set, we 
find that the class of protein targets with the highest θlig values is serine proteases (βII tryptase, factor Xa, 
factor VIIa, thrombin, urokinase; see Table S1). These enzymes contribute four of the ten highest θlig 
values in the Astex set, corresponding to statistically significant enrichment of this target class (p < 0.01). 
Although they are enzymes, the natural substrates of serine proteases are proteins rather than small-
molecules; for this reason, it is perhaps unsurprising that θlig values for such complexes resemble those 
associated with protein interaction sites more than those associated with traditional drug targets. 
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Figure 1  (A) Distribution of θlig values in the PPI and Astex data sets. Ligands bound at protein 
interaction sites (red, median value 0.45) tend to be more exposed than drug-like compounds (blue, 
median value 0.33), with a difference of means that is statistically significant (p < 10-6). As described 
in the text, proteases are an exception in the latter set.  (B) Representative examples of complexes with 
low and high θlig (PDB IDs 1s3v and 1tft, respectively). 
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Since the set of physical forces that underlie binding must be the same for both classes of complexes, we 
next asked how this difference in exposed surface area influences binding affinity. We compared the 
potency of each complex, and found the distributions from the two sets to be essentially the same (Figure 
2a). Due to the larger compound size required to achieve this potency (Figure S2), however, we find that 
inhibitors acting at protein interaction sites bind with less ligand efficiency (binding energy per non-
hydrogen atom (39)) than orally active compounds acting on traditional targets (Figure 2b). A single 
outlier with high ligand efficiency in the PPI set is evident, corresponding to an inhibitor of calpain (1alw 
in Table 1, with ligand efficiency 0.68 kcal/mol per non-hydrogen atom). Further inspection reveals this 
to be partially an artifact of the way in that ligand efficiency is defined, since this inhibitor contains a 
bromine atom: while the potency of this compound is high given its size, the ligand efficiency is further 
exaggerated because it is normalized using the number of non-hydrogen atoms rather than molecular 
weight. Excluding this outlier, we observe a clear relationship between θlig and ligand efficiency in the 
PPI set (Figure 2c), but not in the Astex set (Figure S3). Due to the variation in the molecular weight of 
the compounds within each set, this relationship is not apparent when simply examining potency as a 
function of θlig (Figure S4). 
These results are in agreement with a previous report drawn from a much smaller set of protein 
targets (4), and are also consistent with our observation that the bound inhibitors at protein interaction 
sites retain more exposed surface area: an average atom buries less hydrophobic surface area upon 
binding, so the contribution of an average atom to the binding energy—the very definition of ligand 
efficiency—is expected to be lower (39). 
Properties of complexes produced by virtual screening 
We have shown above that our collection of inhibitors binding at protein interaction sites have 
similar potency as a traditional drug-like set, but that affinity is achieved through a structurally distinct 
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mode of interaction. It is therefore critical to examine how well modern energy functions perform in these 
contrasting regimes. 
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To evaluate the ability of a representative energy function to distinguish known inhibitors from a 
large number of “decoy” compounds, we carried out a mock virtual screening experiment using the FRED 
software package (40-42). Starting from the ZINC database (43), we constructed a “decoy library” of 
10,000 compounds with chemical properties (molecular weight and XlogP) matched to the inhibitors in 
the Astex and PPI sets. To eliminate potential challenges associated with sampling, we used OMEGA 
(44-46) to build up to 300 conformers of each compound to be used for docking. We also included the 
active conformer of the known inhibitor (taken from the crystal structure of the protein–ligand complex) 
in our virtual screen. The exact active conformer of an inhibitor is generally not present in a screening 
library, and adding it to the set should, at least in theory, simplify the screening problem. As an indicator 
of how favorably a protein’s known inhibitor is scored, we use its rank relative to the members of the 
decoy library. As an important caveat, we note that the decoy compounds are not necessarily inactive. 
Nonetheless, we expect that even if the decoy library does contain a small fraction of compounds that are 
active, the known inhibitor should rank with these among the top scoring compounds. 
Figure 2  (A) Distribution of potency values in the Astex and PPI sets. Our set of ligands bound at 
protein interaction sites (red, median value 1.0 µM) have similar potency to drug-like compounds 
(blue, median value 0.07 µM). No statistically significant difference in means is observed (p = 0.105).  
(B) Distribution of ligand efficiencies in the Astex and PPI sets. The ligand efficiency of inhibitors 
bound at protein interaction sites (red, median value 0.29 kcal/mol•atom) tends to be lower than the 
ligand efficiency of drug-like compounds (blue, median value 0.36 kcal/mol•atom), and the difference 
in the means is statistically significant (p < 0.007, or p < 0.0002 upon removal of the single bromine-
containing outlier described in the text).  (C) The relationship between θlig and ligand efficiency in the 
PPI set. As expected, there is a negative correlation between these properties, with a statistically 
significant non-zero Spearman rank correlation coefficient (p < 0.006). 
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Figure 3  To test the ability of virtual screening tools to distinguish known inhibitors for the protein 
targets in our test sets, we embedded each inhibitor in a set of 10,000 “decoy” compounds and 
screened this library against each protein target. For each target, we sorted the docked scores for each 
member of the screening library and determined the rank of the known inhibitor. In this figure, we plot 
a cumulative histogram of the percent of protein targets for which the known inhibitor is ranked better 
than the threshold value indicated on the x-axis. Rather than comparing results for individual protein 
targets, this aggregate representation allows comparison of performance between the two test sets 
(Astex and PPI). Here we find that this virtual screening tool has difficulty identifying known 
inhibitors that bind at protein interaction sites (red) relative to its performance in the drug-like set 
(blue), and that the difference in the mean rank of the known inhibitor between the two sets is 
statistically significant (p < 10-6). 
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We carried out this screening experiment for each complex in the Astex set and the PPI set. 
Within each set we collected, at increasing values of a rank threshold, the fraction of targets for which the 
known inhibitor was ranked better than the threshold (Figure 3). As can be appreciated from this figure, a 
perfect method, which would rank the known inhibitor at the top of the list for every target, would lead to 
a vertical rise at the very left of the curve. In contrast, a completely random method would be expected to 
rank the known inhibitor in the top 1% for 1% of the targets, in the top 10% for 10% of the targets, etc., 
leading to a curve that follows the diagonal of the plot area. 
The first notable observation is that FRED performs exceptionally well for traditional targets (the 
Astex set) in this intentionally “easy” experiment. Using illustrative thresholds, the known inhibitor is 
ranked within the top 2% of the library (within the top 200 of 10,000 compounds) for 80% of the protein 
targets in the Astex set, suggesting that indeed the known inhibitor is near optimal given the scoring 
function. In contrast, the known inhibitor is ranked in the top 2% of the library for only 50% of the targets 
in the PPI set. As shown in Figure 3, this difference in performance holds irrespective of the threshold 
applied—in other words, performance on the Astex set is superior regardless of whether one counts 
“successes” as protein targets for which the known inhibitor is ranked in the top 5%, top 10%, top 25%, 
etc. Given the design of this experiment, the dramatically worse performance for the PPI set points 
strongly to a deficiency in discrimination of the correctly bound inhibitor from bound decoy compounds 
if the known inhibitor retained a large fraction of exposed surface area upon binding (high θlig). 
To eliminate the possibility that this difference in performance originated from a bias in the 
composition of our decoy library (e.g., our library could be comprised of decoys that are viable inhibitors 
of protein interaction sites but easy to rule out as enzyme inhibitors), we carried out an analogous 
experiment in which we used the DUD-E server (37) to build a separate set of 50 decoy compounds for 
each target, matched to the chemical properties of the known inhibitor. We observe the same performance 
difference between the Astex set and the PPI set in this experiment (Figure S5) as in the previous 
screening experiment. The observed difference in performance between these two sets of target proteins 
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holds when another software package, DOCK 6.6 (47), is used to carry out the virtual screen (Figure S6), 
indicating that particular details specific to FRED are not responsible for the observed differences. 
 
 
 
  
Figure 4  (A) For each of the active compounds in the PPI set, the root mean square deviation 
(RMSD) of the docked active compound is computed relative to the crystal structure, and reported as a 
function of the rank of the active compound in the virtual screening experiment. Approximately half 
the compounds that were not ranked highly were mis-docked (high RMSD), while the other half were 
correctly docked but still did not rank well relative to the decoy compounds (low RMSD but high 
rank).  (B) The difference in score between the docked active compound and the crystal structure is 
shown as a function of the RMSD. The mis-docked structures scored better than the crystal structure 
in all cases (positive score differences), suggesting that the energy function did not provide the correct 
relative ranking of these two poses. 
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Since this screening experiment was explicitly designed to be “easy” with respect to sampling 
(for example, by including the active conformer taken from the crystal structure), we expected that the 
poorer performance on the PPI set stemmed from difficulty assigning the correctly docked pose a suitably 
favorable score. To test this, we collected the RMSD of the top-scoring docked pose of the active 
compound relative to its position in the crystal structure. We find the active compounds that (correctly) 
scored amongst the very top of the library collection were inevitably correctly docked (low RMSD) 
(Figure 4a); this is unsurprising, since one might expect that correctly predicting the pose is usually a 
pre-requisite for correctly identifying an active compound. Of the active compounds which did not score 
in the top 1% of the library, approximately half were correctly docked (RMSD less than 2 Å) with the 
other half dramatically mis-docked (RMSD greater than 5 Å). We then scored each of the crystal 
structures of the same complexes, and computed the difference in score relative to the docked pose. While 
in a few cases the crystal structures scored slightly better that nearly-correct docked poses, each of the 
mis-docked poses scored better than the crystal structure (Figure 4b, high RMSD points all have positive 
score differences). Collectively these results suggest that the screening challenges presented in the PPI set 
lie not with sampling, but rather with assigning the correctly docked ligand a suitably favorable score: 
relative to decoy compounds, and also relative to mis-docked poses of the ligand. 
We then selected the top-ranked compound from each screen, whether it was the known inhibitor 
or a decoy, and evaluated θlig in the docked complex. Intriguingly, the distributions of these values match 
the corresponding distributions from complexes solved with the known inhibitors (Figure 5). In other 
words, though the known inhibitors from the PPI set were often not highly ranked in this screening 
experiment, the highly ranked decoys nonetheless retained a large fraction of exposed surface area upon 
binding (high θlig). Thus, the discrimination problem in the PPI set is not a bias in favor of low θlig 
complexes over high θlig complexes, but rather a failure to discriminate the known (high θlig) inhibitor 
from decoy compounds that also have high θlig values. In contrast, the more extensive burial of 
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compounds in the Astex set may lend additional clues for correctly identifying the cognate inhibitor, 
explaining the relative ease in correctly identifying inhibitors for these targets. These observations further 
suggest that the protein conformation itself is the primary determinant of θlig values in inhibitory 
complexes: unless a pocket suitable for extensive ligand burial is present on the protein surface, it is 
simply not possible to have an inhibitor with low θlig. This constraint, together with the poor ligand 
efficiency associated with high θlig values, suggests limited druggability of these particular protein 
conformations. 
 
 
 
  
Figure 5  The distribution of ligand solvent exposure for the best-scoring compound in each test set is 
similar to the analogous distribution for the experimentally-derived complexes of known inhibitors in 
the corresponding test set. Within a set distributions are very similar for crystal structures of known 
inhibitors, the known inhibitor docked back to the corresponding protein target, and the top-scoring 
compound from among 10,000 “decoy” compounds. 
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We next sought to determine whether this conclusion applies to alternate conformations of these 
particular protein interaction sites. We have recently described an approach for exploring protein 
fluctuations enriched in conformations containing surface pockets suitable for small molecule binding 
(48). We therefore carried out the same experiment described above, this time screening against either the 
unbound protein structure, the structure of the protein in complex with its protein partner, or a structure 
generated via biased simulations. We find similar distributions of θlig for the top-scoring complex when 
screening against these conformations as well (Figure 6), suggesting that these too lack pockets suitable 
for extensive ligand burial that are required for complexes with low θlig. On the basis of this result, 
computational screening against these alternate protein conformations is unlikely to yield inhibitors with 
dramatically higher ligand efficiency. 
1.4 Discussion 
Previous analyses have shown that known to be inhibitors of protein–protein interactions can be 
systematically distinguished from drug-like compounds on the basis of size and shape (49, 50), and also 
that the deep pockets present on traditional drug targets (sites evolved for small-molecule binding) are 
typically absent at protein interaction sites (12, 51). Here, we demonstrate the differences in the 
components of the inhibitory complexes—the compound and the protein target—are manifest in the 
structural features of the complexes themselves. 
Our results further demonstrate that modern virtual screening methods typically are less suited for 
identifying inhibitors of protein interactions than for identifying inhibitors of traditional drug targets. The 
difficulty in discriminating active compounds from decoy compounds may be due to an incomplete 
representation of the underlying physical forces that govern binding in this alternate structural regime; or, 
more simply, these methods may have been parameterized for optimal performance when applied to 
traditional drug targets at the expense of performance on non-traditional targets. 
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Figure 6  The distribution for the extent of ligand solvent exposure (θlig) for the best-scoring 
compound in a screen against PPI targets is similar regardless of whether the protein conformation 
used in docking corresponds to an inhibitor-bound structure (red), the unbound structure (green), a 
protein–bound structure (brown), or a structure generated from simulations biased towards pocket-
containing conformations (pink). 
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Nonetheless, the results from the virtual screening experiments described here demonstrate that 
the protein conformations tested can only harbor a relatively exposed ligand, because they present 
relatively flat surface pockets. This feature of bound complexes does not preclude identification of 
potently binding compounds; rather, it simply implies that such compounds will require many atoms to 
achieve this potency, and therefore may violate Lipinski’s “rule-of-five” criteria for oral availability (27, 
28). For enzymes, the rule-of-five compliance of the natural endogenous substrate has been shown to be a 
good predictor of druggability (14), since inhibitors may occupy similar chemical space. For protein 
targets not naturally evolved to bind small-molecules, the natural binding partner cannot be used to draw 
such inferences. Collectively, our results do not suggest that protein interaction sites are necessarily less 
“bindable” than traditional drug targets, but rather that the size of compounds required for the desired 
potency may make protein interaction sites intrinsically less “druggable.” 
Our conclusions are also highly complementary to those reached in a previous study comparing 
inhibitory complexes of enzyme versus non-enzyme drug targets (34) through a survey of the MOAD 
database (32). Both types of target are “traditional” by our definition, in that both have evolved to bind 
small-molecules. Interestingly, the authors of this study find higher ligand efficiency in non-enzyme 
complexes, and propose that the origin of this difference stems from the fact that non-enzyme ligands 
(signaling molecules such as hormones) are typically more “encapsulated” than their enzyme counterparts 
(34). This suggestion is in direct agreement with our observations: ligand efficiency of inhibitors bound at 
protein interaction sites (median value 0.29 kcal/mol•atom) is lower than that of inhibitors of these 
“traditional” enzyme and non-enzyme targets (median 0.36 and 0.41 kcal/mol•atom, respectively (34)), in 
keeping with the limited degree to which the protein surface can accommodate these ligands. 
While inhibitors bound to the protein interaction sites studied here can only achieve limited burial 
(and thus poor ligand efficiency), it is important to note that the protein conformation was fixed 
throughout these docking experiments. This restriction of the protein surface, in turn, may have 
influenced our observed recapitulation of θlig values. Achieving improved ligand efficiency for ligands 
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binding to protein interaction sites is expected to require that the protein undergo conformational changes 
to induce formation of alternate pocket shapes, but it is unclear a priori what range of pocket shapes are 
available at a given protein surface. A number of methods have recently been described to preferentially 
explore alternate conformations of protein surfaces suitable for small-molecule binding (48, 52, 53). 
While our studies presented here did not find that such conformations would be likely to bind a small-
molecule with high ligand efficiency, such an approach may nonetheless prove useful in rapidly screening 
protein interaction sites for those targets which are not only “bindable”, but also “druggable” in this sense. 
Alternatively, fragment screening approaches (54)—rapidly gaining popularity in campaigns targeting 
protein interaction sites (55)—may also provide a route for identifying moieties that bind with high ligand 
efficiency. The existence of such fragments may imply that the protein surface can provide surface 
pockets suitable for extensively burying at least some ligands. 
The number of crystal structures of distinct protein interaction sites bound to small-molecule 
inhibitors accumulated in the literature to date remains small (Table 1), and thus this study provides a 
snapshot of the field at present from these available examples. Accordingly, we cannot rule out design 
bias in these set of examples, or insufficient exploration of chemical space in this relatively new field. It 
will be interesting to learn, over the upcoming years, whether the challenges described in this study can 
be circumvented through new approaches. Meanwhile, the number of examples of small-molecules 
directly inhibiting binding at other types of recognition sites is even fewer. Nonetheless, we anticipate 
that inhibitors of these other “challenging” targets, such as protein–nucleic acid interactions, may share 
the same poor ligand efficiency—and thus limited druggability—as we describe here for inhibitors of 
protein–protein interactions. In order to access these many diverse and biologically critical targets, then, 
we may need to carefully select proteins amenable for complexes with low θlig, target allosteric sites that 
can accommodate extensively buried ligands, or develop new approaches to improve the delivery and oral 
accessibility for compounds outside the “rule-of-five” chemical space. 
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Protein 
target PDB id 
Inhibitor 
molecular 
weight (Da) 
Potency (µM) 
Ligand efficiency 
(kcal/mol per non-
hydrogen atom) 
θlig 
ZipA 1y2f 424 12 0.22 0.57 
HPV E2 1r6n 608 0.18 0.22 0.56 
XIAP-BIR3 1tft 535 0.005 0.29 0.52 
HIV-gp41 2kp8 580 14 0.15 0.51 
S100B 3gk1 279 80 0.29 0.49 
IL-2 1pw6 534 6 0.2 0.47 
PCNA 3vkx 651 3 0.33 0.47 
Grb2-SH2 3in7 556 -NR- -NR- 0.46 
Menin 4gq4 415 0.022 0.39 0.45 
VHL 3zrc 410 5.4 0.24 0.45 
TNFα 2az5 548 22 0.16 0.45 
calmodulin 1ctr 408 1 0.29 0.43 
clathrin 4g55 475 12 0.24 0.42 
Mdm2 4erf 478 0.0004 0.4 0.41 
SHANK 
PDZ 3o5n 304 17.2 0.29 0.40 
integrin 2vc2 523 -NR- -NR- 0.40 
BRD4 2yel 423 0.0155 0.33 0.39 
calpain 1alw 308 0.3 0.68 0.38 
Bcl-xL 1ysi 552 0.036 0.27 0.38 
HIV 
integrase 4e1n 438 0.019 0.33 0.37 
WDR5 3ur4 383 0.45 0.31 0.34 
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1.5 Methods 
Protein data sets 
To build the PPI set, we merged entries from the 2P2I (56) and TIMBAL (57) databases and then 
supplemented this collection with additional recent examples from our own curation of the literature. We 
eliminated from consideration any complexes with inhibitors of molecular weight outside the range 200 
Da – 675 Da, to discard small fragments and large peptide-like compounds. We further excluded 
structures containing proteins with co-factors, proteins closely related in sequence to other members of 
our set, and all examples of covalently bound inhibitors. In cases where more than one suitable inhibitor-
bound structure has been solved, we retained the structure in complex with the most potent ligand; we 
have carried out the experiments described here with other complexes as well and find similar results 
(data not shown). Our set contains compounds with molecular weight range 279 – 651 Da (mean: 468, 
standard deviation: 102 Da) and XlogP range of -4.9 – 6.5 (mean: 2.6, standard deviation: 2.9). Overall 
our set contains structures of 21 non-redundant proteins, each in complex with a unique inhibitor bound at 
a protein interaction site (Table 1): to our knowledge this represents the largest such collection reported 
to date. 
The Astex diverse set contains 85 protein–ligand complexes (35), intended as examples of drug-
like complexes (indeed, 23 of the ligands are approved drugs). For appropriate comparisons to our PPI 
Table 1: Inhibitors bound to protein interaction sites, the PPI set. Potency is taken from 
reported Kd or Ki values where available; if unavailable, IC50 values were used instead. In two cases 
(“-NR-”), no measure of potency has been reported. θlig indicates the fraction of ligand SASA exposed 
in the complex, as defined in Equation 1. 
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set, we refined this set by removing examples containing a protein cofactor or second ligand at the 
binding site (typically NADPH, FAD, ATP, heme, or metal ions). We again removed any complexes with 
inhibitors outside the molecular weight range 200 Da – 650 Da. Overall the Astex set we used in these 
studies consisted of 46 binary protein–ligand complexes (Table S1), with molecular weight range 208 – 
576 Da (mean: 362, standard deviation: 89 Da) and XlogP in the range -3.8 – 5.4 (mean: 1.9, standard 
deviation: 2.0). 
Molecular properties were calculated using the MolProp toolkit version 2.1.5 (OpenEye Scientific 
Software, Santa Fe, NM) (58). 
Computational screening 
Starting from the ZINC database of commercially available compounds (43), we compiled a set 
of 10,000 randomly selected compounds with molecular weight between 200 and 750 Da. These 
compounds served as “decoy” compounds for the screening experiment (Figure 3). 
In a separate experiment, we instead used the DUD-E server (37) to generate a set of 50 “decoy” 
compounds specifically matched to the known inhibitor of the intended target; in other words, each 
protein target was screened against a custom compound library built to match the chemical properties of 
the known inhibitor of this protein target (Figure S5). 
For each decoy compound as well as for the known inhibitor, we used the OMEGA version 2.4.3 
software (44-46) to generate up to 300 conformers, using default parameters. Charges were added using 
the QuacPac version 1.5.0 toolkit (OpenEye Scientific Software, Santa Fe, NM) (59). As described 
earlier, we included the ligand conformation observed in the crystal structure among the conformers for 
the known inhibitor. 
We carried out computational docking using the FRED version 3.0.0 software (40-42), a part of 
the OEDocking suite (OpenEye Scientific Software, Santa Fe, NM). The binding site for each protein was 
defined based on the bound ligand in the crystal structure, using the OEDocking 'receptor_setup' utility. 
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All FRED docking runs were carried out using the default parameters and the resulting poses were ranked 
using the Chemgauss4 score. 
Additional docking calculations were carried out using DOCK version 6.6 (47). The molecular 
surface for each protein target was calculated using the dms program, and spheres were generated in the 
active site using the sphgen program (both are available as DOCK utilities). All spheres within 10 Å of 
the bound ligand from the crystal structure were retained. A grid was generated and the ligand was 
docked using the default parameters; then the grid score was used to rank each docked complex. 
The same set of decoy compounds were used for the experiment using FRED and the analogous 
experiment using DOCK. 
Alternate protein conformations 
Alternate pocket-containing protein conformations were generated via biased simulations as 
described elsewhere (48). Briefly, we applied a biasing potential proportional to the size of the surface 
pocket, and carried out Monte Carlo simulations adapted from refinement protocols used in comparative 
modeling applications. This methodology is implemented in the Rosetta software suite (60), and is freely 
available for academic use (www.rosettacommons.org). 
Simulations were carried out for the following list of proteins (with PDB code for the unbound 
starting structure used in the simulation and the “target” residue at which the biasing potential was 
applied):  Bcl-xL (1r2d, 141), BRD4 (2oss, 146), FKBP12 (2ppn, 26), HPV E2 (1r6k, 33), IL-2 (1m47, 
42), HIV integrase (3l3u, 178), Mdm2 (1z1m, 61), menin (4gpq, 278), XIAP-BIR3 (1f9x, 308), ZipA 
(1f46, 85). In each case 1000 output structures were generated, and virtual screening was then performed 
using the lowest-energy pocket-containing conformation. 
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Statistical analysis 
Probability densities were estimated using standard kernel techniques in the R statistical 
computing environment (61). 
The statistical significance of differences in means between distributions was evaluated using a 
standard two-tailed nonparametric permutation test. Briefly, this test works by combining the two data 
sets in question, D1 and D2 (with n1 and n2 observations, respectively) into a single data set D (with n = n1 
+ n2 elements). A pair of data sets, D1' and D2', are then created by random sampling from D. These data 
sets contain the same number of elements as the original data sets (i.e., n1 and n2), but are constructed 
from a random partitioning of the original observations. For a given randomized pair, we can calculate the 
difference in means as tR = | µ(D1ʹ′) - µ(D2ʹ′) |, where µ(X) is the sample mean of data set X. This procedure 
is repeated to generate N randomized replicates, producing a distribution of tR values. This represents an 
estimate of the distribution of differences in means, given the null hypothesis that D1 and D2 are drawn 
from distributions of the same mean. 
This distribution is then compared to the observed difference in means, tobs = | µ(D1) - µ(D2) |, in 
order to estimate a p-value of that observed difference. In the set of N random replicates, we calculate the 
number of replicates Ngeq where tR ≥ tobs. The p-value is then defined as p = Ngeq / (N + 1). For all p-values 
quoted in this work, the test outlined above was performed using the “twotpermutation” method 
implemented in the DAAG package in R (61), with N = 106 replicates. 
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2.1 Abstract 
Protein-protein interactions represent an exciting and challenging target class for therapeutic 
intervention using small molecules. Protein interaction sites are often devoid of the deep surface pockets 
presented by “traditional” drug targets, and crystal structures reveal that inhibitors typically engage these 
sites using very shallow binding modes. As a consequence, modern virtual screening tools developed to 
identify inhibitors of traditional drug targets do not perform as well when they are instead deployed at 
protein interaction sites. To address the need for novel inhibitors of important protein interactions, here 
we introduce a new docking strategy specifically designed for this regime. Our method, termed DARC 
(Docking Approach using Ray-Casting), matches the topography of a surface pocket “observed” from 
within the protein to the topography “observed” when viewing a potential ligand from the same vantage 
point. We applied DARC to carry out a virtual screen against the protein interaction site of human 
anti-apoptotic protein Mcl-1, and found that 6 of the top-scoring 21 compounds showed clear inhibition in 
a biochemical assay. The Ki values for these compounds ranged from 1.2 to 21 µM, and each had ligand 
efficiency comparable to promising small-molecule inhibitors of other protein-protein interactions. These 
hit compounds do not resemble the natural (protein) binding partner of Mcl-1, nor do they resemble any 
known inhibitors of Mcl-1. Our results thus demonstrate the utility of DARC for identifying novel 
inhibitors of protein-protein interactions. 
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2.2 Introduction 
Protein-protein interactions comprise the underlying mechanisms for cell proliferation, 
differentiation, and survival; manipulation of these interactions thus represents a promising avenue for 
therapeutic intervention in a variety of settings. Despite the urgent need for small-molecule modulators of 
protein interactions, however, as recently as five years ago the dearth of success stories meant that even 
the druggability of this target class was very much in question (3, 62). At the same time, the challenges 
associated with these important targets help spur refinement of innovative new techniques, including 
fragment-based methods (63), peptidomimetics (64), and non-peptidic mimetics of protein secondary 
structural elements (65, 66). By now, these advances have enabled discovery of inhibitors against many 
different protein-protein interactions, and have led to an impressive array of compounds in various stages 
of clinical trials and pre-clinical optimization (67, 68). 
Modern methods for structure-based virtual screening have proven effective for a variety of 
applications, providing novel hits to address a very wide range of “traditional” targets such as enzymes 
and G protein-coupled receptors (69, 70). Unfortunately, structure-based virtual screening tools for 
identifying small-molecule inhibitors of protein-protein interfaces have lagged behind: due to their 
relatively exposed binding modes, the same docking methods that perform well for traditional drug 
targets struggle to correctly identify compounds that disrupt protein interactions (71). This problem is 
particularly acute because the natural partners of these targets – proteins – cannot easily be used for 
inspiration in designing small-molecule inhibitors or as templates for ligand-based virtual screening, as is 
possible for many enzymes (72, 73) and G protein-coupled receptors (74). 
In a number of cases, protein structures have been solved both in complex with a biological 
protein partner and also in complex with a small-molecule inhibitor. Comparison of the unbound protein 
structure to the equivalent structure in complex with a small molecule shows that binding is not 
associated with a large conformational change; and yet, the concave pocket on the protein surface in 
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which the small molecule binds is often absent in the unbound structure, so that the flat surface of the 
unbound structure must often undergo local rearrangement to reveal the small-molecule binding site (4). 
This has confounded structure-based methods for identifying inhibitors – how can the protein structure be 
used to identify an inhibitor, if the protein structure will change upon binding? 
We recently described a method for identifying protein surface pockets suitable for small-
molecule binding, from either co-crystal structures or from simulations starting from the unbound protein 
structure (75). Here, we introduce a method that we call DARC (Docking Approach using Ray-Casting) 
for matching these surface pockets to shape-complementary small molecules. Since many inhibitors of 
protein interactions are found to bind in shallow flat pockets on the protein surface (4, 71), this method is 
specifically designed for such protein-ligand interactions. Further, our method is intrinsically low-
resolution, to allow for minor conformational variation of the protein upon ligand binding. We anticipate 
this method will provide suitable starting points for cases in which the protein structure is not perfectly 
optimal for the ligand, and cases in which further small conformational changes of the protein are 
expected to accompany ligand binding. 
2.3 Computational Approach 
Computational methods are implemented in the Rosetta software suite (60); Rosetta is freely 
available for academic use (www.rosettacommons.org), with the new features described here included in 
the 3.6 release. 
Scoring with DARC 
To map the pocket shape on the protein surface, we use a variation of the LIGSITE (76) 
algorithm described fully in our earlier work (75). In its most basic form, this method involves building a 
three-dimensional grid around a protein (or select region of a protein), then tagging the grid points that are 
covered by the protein. Next, each grid point not covered by the protein is examined to determine whether 
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the point is bounded on two opposing sides by the protein along any direction of the grid, including 
diagonals. A continuous group of such special points are labeled a “pocket.” We then restrict this 
collection of “pocket” points to those “surface pocket” points that immediately contact the protein: these 
points together define the concave surface with which a ligand may interact. 
 
  
Figure 1: Docking Approach using Ray-Casting. (A) DARC first casts a set of rays emanating from 
an origin within the protein (red dot), and maps the topography of the surface pocket by monitoring 
intersection of these rays with the pocket (left). To evaluate the shape complementary of a given ligand 
for this pocket, DARC casts the same rays (from the same origin) and monitors their intersection with 
the ligand (right). If ligand (in its current position and orientation) is perfectly shape-complementary 
to the pocket, each ray will intersect the ligand at the same distance from the origin as it intersected the 
protein surface pocket. By moving the ligand to maximize this shape complementarity, a ligand can be 
docked into a protein surface pocket. (B) A schematic diagram of the complete workflow split into 
three stages: pre-DARC preparation, DARC, and post-DARC re-ranking/filtering of the docked 
models. 
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From an “origin” point within the protein (determination of this point is described in 
Supplementary Methods), we then cast a series of rays towards the surface pocket; each ray connects the 
origin point to one “surface pocket” point (Figure 1a). For each ray we express the position of the 
“surface pocket” point relative to the origin using spherical coordinates (θ,φ,ρpocket); collectively these 
spherical coordinates represent a map of the binding pocket’s topography when viewed from the protein 
interior. 
When viewed from the same vantage point (the origin), the topography of a suitably-bound ligand 
is expected to be highly complementary to that of the protein’s binding pocket. To evaluate the degree of 
complementary, we therefore cast the same set of rays (defined by their angles θ and φ), and determine 
the distance at which each ray first intersects the ligand (Figure 1a). If the ligand is indeed 
complementary to the pocket, the distance to the ligand (ρligand) for a given ray will closely match the 
distance to the pocket (ρpocket) for the corresponding ray. 
We define the DARC “overlap score” as the degree to which the pocket and ligand topographies 
match, by summing over all rays as follows: 
  DARC overlap score =
c1* ρligand − ρpocket( )
c2* ρpocket − ρligand( )
c3
c4
if ρpocket < ρligand
if ρligand < ρpocket
if raydoesnot intersect ligand
if raydoesnot intersect pocket
"
#
$
$
%
$
$
&
'
$
$
(
$
$
rays
∑   (1) 
From a physical perspective, rays that reach the pocket before the ligand indicate underpacking 
between protein and ligand (condition #1); alternatively, rays that reach the ligand before the pocket 
indicate a steric clash (condition #2). Rays that do not intersect the small molecule at all are penalized as 
well (condition #3); from a physical perspective, this corresponds to the ligand not completely filling the 
pocket. Finally, we include a series of rays that do not intersect the pocket; intersection of these rays with 
the ligand indicates that the ligand is too large for the pocket (condition #4). 
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For a given set of rays, evaluating the intersection distance of each ray with the ligand is a task 
that is naturally very amenable to parallel computing; indeed, the need to efficiently carry out the related 
“ray tracing” operation provided motivation for development of graphics processing units (GPUs). We 
have recently demonstrated that the ray-casting approach we describe here can also be carried out on 
GPUs, leading to dramatic speed enhancement relative to the analogous calculation on a CPU alone (77). 
Determination of the values for parameters c1/c2/c3/c4 used in these studies is described in 
Supplementary Methods. 
Docking with DARC 
Determining the optimal bound pose of a small molecule within a pocket (i.e. “docking”) entails 
varying the ligand position and orientation to minimize the DARC score (Equation 1). Though the first 
derivative of the DARC score can be calculated with respect to the ligand position and orientation, we 
instead carry out a derivative-free minimization using the particle-swarm optimizer implemented within 
the Rosetta software suite (60). The ligand internal degrees of freedom are held fixed during this search; 
to account for ligand flexibility, we prebuild ligand “conformers” using OMEGA (44-46) and 
independently dock each of these. The final DARC score for a given ligand is taken to be the minimum 
DARC score from among each of its docked conformers. 
Application of DARC for virtual screening is summarized though the workflow in Figure 1b. 
The starting pocket shape derives from a protein crystal structure, and can be an unbound structure, a 
bound structure in which the ligand has been discarded, or a structure generated from simulation (e.g. the 
“pocket optimization” simulations we have described for identifying low-energy pocket-containing 
conformations (75)). 
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2.4 Results 
Building a virtual screening benchmark 
Comparing DARC to other methods for virtual screening requires development of a benchmark to 
evaluate the performance of each method for correctly identifying known inhibitors from among “decoy” 
compounds. Assembling a large benchmark set is complicated by the relatively small number of available 
crystal structures of small-molecule inhibitors of protein interactions that have been solved in complex 
with their protein targets. Rather than assemble many tests with a very small number of active compounds 
(known inhibitors), we instead built two separate benchmark tests around protein interaction sites for 
which numerous chemically diverse inhibitors have been reported: Bcl-xL’s interaction with Bak 
peptides, and XIAP’s interaction with Smac/Diablo peptides. These two proteins (and their homologs) 
were excluded from parameterization of DARC (see Table S1 and Supplementary Methods), to ensure 
that DARC would not inadvertently be trained to perform well against these two protein targets. 
When generating a set of “decoy” compounds for this screening experiment, it is important that 
these compounds be suitably matched to the “active” compounds. If the decoy compounds are 
systematically different in some physicochemical property, for example, a docking method may 
successfully pick out active compounds simply due to some implicit bias (e.g. by simply picking the 
largest compounds, or the most hydrophobic, etc.). On the other hand, it is important to consider that 
decoy compounds are not necessarily inactive, but rather “presumed inactive”: typically they have not 
been explicitly tested experimentally against the target proteins in the benchmark to ensure they are not 
active. If decoy compounds are too similar to active compounds in chemical structure, certain decoys may 
themselves be active, which will confound analysis of the results (because the “right answer” in the 
benchmark is to label decoy compounds as inactive). 
To generate well-matched decoy compounds for these benchmarks, we drew from either i) a set 
of 85 drug-like compounds that comprise the Astex Diverse Set (35), or ii) a set of 6912 compounds 
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reported to inhibit a different protein-protein interaction than our protein targets, compiled from the 
TIMBAL database (78, 79). 
To reduce the likelihood that “decoy” compounds might be active, we removed any decoy 
compounds that exhibited strong chemical similarity to a compound in the “active” set for this target 
(2D Fingerprint Tanimoto score (80) > 0.7). To ensure non-redundancy of the active set and 
non-redundancy of the decoy set, we also removed any compound with strong chemical similarity to 
another compound already present in the same set (2D Fingerprint Tanimoto score > 0.7). 
For Bcl-xL this approach yielded 27 (diverse) active compounds, with 33 decoy compounds from 
the Astex set or 328 decoy compounds from the TIMBAL set. For XIAP this yielded 14 (diverse) active 
compounds, with 45 decoy compounds from the Astex set or 425 decoy compounds from the TIMBAL 
set. Though smaller than the TIMBAL decoy sets, the Astex decoys have the advantage that these 
compounds have typically been advanced through further optimization for their respective targets; this 
makes the Astex decoys less likely to exhibit (undesired) activity against Bcl-xL or XIAP. 
 
In addition, we also generated a third set of decoy compounds using the DUD-E server (81). In 
this case, we identified 50 “custom” property-matched decoys from each active compound. Thus, the 27 
compounds active against Bcl-xL led to a set of 1350 DUD-E decoys, and the 14 compounds active 
against XIAP led to a set of 700 DUD-E decoys. The careful matching of the decoys’ physicochemical 
properties to those of specific active compounds makes this a much more challenging benchmark; at the 
same time, however, there is an increased likelihood that some decoy compounds may themselves be 
active against the target protein. 
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Figure 2: Virtual screening benchmark experiment using an inhibitor-bound protein structure. 
(A) This receiver operating characteristic (ROC) plot compares the performance of various methods 
(DARC, DOCK, AutoDock, rDock, PLANTS, and ROCS) for predicting whether a given compound 
is active against a particular protein interaction site. Drug-like “decoy” compounds were drawn from 
the Astex diverse set, then further filtered to remove any compounds that are similar in chemical 
structure to an active compound or any other decoy compound. The results are presented on a semi-log 
plot to highlight the “early” performance of the methods; the grey curve indicates the random retrieval 
of compounds (i.e. a random predictor). Left: discriminating 27 diverse compounds active against 
Bcl-xL from among 33 matched decoy compounds. Right: discriminating 14 diverse compounds 
active against XIAP from among 45 matched decoy compounds. (B) DARC-docked models of 
representative active compounds against Bcl-xL (left) and XIAP (right). These compounds were not 
chemically similar to those used in solving these crystal structures (such compounds were excluded 
from this benchmark). 
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Screening against a ligand-bound protein structure 
The challenge in virtual screening entails identifying as many active compounds as possible from 
a library (true positives), while minimizing the number of inactive compounds incorrectly assigned as 
active (false positives). A very stringent score cutoff for any method will result in few compounds being 
assigned as active (such that some active compounds will be missed), whereas relaxing this cutoff will 
lead to many more compounds assigned as active (such that more false positives will be included). Since 
only a small fraction of the total compound library is expected to be further evaluated or validated 
experimentally, a typical goal for virtual screening is to rank active compounds at the very top of the 
sorted list (good “early” behavior), corresponding to the ability to build a small subset of the original 
library that is strongly enriched in active compounds (82). The “late” behavior (the fraction of the library 
that must be screened to ensure no active compounds are missed) is irrelevant for virtual screening 
applications, since a screening tool that offers to eliminate only a small fraction of (inactive) compounds 
from a large library is not particularly useful. 
We started from the crystal structures of Bcl-xL and XIAP, each solved in complex with an 
inhibitor that had been excluded from our library of active compounds. In addition to DARC, we used 
five other methods to score and rank each compound in this benchmark experiment. Four of these (DOCK 
(83, 84), AutoDock (85), rDock (86), and PLANTS (87)) are receptor-based screening tools that we used 
to dock each compound in the protein interaction site of each protein. The fifth (ROCS (88-90)) is a 
ligand-based screening tool, which ranks compounds on the basis of how well their three-dimensional 
structure mimics the volume and chemical features of a template – in this case, the structure of the 
inhibitor solved in complex with the target protein. Parameters used for each of these other packages are 
included in the Supplementary Methods. 
Given the rank order of each compound using each of the three methods, we prepared separate 
receiver operating characteristic (ROC) curves for both Bcl-xL and XIAP, corresponding to an 
experiment in which we screen a library comprised of active compounds and Astex decoys (Figure 2a). 
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Each point on such a plot corresponds to a given score cutoff, and each point indicates the fraction of 
active compounds collected at this cutoff, as a function of the inactive compounds incorrectly assigned as 
active at this cutoff. On this plot, the critical “early” behavior described earlier corresponds to a steep rise 
at the leftmost part of the plot: a useful method for screening must pick out as many active compounds as 
possible while accumulating a very small fraction of the inactive compounds. All three methods 
outperform the behavior that would result from randomly ranking the compounds in the library (grey 
curve), especially in this “early” region. We also observe similar results when carrying out the same 
screening experiment using decoy compounds drawn from the TIMBAL set rather than from the Astex set 
(Figure S1). With the exception of ROCS applied to XIAP, meanwhile, none of the methods perform at a 
comparable level when used to distinguish known active compounds from their closely-matched decoys 
in the DUD-E set (Figure S2). 
As seen in representative examples of docked active compounds (Figure 2b), the DARC-
generated models exhibit clear shape complementarity that allowed these compounds to be (correctly) 
identified as true ligands; experimentally-derived structures of these compounds in complex with their 
protein partners have not been reported to date. While low-resolution considerations of shape 
complementarity alone cannot be sufficient to reliably predict binding affinity or details of the 
interactions, it is striking that for these two benchmark tests the simple approach employed by DARC 
successfully distinguishes active from inactive compounds with similar accuracy as more sophisticated 
methods. We further note that the performance of DARC in this benchmark is remarkably robust to the 
location of the “origin” point from which rays emanate, provided a reasonable approach is used to define 
this point (Figure S3). Thus, these observations support the hypothesis that the crude pocket shape on the 
protein surface provides a strong restriction on the chemical “shape space” of inhibitory compounds. 
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Screening against a “pocket optimized” protein structure 
The fact that a protein interaction site is likely to undergo a conformational change upon inhibitor 
binding (4) makes the choice of receptor conformation of particular interest for this target class, especially 
given that the performance of most approaches decreases considerably when an unbound starting 
structure is used in place of a ligand-bound starting structure (91). A variety of methods exist for 
incorporating receptor flexibility, typically by docking against multiple receptor conformations from 
either crystal structures (92-96) or simulation (97-99). 
Rather than start from unbound crystal structures of Bcl-xL and XIAP – which lack the surface 
pocket required for inhibitor binding – we instead started from conformations generated using the “pocket 
optimization” approach we have recently described (75). Briefly, we developed a biasing potential that 
Figure 3: Virtual screening benchmark experiment using protein structures from “pocket 
optimization” simulations. (A) This benchmark experiment involves discrimination of the same 
active versus “decoy” compounds as in Figure 2, however this time compounds were screened against 
a protein conformation generated via “pocket optimization” simulations initiated from an unbound 
crystal structure (instead of protein conformations from an inhibitor-bound crystal structure). The 
results are again presented on a semi-log plot to highlight the “early” performance of the methods; the 
grey curve indicates the random retrieval of compounds (i.e. a random predictor). (B) Models of 
representative active compounds docked by DARC to the “pocket optimized” conformation of 
Bcl-xL (left) or XIAP (right). (C) The performance of DARC in this benchmark is essentially 
equivalent when screening against a known ligand-bound structure (solid black line), the lowest-
energy “pocket optimized” conformations (i.e. as described in the previous panels) (solid red line), or 
any of five other low-energy “pocket optimized” conformations (dashed red lines); this observation 
demonstrates the insensitivity of the method to details of the protein structure. 
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drives conformational sampling in molecular mechanics simulations towards conformations containing 
surface pockets suitable for small molecule binding. This biasing potential operates solely on simple 
geometric considerations, so that the shapes of the resulting surface pockets are influenced solely by 
properties of the protein surface and not knowledge of any particular ligand. Starting from unbound 
crystal structures, we carried out simulations to generate “pocket optimized” conformations of Bcl-xL and 
XIAP: conformations containing a surface pocket, but without the precise details that would be encoded 
in a ligand-bound structure (our application of this approach to generate these protein conformations is 
described in Supplementary Methods). 
We re-screened the same compound library described earlier, this time using a “pocket 
optimized” conformation of Bcl-xL or XIAP (Figure 3a). We did not include ROCS in this stage of the 
benchmark, since there is no structure of a cognate ligand available for this protein conformation that 
could be used as a template. Unsurprisingly, the performance of DOCK, AutoDock, rDock, and PLANTS 
all suffer dramatically in this more challenging regime. In contrast, the performance of DARC is 
remarkably similar to the earlier experiment, demonstrating that the low-resolution nature of the 
underlying calculations makes DARC relatively robust to slight mismatches between protein and ligand. 
Indeed, representative examples of active compounds docked to these alternate conformations 
demonstrate that the overall pocket shapes remain complementary to these ligands (Figure 3b). We note 
that these observations also hold when carrying out the same experiment using decoy compounds drawn 
from the TIMBAL set rather than the Astex set (Figure S4), but that again all of these methods exhibit 
diminished performance against the DUD-E set (Figure S5). 
In summary, slight differences in these protein conformations lead to diminished performance 
from other receptor-based docking methods in this regime, but DARC performs equally well in this 
experiment as in the previous benchmark that used protein conformations from ligand-bound crystal 
structures. This finding is confirmed by extending this experiment to consider a series of five more 
distinct low-energy conformations for each protein, as generated by the “pocket optimization” approach: 
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we find that the performance of DARC in this benchmark is notably insensitive to the precise details of 
the protein conformation (Figure 3c). 
Collectively, these experiments point to different regimes in which each class of method is 
expected to prove superior. Detailed docking methods, such as DOCK, AutoDock, rDock, and PLANTS, 
are expected to out-perform DARC if the protein structure is solved in complex with a ligand of similar 
chemotype to the desired compounds. By contrast, DARC allows greater discrimination if the protein 
conformation is not quite optimal for the ligand: this can occur when one wishes to discover inhibitors 
with a radically different chemotype than known ligands, or when the protein conformation derives from 
simulation. 
Identifying novel Mcl-1 inhibitors using DARC 
To evaluate the performance of DARC in a realistic application, we next applied this approach to 
screen for novel classes of inhibitors for Mcl-1, a member of the Bcl-2 family of proteins. Individual 
members of this protein family can serve either a pro- or anti-apoptotic role, and interact with one another 
through a structurally-conserved binding motif. Small-molecule inhibitors of Bcl-2/Bcl-xL have shown 
promising efficacy in overcoming chemo/radioresistance in various tumor models including prostate 
cancer (100-104). One such compound is ABT-737, a potent Bcl-2/Bcl-xL inhibitor (104); a more recent 
Bcl-2-selective derivative of this compound is currently in clinical trials (105). Recent studies have shown 
that cancer cells resistant to ABT-737 have high levels of Mcl-1, and that knockdown of Mcl-1 promotes 
ABT-737-induced apoptosis (89, 102, 103, 106, 107). Taken together, these observations motivate the 
pressing need for development of potent and selective inhibitors of Mcl-1 in treating of a variety of 
cancers, to be used either as a single agent or in combination with inhibitors of Bcl-2/Bcl-xL (108). 
The strong evidence supporting the potential impact of effective Mcl-1 inhibitors has spurred 
intense efforts using a variety of complementary approaches (108, 109), including high-throughput 
screening of standard libraries using a fluorescence polarization competition assay (110, 111), and of an 
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sp3-rich library using differential scanning fluorimetry (112). Aiming to build upon the success of the 
ABT-737 series for Bcl-2, several groups have since applied similar NMR-based fragment screening to 
Mcl-1; fragment hits were prioritized on the basis of ligand efficiency (binding free energy per 
heavyatom), first yielding weakly-binding compounds that were subsequently merged or elaborated to 
give inhibitors with improved potency at the expense of some ligand efficiency (113-116). Inspired by the 
helical conformation adopted by Mcl-1’s interaction partners, a number of groups have grafted the 
interaction partners’ sidechains onto small-molecule scaffolds that allow them to be presented in a similar 
geometry (117-119), or have used “stapled” derivatives of the helical peptides (120-122). Such 
approaches predicated on mimicry of a known helical binding partner can rapidly lead to potent 
inhibitors, but the large chemical scaffolds required to recapitulate the helical geometry diminish from 
their ligand efficiency. 
Like other members of the Bcl-2 family, Mcl-1’s interaction partners bind to an exposed 
hydrophobic groove on the protein surface (123). We recently applied our “pocket optimization” 
approach to this protein surface, and generated ensembles of low-energy Mcl-1 conformations that 
present surface pockets suitable for small molecule binding (124). Among these ensembles we find 
conformations similar to those observed in crystal structures of Mcl-1 bound to diverse small-molecule 
ligands, and we also observe “distinct” conformations that have not yet been observed in any 
experimentally-derived structures (124). We elected to use DARC to screen chemical libraries for 
compounds that would complement one of two Mcl-1 conformations: either an experimentally-derived 
conformation, or a conformation derived from “pocket optimization” simulations. At the time we initiated 
these studies no unbound structure was available (125), so for the former we used a peptide-bound crystal 
structure (PDB ID 2pqk) (123). For the latter, we used the lowest-energy pocket-containing conformation 
generated from 1000 independent trajectories. 
Drawing from the ZINC database (43), we compiled a small virtual library corresponding to 
62,442 highly-diverse compounds with drug-like properties (MW ≤ 500 Da, xlogP ≤ 5, etc., see 
 
 
46 
Supplementary Methods) available for immediate purchase from a commercial vendor. We then applied 
DARC to separately dock and rank each compound using the peptide-bound structure of Mcl-1, and also 
separately using the “pocket optimized” conformation of Mcl-1. 
The docked models produced by DARC are intrinsically low-resolution, since they rely only on 
matching the protein-ligand topography. To achieve further high-resolution discrimination, we therefore 
included an additional final step (Figure 1b): for each of the top ranked 10% of the complexes produced 
by DARC we carried out fullatom gradient-based minimization in Rosetta, using the standard Rosetta 
fullatom energy function (60) and ligand parameter definitions (126). All internal dihedral angles of the 
protein were included as degrees of freedom, along with the ligand position and orientation relative to the 
protein. We then filtered the resulting models to remove those with no intermolecular hydrogen bonds or 
an abundance of buried unsatisfied polar groups. From the remaining models, we then purchased the 
top-scoring 21 compounds on the basis of DARC score (Table S2). Of these 21 compounds, 11 were 
identified by screening against the (peptide-bound) crystal structure of Mcl-1, and the other 10 were from 
screening against the “pocket optimized” structure. 
The structural basis for the favorable scores in our DARC screen is evident from the models of 
these compounds in complex with Mcl-1 (Figure 4a). In each case the ligand – in its modeled 
conformation – exhibits exquisite shape complementarity for the protein surface; this is unsurprising, 
given that the DARC score is expressly built to identify the ligand position, orientation, and conformation 
that will maximize similarity to the topography of the protein surface. Nonetheless, there is also clear 
diversity amongst the models: the ligand shapes are different from one another, and they fill the protein 
surface pocket in distinctly different ways. In the case of M0, for example, a hydrophobic groove on the 
Mcl-1 surface is neatly complemented by the spatial arrangement of the two aromatic rings in the selected 
ligand conformation. 
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Figure 4: DARC can be used to identify novel inhibitors of human Mcl-1. Screening was 
carried out against the protein interaction site of Mcl-1, and 21 of the top-scoring compounds were 
tested in a biochemical assay. (A) Docked models generated by DARC for six compounds emerging 
from our screen. Compounds were screened either against an experimentally-derived peptide-bound 
structure of Mcl-1, or against an Mcl-1 conformation generated via “pocket optimization” simulations. 
(B) The chemical structures of the compounds in each model are shown. We note that some of these 
have reactive functional groups: such compounds could be removed from the library prior to 
screening, in applications where such moieties are undesirable. (C) The most likely activity of each 
compound was predicted using the Similarity Ensemble Approach (SEA). None of these compounds 
are assigned as likely inhibitors of Bcl-2-family proteins, underscoring their lack of similarity to 
known inhibitors of this family. (D) Each of these six compounds inhibit Mcl-1’s interaction with a 
FITC-labeled cognate peptide, as determined via fluorescence polarization. CHAPS detergent (0.1%) 
was included in this assay, to ensure that these results were not due to compound aggregation; we also 
observe equivalent inhibition in the absence of CHAPS. Each curve is fit to a one-site inhibition 
model, with a single free parameter in the fitting. 
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The selected compounds also represent a diverse array of different chemical scaffolds 
(Figure 4b), with no evident similarity to one another. It must be noted that of the compounds shown, 
only M7 (a natural product) is devoid of potentially reactive functional groups. This is, of course, a 
reflection of the screening library: in a typical drug discovery application, such compounds should be 
removed from the library prior to screening since their potential for advancement is likely to be extremely 
limited (127). For the purpose of evaluating the performance of DARC in this virtual screening 
experiment, however, we did not exclude such compounds. 
By visual inspection, the structures of these compounds bear no obvious resemblance to any 
known inhibitors of Mcl-1, or to any known inhibitors of any other Bcl-2 family members. To 
systematically identify biologically active compounds most resembling these compounds, we applied the 
Similarity Ensemble Approach (SEA); this method uses ligand similarity to identify likely receptors for a 
query ligand (128). In most cases SEA identifies chemical scaffolds with clear resemblance to our 
queries, but these related compounds have each been described in the context of very different activities 
(Figure 4c); even delving further into each list, we did not find similarity to other inhibitors of Bcl-2 
family members. This observation highlights the fact that these compounds would have been very 
difficult to pick out using ligand-based screening, due to their lack of similarity to any known inhibitors 
of this protein family. The most likely activity of each compound was predicted using the Similarity 
Ensemble Approach (SEA) (128). 
We next examined the ability of each compound to inhibit the interaction of Mcl-1 with one of its 
binding partners. We used a fluorescein-labeled peptide derived from the Noxa protein, which exhibits an 
increase in polarization upon Mcl-1 binding (Figure S6a). Upon addition of a known Mcl-1 inhibitor, 
AT-101 (i.e. R-(-)-gossypol), we observe a dose-dependent decrease in polarization that confirms this 
compound competes with Noxa for Mcl-1 binding, and is consistent with previously reported data (129) 
(Figure S6b). Using this assay we find that 6 of the 21 compounds from our computational screen (M0, 
M1, M5, M6, M7, and M8) inhibited the interaction between Mcl-1 and its cognate peptide, with Ki 
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values ranging from 1.2 to 21 µM (Figure 4d, Table 1). We also observe activity for 4 additional 
compounds (M11, M12, M17, and M20), with Ki values ranging from 35 to 100 µM (Table 1). For the 
remaining 11 compounds, we did not observe any activity. 
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 Given the chemical structures of the six most potent compounds, these observed Ki values 
correspond to ligand efficiency (binding free energy per heavyatom) of 0.21 to 0.27 kcal/molŊheavyatom, 
which is typical of other promising small-molecule inhibitors of protein-protein interactions reported in 
the literature (68). With respect to other Mcl-1 inhibitors in particular, these six initial hits are less active 
than the most potent compounds arising from screens of libraries designed to mimic the sidechain 
interactions of helical cognate peptides (117-119); however, the DARC hits exhibit greater ligand 
efficiency, due to the extensive size of the compounds designed for mimicry of the helix. 
Figure 5: Evaluating DARC’s model of the M0/Mcl-1 complex. (A) Though M0 was 
identified in a screen against a peptide-bound conformation of Mcl-1, M0 (peach) is distinctly not 
mimicking the interactions of the cognate peptide (light gray). In the DARC-generated model M0 
competes with the N-terminus of the peptide for Mcl-1 binding, but fits more deeply into the Mcl-1 
surface pocket than the peptide sidechains. (B) This M0 binding mode is distinctly different from that 
of known Bcl-xL inhibitors such as ABT-737 (green), which instead overlap with the C-terminus of 
the peptide-binding site. The surface of the Bcl-xL protein is shown (grey), solved in complex with 
ABT-737. (C) Other recently-described inhibitors of Mcl-1, including the representative example 
shown here (dark pink), bind at a similar location to M0; however, each distinct series of inhibitors 
induce their own unique Mcl-1 conformational change to allow deeper ligand burial. (D) The locations 
of two M0 positions that play key roles in our model of the complex: the 6’-methoxy group (yellow) 
and the unsubstituted 5-position (green). (E) A model of the D1, the most potent M0 derivative, in 
complex with Mcl-1. This compound preserves the crucial 6’-methoxy group, and embellishes the 
5-position with a chlorine substitution to improve packing. Closely analogous compounds to D1 that 
lack the methoxy group at the 6’-position (D3) or that lack the chlorine at the 5-position (D5) exhibit 
reduced activity. 
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Superposition of the modeled complexes for each of the DARC hits with the structure of Mcl-1 
bound to a cognate peptide reveals that these compounds are decisively not recapitulating the interactions 
of the helical peptide (Figure 5a). While the cognate peptide uses a cluster of aliphatic residues at its 
N-terminus and aromatic residues at its C-terminus, compound M0 (as a representative example) occupies 
only the regions of the Mcl-1 surface engaged by the N-terminus of the peptide. Given that it is not 
constrained to fit onto the backbone of the helix, this compound also fits more deeply into the binding 
pocket on the Mcl-1 surface. In contrast, the most potent of the helix-mimetics was designed to 
recapitulate the complete set of interactions provided by the helical template (117). The sidechains that 
comprise these interactions are separated by a span of 15 residues in sequence, and while this led to an 
inhibitor with Ki of 0.2 µM, the large chemical scaffold needed to present these interactions reduced the 
ligand efficiency of this compound to 0.21 kcal/molŊheavyatom. 
While the underlying methodology used in our DARC screen did not explicitly select for 
compounds that bind in place of the N-terminus of the cognate peptide, each of the resulting hits 
complemented this region. This is in stark contrast to the binding modes observed in crystal structures of 
Bcl-xL solved in complex with potent inhibitors such as ABT-737 and WEHI-539: each of these bind to 
the region of the protein surface used by the C-terminus of the cognate peptide, and thus have relatively 
little overlap with the models of the DARC hits (Figure 5b). In the time since we carried out our 
computational screen, crystal structures of Mcl-1 solved in complex with four distinct classes of inhibitor 
have been reported (112-114, 130), and in each case the ligand occupies the region of the protein surface 
corresponding to the N-terminus of the cognate peptide. Thus, the lack of DARC hits complementing the 
protein surface used by inhibitors of Bcl-xL may indicate a lack of druggability for the analogous surface 
of Mcl-1. 
In contrast to Mcl-1 inhibitors derived by mimicry of the cognate helix, the most promising hits 
emerging from fragment screens initially proved less potent than those identified by DARC but had 
superior ligand efficiency (113-116). One representative class of fragments inhibited Mcl-1 with Ki of 
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only ~100 µM, albeit with a promising ligand efficiency of about 0.3 kcal/molŊheavyatom (113). NMR-
derived models of the binding mode for this class of compound suggested that they induce a 
conformational change in Mcl-1, which in turn produces a very deep pocket required for binding; upon 
merging with another fragment class, crystallography confirmed that the larger compound also induced 
this conformational change (113). In retrospect, each of the Mcl-1 crystal structures in complex with an 
inhibitor (solved after completion of our screen) revealed a conformational change that allowed the ligand 
to access a deep pocket that was not evident from the unbound or peptide-bound structures (112-114, 130) 
(Figure 5c). The observation that extensive ligand burial is related to high ligand efficiency (across many 
small-molecule inhibitors of protein-protein interactions) (71) is thus consistent with the impressive 
ligand efficiency of these (deeply buried) Mcl-1 fragment hits. However, such conformations were not 
among those included in our DARC screen, and accordingly the DARC hits could not have taken 
advantage of the deep pockets presented upon conformational rearrangement of the protein. 
Evaluating the DARC model of M0 binding 
To gauge the veracity of the modeled complexes that led to selection of these compounds, we 
sought to ask whether such a model could be used to explain the structure-activity relationship (SAR) 
observed across a series of related compounds. Despite the fact that M0 (2’,4-dihydroxy-3,4’,6’-
trimethoxychalcone) was the least potent of the six hits in our original screen, the straightforward 
synthetic accessibility of the chalcone series prompted us to select this scaffold for further investigation. 
Before designing a series of analogs, however, we noted that other chalcones are known to form 
covalent adducts to proteins (the chalcone α,β-unsaturated carbonyl system is a Michael acceptor and thus 
may react with unpaired cysteine sidechains) (131, 132). We therefore carried out analysis via surface 
plasmon resonance (Figure S7) and HSQC chemical shift mapping (Figure S8) to further characterize 
this interaction (see Supplementary Results). Taken together, the stoichiometric Hill coefficient (133) and 
insensitivity to the presence of detergent (134) in the fluorescence polarization assay, the fact that the 
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SPR response did not exhibit super-stoichiometric behavior (135), and the observation of a small number 
of distinct chemical shift differences in the HSQC spectrum (136) all provide evidence that the observed 
activity of M0 is not due to compound aggregation that deactivates Mcl-1, but results from specific 
binding. The NMR experiment also supports two features of our model for M0 binding: first that the M0 
binding mode is not completely overlapping with that of the Bcl-xL inhibitors (Figure 5b), and second 
that M0 binding does not induce extensive protein conformational changes as seen in other Mcl-1 
inhibitors (Figure 5c). 
We then proceeded to produce a variety of M0 derivatives, using a simple aldol condensation 
reaction (Figure S9). We were concerned that designing these analogs from our model of the M0/Mcl-1 
complex might bias the resulting series towards certain regions of chemical space, and thus not provide a 
fair assessment of our model. In order to evaluate the structure-activity relationship more objectively, we 
therefore designed a set of compounds by selecting the most readily available starting materials, based 
only upon the chemical structure of M0 and without consideration of our model of the complex. Using the 
same fluorescence polarization competition assay described earlier, we characterized a total of 27 analogs 
of M0 (Table 2, Figure S10). As described below, the SAR deduced from this series presents a 
compelling narrative when interpreted using our model of M0 binding (Figure 5d). 
The most potent of these M0 analogs are D1 and D2: they each inhibit Mcl-1 about 7-fold more 
potently than M0. Compounds D1 and D2 differ only by a single methoxy versus fluorine substitution at 
the 3-position; M0 harbors a methoxy here. This methoxy group is exposed in our model of the M0/Mcl-1 
complex, consistent with the observation from D1 versus D2 that its replacement with fluorine does not 
affect activity. Compounds D1 and D2 together share three differences relative to M0: both have a 
chlorine at the 5-position, both have a methoxy group at the 5’-position, and both lack the 2’-hydroxyl of 
M0. The latter two positions are exposed in our model of M0 binding, and are thus assumed not to 
strongly affect activity. In contrast, the 5-position (unsubstituted in M0) faces towards the protein, and 
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points towards a small cavity (Figure 5d): thus, the improved packing resulting from this substitution 
may explain the slightly enhanced potency of D1/D2 relative to M0. 
The only other two compounds in this series with potency exceeding that of M0 are D3 and D4; 
this equipotent pair again differs only by the same fluorine versus methoxy substitution that distinguished 
D1 and D2. Relative to D1/D2, compounds D3/D4 lack the 5’- and 6’-methoxy groups. While the 
5’-position is unsubstituted and exposed in our model of the M0/Mcl-1 complex, the 6’-methoxy group is 
deeply buried in a hydrophobic cavity (Figure 5d); loss of this interaction may explain the reduced 
potency of D3/D4 relative to D1/D2. 
Across this series of 27 M0 analogs, only compounds D1-D4 proved more potent than M0. While 
the SAR described above is consistent with our model of M0 binding, these results are also notably 
inconsistent with the behavior expected if these compounds were simply carrying out thia-Michael 
additions. Kinetic studies using a model thiol (cysteamine) demonstrate that the presence of the 
6’-methoxy group decreases reactivity, and the 2’-hydroxy group increases reactivity (137). Through the 
comparisons above, we find that the most potent compounds for inhibition of Mcl-1 correspond to those 
expected to be least reactive, further implying that the inhibition we observe is not due to reactivity of 
these compounds with Mcl-1’s unpaired cysteine sidechain. 
Through the results presented in Table 2 we demonstrate that chalcones are not “privileged 
scaffolds” (138, 139) for inhibition of Mcl-1, an assertion that is best supported by specific examples. 
Compounds D7/D12/D13/D14 lack the key 6’-methoxy group described earlier (Figure 5d), and 
accordingly are less potent than M0. Compound D5 preserves each of the M0 functional groups that 
interact with Mcl-1 in our model (i.e. the 6’-methoxy group and the 4-hydroxyl group), and accordingly 
exhibits a very similar inhibition constant as M0. Compound D8 maintains the substituents of D2 on one 
ring, but lacks the substituents on the other ring (including the 6’-methoxy group), and is thus less potent. 
Compounds D9/D10/D11 maintain the 6’-methoxy group but harbor a variety of alternate substituents on 
the other ring, making them less potent as well. Compounds harboring extra fused rings 
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(D20/D21/D22/D23) are inevitably less potent, as are compounds in which the chalcone linkage has been 
replaced with a flavone (D24/D25/D26/D27). Overall, the assertion that chalcones are not privileged 
scaffolds for inhibition of Mcl-1 or generic helix-mimetics is supported by the observation that most 
analogs presented here – designed without consideration of our model of binding – inhibit Mcl-1 less 
potently than the parent compound M0. In summary then, it is the precise complementary of select 
compounds for the surface of Mcl-1 that dictate their activity, and not some property of this chemical 
scaffold. 
Ultimately, direct structural evidence will be required to confirm that these compounds are indeed 
binding via the designed pose. Unfortunately, our efforts to crystallize Mcl-1 in complex with a member 
of this chemical series have not yet proven successful. Validating the models that lead to selection of 
active compounds through structural biology will be important not only for retrospective evaluation of the 
DARC models, but also as a starting point for inspiring design of subsequent analogs. Accordingly, we 
used DARC to compare our model of the M0/Mcl-1 complex to a model in which M0 was replaced with 
D1 (Figure 5e). We find that DARC scores D1 even more favorably than M0, due to the improved 
packing resulting from substitution of chlorine at the 5-position. Thus, we expect that compounds with 
even better shape complementarity for Mcl-1 than those selected in our initial screen – compounds such 
as D1 – can be identified by screening larger chemical libraries with DARC. By further analogy to D1, we 
anticipate that such compounds will also exhibit superior potency relative to the initial hits described in 
this first screen. Despite the improved potency relative to M0, we nonetheless note that compound D2 
does not exert the desired biological effect using an in vitro cellular assay (see Supplementary Results) 
(Figure S11). This underscores the need to test candidate inhibitors in cellular assays as well, since 
biochemical activity may not necessarily translate to cellular activity. Indeed, careful analysis has shown 
that a number of other inhibitors, each with comparable binding affinity for Mcl-1 as that of compound 
D2, also appear not to act on Mcl-1 in cells (111, 140, 141). 
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Compound Chemical structure Ki (µM) L.E. 
(kcal/molŊheavyatom) 
M0 
 
21 0.27 
M1 
 
1.2 0.24 
M5 
 
12 0.21 
M6 
 
9 0.23 
M7 
 
7 0.27 
M8 
 
12 0.21 
M11 
 
35 0.20 
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M12 
 
~80 0.19 
M17 
 
43 0.20 
M20 
 
~100 ~0.19 
 
 
 
 
 
Compound Chemical structure Ki (µM) L.E. 
(kcal/molŊheavyatom) 
M0 
 
21 0.27 
D1 
 
2 0.29 
N
OS NH
O
H
N S
O
F
O
NH+
O
N
N
N
N
O-
N Cl
O
O O
O
O
OH
OH
3' 1'
5'
1
2
5
6
O
Cl
O
O
OHO
O
Table 1: DARC screening hits confirmed experimentally as inhibitors of Mcl-1. The 
complete set of DARC hits (including those that did not inhibit Mcl-1) are included as Table S2. Ki 
values are determined via a fluorescence polarization competition assay (see Supplementary Methods). 
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D2 
 
3 0.30 
D3 
 
7 0.33 
D4 
 
10 0.31 
D5 
 
28 0.33 
D6 
 
20 0.32 
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40 0.25 
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D10 
 
>50 N.D. 
D11 
 
>50 N.D. 
D12 
 
>50 N.D. 
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>50 N.D. 
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D18 
 
>50 N.D. 
D19 
 
>50 N.D. 
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>50 N.D. 
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>50 N.D. 
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D26 
 
>50 N.D. 
D27 
 
>50 N.D. 
 
 
  
O
O
O O
O
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O
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O O
O
NH2
Table 2: Chemical analogs of M0. We designed and synthesized a series of 27 M0 
derivatives, and tested each of these for inhibition of human Mcl-1 using a fluorescence polarization 
competition assay (see Supplementary Methods). This series of analogs was designed without 
consideration of DARC’s model of the M0/Mcl-1 complex, to allow unbiased evaluation of the model. 
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2.5 Discussion 
Screening on the basis of surface topography 
Since the protein surfaces of “traditional” drug targets have evolved to bind some cognate small-
molecule ligand, they typically include a deep pocket or groove that can be targeted by inhibitors. In 
contrast, protein interaction sites typically do not include such surface features, and accordingly small-
molecule inhibitors acting at these sites rely on shallower bound poses (71). Because these shallow 
binding modes prove challenging to predict by conventional docking approaches, modern virtual 
screening tools exhibit diminished performance when used to predict inhibitors of protein interactions 
(relative to their performance when applied to “traditional” drug targets) (71). Here we present DARC, an 
entirely new approach to docking and virtual screening. By matching the topography of the protein 
surface to the buried face of the ligand, we find that DARC outperforms popular canonical tools (DOCK, 
AutoDock, rDock, and PLANTS) when screening for inhibitors of protein-protein interactions. 
Given the importance of shape complementation for binding, several other fast approaches have 
been described to rapidly evaluate poses and enable large-scale virtual screening. These include methods 
based on Fourier correlation theory (142, 143), spherical harmonics (144, 145), geometric hashing (146), 
and negative images (147-149). Most recently, others have used variations of ray-casting to compare 
internal pockets in proteins to one another (150, 151). In addition to their intended usage, a subtle – but 
very important – difference between the latter work and DARC is the origin from which rays emanate. 
This other study casts rays from within the pocket (at the center of mass), resulting in a shape description 
that is most useful when the pocket is mostly (or completely) enclosed by the protein (150, 151). In 
contrast, DARC casts rays that originate from “behind” the pocket (i.e. inside the protein): this instead 
emphasizes shape complementarity at the deepest regions of the binding groove, and is thus better suited 
for describing the shallow bound poses typical of small-molecule inhibitors acting at protein interaction 
sites. 
 
 
63 
While shape complementarity is clearly a necessary feature of ligands that will bind to a protein 
surface, this alone obviously cannot be sufficient. In the present study, we used DARC to optimize and 
evaluate surface shape complementarity without consideration of electrostatic complementarity or 
solvation effects; for this reason, we included a “re-ranking” step in our virtual screen against Mcl-1 to 
filter out models with no intermolecular hydrogen bonds or an abundance of unsatisfied buried polar 
groups. In retrospect, the hydrophobicity of the Mcl-1 surface pocket provided a convenient testing 
ground for the ability of DARC to identify shape-complementary ligands, without the complication of 
polar groups on the protein surface. In future, however, we expect that incorporation of electrostatic 
complementarity into DARC lead to improved performance in virtual screens against protein surfaces that 
display surface polar groups (152). 
Approaches for identifying inhibitors of protein-protein interactions 
In many cases, artificial ligands that bind to a specific protein surface bear some resemblance to 
an endogenous ligand that also binds to that surface: analysis of precedented drug targets shows that 
knowledge of a substrate, product, or effector with “drug-like” physicochemical properties is a good 
predictor of druggability for a given protein surface (153). Analogs of endogenous ligands can also 
provide a starting point for designing inhibitors (154). In the case of protein interaction sites, however, the 
natural ligand is not a small molecule and thus does not provide an obvious template from which to start. 
This has driven advances in new methodologies for identifying inhibitors of these “non-traditional” 
targets, most notably including mimicry of key interacting groups of the protein partner (117-119, 155-
157) and fragment-based approaches (113, 158-160). 
In addition to chemical scaffolds that mimic secondary structural elements (117-119), exciting 
new computational approaches have facilitated identification of compounds that instead mimic the 
geometric orientation of key “hotspot” or “anchor” sidechains in a protein-protein interface (155-157). 
While either mimicry-based approach may provide a robust starting point for recapitulating the 
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interactions of a protein partner using a small-molecule scaffold, both are likely to encounter the same 
intrinsic limitation: ligand efficiency is unlikely to exceed that of the interacting groups from the protein 
partner, which in turn is usually less than that those achieved by small-molecule inhibitors that do not 
explicitly mimic interactions of the protein partner (4). Accordingly, an important advantage of de novo 
structure-based screening methods that do not rely on mimicry, such as DARC, is the potential to identify 
inhibitors that achieve superior ligand efficiency through deeply buried interactions not available to a 
protein-based ligand. 
In contrast, fragment-based approaches often prioritize small compounds with very high ligand 
efficiency from the outset: this allows exploration of deep crevices that would not necessarily be evident 
from the structure of the protein-protein complex. Here, the challenge often lies in elaborating initial 
fragment hits (by growing, merging, or linking them) into larger compounds that maintain these highly 
productive interactions (161, 162). In our DARC screen against Mcl-1, we focused on compounds larger 
than traditional fragments: this led to initial hits with easily detectable activity, albeit at some expense of 
ligand efficiency. Much as the “multiple solvent crystal structures” method (163) uses very small 
fragments to probe the protein surface for productive interactions with isolated functional groups, 
screening a commercially-available library of “prototype” compounds – as we have done here – allows 
rapid evaluation of specific protein-ligand interactions predicted in silico, and can provide potential 
chemical scaffolds for further optimization. 
Screening against multiple protein conformations 
The compounds identified as “hits” by DARC, and by structure-based screening methods in 
general, naturally depend on the conformation of the protein target. With respect to inhibitors of protein-
protein interactions in particular, a number of examples have been shown to bind concave surface pockets 
that are absent in the corresponding unbound protein structures: these “cryptic” pockets are revealed by 
local conformational changes associated with inhibitor binding (4). In the case of Bcl-2 family members, 
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the protein surface can also adopt a number of different conformations to accommodate ligands with 
radically different shapes and chemical properties (124). 
Variation in the protein structure is most commonly included in virtual screening by first 
generating an ensemble of relevant conformations from crystal structures (92-96) or simulation (97-99), 
and then separately screening against each of these conformations. Nonetheless, identifying the optimal 
conformations to include in these ensembles is still a challenging task (164-166). By preferentially 
exploring conformations that contain a surface pocket suitable for binding some (unspecified) ligand (75), 
the “pocket optimization” approach provides a natural complement to DARC screening. In principle, each 
of these low-energy pocket-containing conformations represents a starting point for screening, and 
capturing the potential diversity of pockets on the protein surface will be essential for fully realizing the 
available diversity of potential inhibitors. 
In our Mcl-1 screen, DARC identified inhibitors both when screening against the peptide-bound 
conformation and when screening against the pocket-optimized conformation. Due to the conformations 
selected for these screens, however, our models did not take advantage of deep pockets that have been 
observed in recent inhibitor-bound crystal structures of Mcl-1 (112-114, 130) (Figure 5c): the particular 
pocket-optimized conformation used in our screen was much more similar to the peptide-bound 
conformation, making these deep pockets unavailable to DARC. Careful analysis showed that similar 
conformations to those observed in the inhibitor-bound crystal structures were indeed represented in the 
ensemble produced by pocket optimization (124), but were not included here because we only screened 
against a single pocket-optimized conformation. In future, then, inclusion of additional pocket-containing 
protein conformations may allow identification of inhibitors that bind more deeply, and exhibit improved 
ligand efficiency. 
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Advantages to structure-based virtual screening 
Enhanced and reliable tools for structure-based virtual screening will enable development of new 
tool compounds, particularly in academic settings where the costs associated with large-scale biochemical 
(or phenotypic) screening can be prohibitive. However, the ability to precisely complement a specific 
surface pocket also makes structure-based virtual screening particularly attractive in a variety of other 
contexts that may prove challenging for traditional biochemical screening. These include building 
“conformation-selective” inhibitors (such as compounds that are sensitive to the phosphorylation state of 
a kinase activation loop (167)), targeting sites that enable unique binding kinetics (such as a newly-
discovered pocket on ERK1/2 (168)), and building allosteric inhibitors that address both the wild-type 
and drug-resistant isoforms of a target (such as BCR-ABL (169) or HIV-1 protease (170)). 
In light of the plasticity of many protein interaction sites (4), these tools may also prove 
particularly useful for designing inhibitors that exhibit specific selectivity profiles. We have shown that 
the activity of a given compound against various members of the Bcl-2 family can be predicted from 
whether or not each protein samples a complementary surface pocket (124). In other words, a given 
compound will inhibit those Bcl-2 family members that include conformations to suitably accommodate 
this compound, but will not inhibit other family members that cannot adopt such conformations. By 
identifying “common” pockets harbored on the surfaces of multiple family members, it may be possible 
to identify inhibitors designed to act against multiple family members (pan-inhibitors). “Pocket 
optimization” simulations also reveal highly unique pockets for each family member, that are sampled by 
one family member but are not accessible to any other family member (124). Thus, DARC’s ability to 
identify ligands that precisely address a given family member’s unique “signature” pockets may also 
provide a means to identify highly selective compounds at a very early stage of development. 
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2.6 Methods 
Detailed descriptions of computational and experimental methods are provided in the 
Supplementary Methods section, along with sample command-lines and instructions for using DARC. 
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3.1 Abstract 
Over the past decade, protein-protein interactions have emerged as attractive but challenging 
targets for therapeutic intervention using small molecules. Due to the relatively flat surfaces that typify 
protein interaction sites, modern virtual screening tools developed for optimal performance against 
“traditional” protein targets perform less well when applied instead at protein interaction sites. Previously, 
we described a docking method specifically catered to the shallow binding modes characteristic of small-
molecule inhibitors of protein interaction sites. This method, called DARC (Docking Approach using Ray 
Casting), operates by comparing the topography of the protein surface when “viewed” from a vantage 
point inside the protein against the topography of a bound ligand when “viewed” from the same vantage 
point. Here, we present five key enhancements to DARC. First, we use multiple vantage points to more 
accurately determine protein-ligand surface complementarity. Second, we describe a new scheme for 
rapidly determining optimal weights in the DARC scoring function. Third, we incorporate sampling of 
ligand conformers “on-the-fly” during docking. Fourth, we move beyond simple shape complementarity 
and introduce a term in the scoring function to capture electrostatic complementarity. Finally, we adjust 
the control flow in our GPU implementation of DARC to achieve greater speedup of these calculations. 
At each step of this study, we evaluate the performance of DARC in a “pose recapitulation” experiment: 
predicting the binding mode of 25 inhibitors each solved in complex with its distinct target protein (a 
protein interaction site). Collectively, we find that the five enhancements described here – which together 
make up DARC 2.0 – lead to dramatically improved speed and performance relative to the original 
DARC method. 
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3.2 Introduction 
Protein-protein interactions underlie most biological processes (171-173), and as such many of 
the individual proteins and networks involved in these interactions are implicated in assorted human 
diseases (174-177). Modulating key protein interactions using small molecules can provide exciting 
opportunities to develop novel therapeutics, leading to extreme interest in this target class for drug 
discovery (4, 178-181). Whereas almost all drugs currently in the clinic inhibit one of several 
“traditional” target classes (G protein-coupled receptors, enzymes, nuclear receptors, transporters, and ion 
channels) (1, 11), protein-protein interactions now stand among a broad new emerging class of “non-
traditional” targets (182, 183). 
Unlike enzymes and other traditional drug targets, protein surfaces evolved to bind other proteins 
typically lack the deep pockets used as small-molecule binding sites (2, 184, 185). Surveys of small-
molecule inhibitors of protein interactions have revealed that these compounds tend be larger and more 
hydrophobic than traditional drug-like molecules, and reside in regions of chemical space that are less 
represented in commercial libraries (78). Analysis of crystal structures of small-molecule inhibitors bound 
at protein interaction sites also reveals that they tend to use shallower binding modes, leading to worse 
ligand efficiency (binding energy per heavyatom) than their counterparts engaging “traditional” targets 
(71). An ancillary pathology of these shallow binding modes is that sterics provide fewer clues for 
correctly docking candidate inhibitors in virtual screens, and accordingly modern virtual screening tools – 
tools that have been optimized over many years for their performance against “traditional” targets – do 
not fare as well when asked to identify compounds active against protein interaction sites (71). 
To address this, we recently developed an alternative screening approach called DARC (Docking 
Approach using Ray-Casting) (186), a docking method specifically for addressing non-traditional targets 
such as protein interaction sites. The DARC approach is summarized schematically in Figure 1. We 
begin by defining the binding pocket around a given “target” residue (or set of “target” residues) on the 
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protein surface, using a pocket-finding algorithm adapted from the LIGSITE program (76) that we have 
implemented in the Rosetta software suite (75). To identify a ligand that complements this pocket, we 
begin by mapping the topography of the pocket by selecting an “origin” point within the protein interior, 
and casting rays from this origin at each of the pocket points that are in contact with the protein surface. 
Operationally, this step is equivalent to simply converting each of the pocket points into a spherical 
coordinate system (ρ,θ,φ) relative to this origin point, where ρ is the distance from the origin point and 
θ/φ are the polar/azimuthal angles. We additionally include in this step a layer of points outside the 
pocket, to help define the pocket’s boundaries. 
If a ligand docked into this surface pocket is indeed shape-complementary, the surface of this 
ligand when “viewed” from this vantage point (the origin) should have a very similar topography to that 
of the pocket. To map the topography of the ligand, we cast a collection of rays from the origin point, 
with each of the angles (θ,φ) used to map the pocket topography. For each ray, we determine the distance 
of its first intersection with the ligand (if indeed the ray intersects the ligand). We express the difference 
in the “observed” surface topographies of the pocket and ligand as follows: 
 
Shapescore=
c1* ρligand − ρpocket( )
c2* ρpocket − ρligand( )
c3
c4
if ρpocket < ρligand
if ρligand < ρpocket
if raydoesnot intersect ligand
if raydoesnot intersect pocket
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Conceptually, each of the four conditions above represents a distinct type of deviation between 
the two surfaces. In the first case (c1), a ray hits the surface pocket before reaching the ligand: this 
indicates underpacking in the protein-ligand interface. In the second case (c2), a ray intersects the ligand 
before reaching the pocket: this indicates that the ligand’s volume overlaps that of the protein, and thus 
points to a steric clash. In the third case (c3), a ray that intersects the pocket does not intersect the ligand 
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at all: this indicates that the ligand is too small for the pocket. Finally, in the fourth case (c4), a ray that 
intersects the ligand does not intersect the pocket: this indicates that the ligand extends outside the 
binding pocket. 
 
 
 
 
Beyond simply evaluating the shape complementary of a protein-ligand complex, this “shape 
score” can also be used as an objective function for optimization. By adjusting the ligand position and 
orientation to minimize this score, one can use DARC to rapidly dock a ligand into a surface pocket. 
Extending the approach further, by sequentially docking a large number of compounds in this manner one 
Figure 1: Schematic illustration of the DARC approach. We begin by using a geometry-based 
method to define the target pocket on the protein surface. Next, we define a series of rays that emanate 
from a vantage point inside the protein. Collectively, the distance at which these rays reach the protein 
surface describes the topography of the protein surface in this region, as “seen” from this vantage 
point. If a bound ligand is complementary to the protein surface, its surface topography will “look” 
similar to that of the protein surface when viewed from this vantage point; in other words, each ray 
will intersect the ligand at similar distance as its intersection with the protein surface. 
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can use DARC to carry out a virtual screen to identify compounds that complement the shape of some 
surface pocket on a protein of interest. 
Previously, we found that DARC could be used in virtual screening benchmarks to pick out 
known small-molecule inhibitors of Bcl-xL and XIAP that were hidden amongst pools of “decoy” 
compounds. Despite its relatively simple implementation, DARC outperformed other popular virtual 
screening tools at this task – tools that have been developed in the context of “traditional” target classes, 
rather than for inhibitors of protein interactions. We then used DARC to carry out a computational screen 
of 65,000 compounds to identify those that would best complement a pocket on the surface of Mcl-1, an 
anti-apoptotic member of the Bcl-2 protein family. We tested the top 21 DARC hits in biochemical 
assays, and found that indeed 10 of these are inhibitors of Mcl-1, with Ki values ranging from 2 to 34 µM 
for the best 6 compounds. Collectively these results validated DARC for virtual screening at protein 
interaction sites, and demonstrated its usefulness for identifying new inhibitors acting at these sites (186). 
We have drawn upon experiences and observations from our early applications of DARC to 
enhance its performance through the five key ways we describe in this study: (1) We refined the ray-
casting approach, such that rays emanate from multiple origin points to better map the shapes of the 
surface pocket and the ligand. (2) We developed a new strategy for parameterizing DARC in a faster and 
more robust way, thus enabling a broader and more representative set of protein complexes to be included 
in training. (3) We introduced a new scheme to efficiently sample small-molecule conformers “on-the-
fly” in a single docking trajectory, rather than sequentially consider each conformer in a separate 
trajectory. (4) We incorporated electrostatics into the DARC scoring function, allowing simultaneous 
optimization of both shape- and electrostatic-complementarity. (5) We identified the computational 
performance bottleneck in our previous implementation of GPU-DARC (77), and adjusted the control 
flow by transferring additional calculations onto the GPU to resolve this bottleneck. 
As described below, these individual enhancements collectively lead to dramatic improvements in 
DARC’s robustness, accuracy, and speed. 
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3.3 Results 
Previously, we assembled a set of unique proteins for which a crystal structure was available in 
complex with a small-molecule inhibitor of a protein-protein interaction site (71). At the time, there were 
21 such structures available; since then, 4 additional examples have become available. For the studies we 
describe here, we make use of this new set of 25 non-redundant complexes in which a small-molecule 
inhibitor is bound at a protein interaction site (Table S1). 
Enhancement #1: ray-casting using multiple origins 
As described above, the topography of the protein surface is mapped from a vantage point inside 
the protein, using an “origin” point from which rays emanate. The placement of this origin point is critical 
to ensuring that the resulting topography map gives an accurate and complete view of the surface pocket – 
in an intuitive sense, it should be centered “behind” the pocket. For an ideal scenario, in which the surface 
pocket is a purely concave “dimple” on the surface of a near-spherical protein, the protein’s center of 
mass can serve as a natural choice for the origin’s location. In practice, however, the pocket shapes are 
never purely concave, and any ruggedness means that some parts of the protein surface cannot be “seen” 
from a given vantage point. An incomplete description of the protein surface, in turn, limits the ability of 
DARC to identify truly complementary ligands. 
In order to map the protein surface topography more accurately, we therefore modified the ray 
casting approach such that rays emanate from multiple origins: we expected this strategy would better 
“illuminate” all regions of the protein surface. To do so, we begin from a single origin centered 30 Å 
behind the pocket (see Methods). Rotating about a point fixed at the pocket center, we move the origin 
point by ±45o in each of two orthogonal directions, to generate four new origin points. In other words, if 
the z-axis connects the first origin to the pocket center, we rotate in first the xz- and then the yz-plane, by 
±45o each time, to place these four additional origins. 
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Figure 2: Ray-casting from multiple origins. (A) In DARC 2.0, rays emanate from five origin points 
instead of from a single origin point. This allows more of the protein surface to be “visible” to the 
rays, and in turn leads to a more complete representation of the surface topography. (B) For each 
protein-ligand complex in our set (Table S1), we used DARC to dock the ligand back into its cognate 
receptor. Multiple ligand conformations were considered in the search, while the receptor 
conformation was held fixed throughout docking. The RMSD of the docked ligand was evaluated 
relative to its position in the crystal structure of the complex. Each point represents a separate 
complex; points above the diagonal are those for which the use of multiple origins led to better pose 
recapitulation. (C) A representative example of a complex that was better-predicted using multiple 
origins (PDB ID 4luz). Part of the binding pocket points directly into the protein (left side of picture), 
and thus directly at the origin (if a single origin is used). The use of multiple origins allows the “walls” 
of this region of the binding pocket to be included in the surface topography considered for docking. 
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As before, the topography of the protein surface is mapped by casting rays at each of the “pocket” 
gridpoints that directly contact the protein. Rather than retain the distances at which rays from all five 
origins hits a given protein surface point, we only store the distance from the closest origin: each origin is 
thus “responsible” only for those regions of the protein surface pocket that are closest to it, and for which 
that origin is therefore likely to have an optimal vantage point (Figure 2a). 
Having mapped the protein surface pocket using rays cast from multiple origins, we then evaluate 
ligand complementarity exactly as described earlier: we simply cast the rays that emanate from each 
origin towards the ligand, and compare the distances at which these intersect with the ligand to the 
distances at which they intersected the protein surface (Equation 1). This strategy for using multiple 
origins does not increase the total number of rays included in DARC’s calculations, but simply distributes 
the same number of rays among the different origins; accordingly, this new approach does not change the 
time required for docking using DARC. 
To examine the effect of using multiple origins, we used DARC to dock each of the 25 protein-
ligand pairs in our test set (Table S1). In each case we used OMEGA (44, 45, 187) to pre-build a set of 
allowed conformations (“conformers”) for each ligand, and included these in docking; the conformation 
of the protein was held fixed throughout each simulation. For each of these 25 protein-ligand cognate 
pairs, we then evaluated the RMSD of the ligand position in the docked complex relative to its position in 
the corresponding crystal structure. 
We also carried out this “pose recapitulation” experiment using the previously described version 
of DARC (186), which only employed a single origin, and compared the results to those obtained using 
this new “multiple origins” approach (Figure 2b). We find that the RMSD relative to the crystal structure 
is better in 16 of the 25 cases (points above the diagonal), suggesting that the use of multiple origins may 
indeed enable more accurate matching of protein/ligand shape complementarity. Because the 25 
complexes in our set represent paired samples (and are not expected to be normally distributed), we 
employed the (non-parametric and paired) Wilcoxon signed-rank test (see Methods) to compare the 
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results from single versus multiple origins. While this test does identify the difference in performance, it 
does not quite achieve statistical significance (p < 0.054) due to the relatively small size of the test set 
(which, in turn, stems from the fact that few examples of crystal structures of small-molecule inhibitors of 
protein-protein interactions solved in complex with their target proteins are available). 
We note that before inclusion of this new feature in DARC, only one complex in our set was 
docked to within 2 Å RMSD of the crystal structure; using multiple origins, there are now three such 
cases. Examination of the crystallographic complexes for these improved cases reveals that many share a 
binding mode in which the ligand (or part of the ligand) faces directly into the protein (Figure 2c). In 
such cases, rays cast from a single origin would have described only the very bottom of this well; in 
contrast, the use of multiple origins allow the topography of the walls of this well to also be included, and 
thus allow the ligand to be more accurately matched to the contours of the protein surface. 
Enhancement #2: fast and robust weight fitting 
There are four parameters (c1/c2/c3/c4) used by DARC when evaluating shape complementarity 
(Equation 1). Since scaling all four of these by a constant would simply scale the total score, we fix 
c1=1.0 and determine values of the other three parameters accordingly. 
In our original parameterization of DARC (186), we used a small training set of seven protein-
ligand complexes to optimize these weights. We sought to identify the combination of weights that would 
optimally allow each of these seven ligands to be docked back into its cognate receptor such that they 
would match the crystal structures of these complexes. For a given set of weights, then, we assessed 
performance by using DARC to dock these seven pairs, and used the sum of the resulting seven ligand 
RMSDs as our objective function. We used simplex optimization to drive our search of parameter space, 
but each evaluation of this objective function required seven separate calls to Rosetta to carry out the 
required docking. As a result, carrying out this weight fitting procedure typically required about a week of 
computation on a modern CPU. Since we originally carried out this parameterization, additional crystal 
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structures of small-molecule inhibitors of protein interactions in complex with their targets have become 
available; however, our parameterization scheme was already too slow to feasibly add these new 
examples. 
 
 
 
Figure 3: Updated weight-fitting strategy. (A) Schematic illustrating the strategy used in DARC 2.0 
for determining values of the weights that should be applied to the terms in the DARC scoring 
function (Equation 1). For each complex used in training (Table S1), we generate a large set of 
docked complexes involving either the cognate “native” ligand (orange/magenta) or one of many 
“decoy” ligands (green). Using the component energies in these complexes, we identify the set of 
weights that optimally ranks the native ligands ahead of the “decoys”. (B) For each protein-ligand 
complex in our set, we used DARC to dock the ligand back into its cognate receptor using either the 
original DARC weights or the newer weights derived though the approach described here. In the latter 
case, leave-one-out cross-validation was used to ensure the weights were not overfit to the training set. 
Each point represents a separate complex; points above the diagonal are those for which the new 
weights led to better pose recapitulation. 
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To speed up weight fitting, we adapted our approach such that explicit docking at every step 
would no longer be required. We also took this opportunity to parameterize DARC not for its ability to 
simply recapitulate the bound pose of a known ligand, but rather for its ability to optimally distinguish a 
known ligand from among a pool of “decoy” compounds. The latter represents a virtual screening 
scenario, such that the resulting weights may exhibit improved performance for this task. 
We started by first reformulating DARC’s shape complementarity score as follows: 
Shapescore=c1* ρligand − ρpocket
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Relative to our previous formulation (Equation 1), we have simply gathered together the groups 
of rays that meet each one of the four conditions. This is a natural reformulation of this equation, since the 
four weights each apply to one of these four conditions. 
We again turned to our non-redundant set of 25 complexes in which a small-molecule inhibitor is 
bound at a protein interaction site (Table S1); to setup our optimization as a virtual screening problem, 
we built a “compound library” of 650 diverse decoy ligands, and generated 1000 randomly docked poses 
for each compound with each protein in this set. 
The key to the reformulation of DARC’s shape complementarity score above (Equation 2) is that 
the result of ray-casting can be separated from the weights: for a given pose we can pre-compute (and 
store) each of the summations over the rays that meet each of the four conditions. Given some new set of 
weights, we can then apply these four weights to the four stored numbers and trivially update the score of 
the pose with these new weights. 
Collectively, we generated more than 16 million “decoy poses” (25 proteins x 650 ligands x 1000 
randomly docked poses for each protein-ligand combination). Rather than store these decoy poses 
explicitly, we instead simply stored the four “component energies” (the unweighted terms in Equation 2) 
for each decoy pose. Similarly, we pre-computed and stored the four “component energies” for each of 
the 25 native poses. 
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Using this data as input, we then carried out weight fitting as shown in Figure 3a. We used 
simplex optimization (as implemented in the GSL multidimensional minimization library (188)) to search 
parameter space. At every step, we updated the DARC score for each (decoy and native) complex using 
the new weights; for each protein target, we then determined the rank of the native pose relative to each 
of the 650,000 decoy poses involving this protein. As the objective function for this minimization, we 
used the sum of the ranks of the 25 native poses. 
This approach to fitting weights required far fewer computational resources than our previous 
approach; this optimization (using pre-computed component scores) was typically completed in minutes 
(it took under a minute to run 100 iterations). To objectively examine the performance that could be 
expected from the weights obtained by this method, we used leave-one-out cross-validation. For each of 
the 25 proteins in our test set, we developed a unique set of weights trained only on the other 24 proteins; 
we then used this custom weight set to dock the native ligand of interest back into its cognate receptor, 
and evaluated the ligand RMSD relative to the crystal structure of this protein-ligand complex. 
We compared the RMSD of these 25 DARC-docked examples, using our previous DARC 
weights (186) or using the leave-one-out cross-validated weights from our new approach. We note that 
results from the earlier weight-fitting approach were not subjected to cross-validation, due to the large 
computational requirements that would be associated with building numerous “custom” weight sets. We 
further note that the newer weights are not explicitly trained for docking native complexes, but rather for 
discrimination in virtual screening tasks. Nonetheless, we find that the newer weight set proves far 
superior to the original weights (Figure 3b): the ligand RMSD is lower for 17 of the 25 complexes when 
using the newer weights (points above the diagonal). Further, the newer weights perform exceptionally 
well in a number of testcases: there are now 8 examples for which the RMSD was less than 2 Å using the 
new weights, whereas this level of accuracy was only achieved in 3 cases using the older weights. 
Applying the Wilcoxon signed-rank test to compare the differences in RMSD associated with changing 
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the weights (see Methods) also detects this difference in performance, albeit not quite at a level achieving 
statistical significance (p < 0.051). 
We attribute this improvement to the robustness of the newer weight set, which derives from 
training on a larger and more broadly representative set of examples; the previous weight set may have 
been over-fitted to the seven examples in the training set upon which it was based. This is a particularly 
encouraging outlook in light of the intended use for these weights: they may be far-better suited for 
virtual screening than the previous weights, since robust tools for this task will require the ability to 
rapidly and accurately evaluate many diverse ligands (and ideally should prove applicable for diverse 
protein targets as well). 
Enhancement #3: sampling ligand conformers “on-the-fly” 
Efficiently sampling the potential positions, orientations, and conformations of each compound is 
critical to virtual screening. As the size of “purchasable” chemical space continues to increase (189), and 
these compounds continue to be a useful for populating in silico libraries, the speed of virtual screening is 
likely to be of paramount importance for the foreseeable future. It is important to note that the speed of 
modern docking approaches generally scale not only with the size of the screening library, but also with 
the number of conformations considered for an average ligand in the library. 
Modern docking / virtual screening tools address the problem of ligand conformational sampling 
in different ways. Some programs, such as FRED, pre-generate a collection of low-energy ligand 
conformations (“conformers”), then sample each of these individually in separate docking trajectories 
(190). Other programs, such as AutoDock, generate ligand conformers and evaluate their energy in situ 
during docking (85). In the DOCK6 program, ligand conformations can either be generated in situ during 
docking with “anchor-and-grow” incremental construction, or alternatively a set of rigid conformers can 
be pre-generated and screened sequentially (38, 83). In the original implementation of DARC, no 
allowance was made for ligand flexibility; alternate ligand conformations were considered by sequentially 
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docking pre-generated conformers, and the best-scoring member of the resulting set was taken to be the 
final predicted pose (186). 
DARC makes use of particle swarm optimization (PSO) (191) to minimize its objective function 
by varying the ligand’s position and orientation. PSO is a population-based optimization method that 
mimics swarm intelligence and applies a heuristic approach to find an optimal solution (192). Others have 
also used variants of PSO as a fast and efficient optimization method for protein-ligand docking (193-
195). In the case of DARC, we set up the optimization problem such that the displacement and rotation 
relative to some “reference” position of the ligand are the six degrees of freedom included in the search. 
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To increase the efficiency of our sampling, we adapted our approach such that the set of 
(pre-generated) conformers would instead be considered on-the-fly during docking (Figure 4a). We 
reasoned that not every conformer deserved an equal amount of sampling; by focusing more of our 
sampling on the top-scoring conformers, the overall time needed for docking a given compound could be 
reduced. To achieve this, we introduced a seventh degree of freedom in our search: the “conformer 
index.” 
At the start of the simulation, we assigned each of the pre-generated conformers a unique index. 
During the PSO, seven parameters would be included in the optimization: one to indicate which ligand 
conformation should be used, and six to transform the atoms of this ligand to the appropriate position and 
orientation with respect to the protein. This approach is particularly suited to PSO optimization, which 
simultaneously maintains multiple solutions (“particles”) during a docking trajectory; separate 
Figure 4: Screening ligand conformers “on-the-fly” during docking. (A) Previously, ligand 
conformations were docked sequentially through separate docking trajectories, and the ligand 
conformation was ultimately drawn from the best-scoring complex. In DARC 2.0, we instead sample 
ligand conformers during the docking trajectory. (B) Due to the extra degree of freedom associated 
with a single docking trajectory, docking converges more slowly when conformers are sampled “on-
the-fly”. Here, convergence is evaluated by the score difference relative to a “gold standard” (best 
achievable score) for each complex; the results shown are averaged over the 25 complexes in our test 
set (Table S1). For each point in this plot, the number of particles in PSO optimization and the number 
of steps in the docking trajectory were set equal to one another. (C) Despite the fact that individual 
trajectories converge more slowly when conformers are sampled “on-the-fly”, docking is comprised of 
only a single trajectory. Across our set of 25 complexes, this ultimately makes “on-the-fly” sampling 
an average of 18-fold faster than sampling conformers sequentially through multiple docking 
trajectories. 
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populations that make use of different “promising” conformers can each explore their own local clusters 
of solution space, whereas conformers that are not used in any productive poses are sampled less 
frequently. This, in turn, could reduce the overall time required to run the optimization. 
Given that the search space for a given trajectory is now much larger (there is an extra degree of 
freedom), we anticipated that using “on-the-fly” conformer sampling would lead to slower convergence 
than a trajectory in which only a single conformer was considered. To test this, we first used “sequential” 
conformer docking with very intensive sampling (1000 particles and 1000 steps) to identify the optimal 
score that could be obtained when docking the native ligand back into its cognate receptor, for each of the 
25 complexes in our set (Table S1). Next, to assess convergence, we asked how closely the scores for 
each complex would approach these “gold standard” scores as the amount of sampling was reduced by 
simultaneously lowering the number of particles and steps in the search. 
As expected, we indeed find that convergence to near-optimal solutions occurs more slowly with 
“on-the-fly” sampling instead of sequential sampling (Figure 4b). Whereas the optimal solutions are 
obtained using only 300 particles / 300 steps of sequential sampling, 600 particles / 600 steps were 
required for convergence when using sampling “on-the-fly”. Despite the need for more sampling per 
trajectory, however, the advantage of on-the-fly sampling lies in the fact that only a single trajectory is 
needed. Since we use an average of 163 conformers for the ligands in our test set (Table S1), and 
sequential sampling requires that a separate trajectory be carried out for each conformer, the average 
runtime for sequential sampling is much longer (Figure 4c). Comparing the runtime required for 
equivalent sampling (300 particles / 300 steps of sequential sampling versus 600 particles / 600 steps of 
on-the-fly sampling), we find that on average an 18-fold speedup is achieved when on-the-fly conformer 
sampling is used. 
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Enhancement #4: inclusion of electrostatic complementarity 
Complementarity between a ligand and its binding pocket on the protein surface is the guiding 
principle in protein-ligand docking, and the success of DARC to date is based on this fundamental 
principle. In its original inception, DARC was purely based on optimizing and identifying shape 
complementarity between the surface of the ligand and the surface of the protein (186). In addition to 
shape complementarity, however, the chemical complementarity of the interacting surfaces is clearly 
essential for protein-ligand recognition. In addition to the well-established electrostatic complementarity 
between evolved protein-protein binding partners (196, 197), it has more recently been recognized that 
small-molecule inhibitors of protein-protein interactions sometimes (inadvertently) mimic the 
electrostatic patterning of the natural binding partner, in order to optimally complement the charge 
distribution presented by the surface of the target protein (198). 
Of course, other docking methods recognize the importance of electrostatic complementarity, and 
include its contribution through various approaches. Since most virtual screening tools do not incorporate 
receptor flexibility during docking, typical modern approaches pre-generate an “electrostatic grid map”, 
and use this to calculate the electrostatic interaction energy given the position of the ligand. Broadly 
speaking, this is strategy utilized in both AutoDock4 (through AutoGrid) (85, 199) and the DOCK suite 
(83, 200). 
While DARC was originally predicated on matching the surface shapes of the ligand and the 
protein surface, we quickly noted (by inspection of mis-docked structures) that a number of ligands 
exhibited pseudo-symmetry when examined purely on the basis of their shapes. In other words, docking 
without consideration of chemical complementarity very quickly highlighted the limitations of docking 
on the basis of shape complementarity alone. 
To address this, we built into DARC the ability to capture electrostatic complementarity using the 
most common approach employed by other modern docking tools. Given the (fixed) receptor 
conformation, we solve the Poisson-Boltzmann equation to calculate the electrostatic potential at a series 
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of gridpoints that span the surface pocket of interest (Figure 5a). For convenience and speed, here we 
used the finite difference Poisson-Boltzmann solver included in OpenEye’s ZAP toolkit (201) for this 
task (see Methods). 
 
 
 
 
 
 
 
Figure 5: Incorporation of electrostatic complementarity into DARC 2.0. (A) The electrostatic 
potential is evaluated at a series of grid points over the whole protein using the finite difference 
Poisson-Boltzmann solver included in OpenEye’s ZAP toolkit. We use trilinear interpolation of the 
closest gridpoints to determine the electrostatic potential at points corresponding to locations of ligand 
atoms, and then use the ligand partial charges to compute the electrostatic interaction energy 
(Equation 3). (B) For each protein-ligand complex in our set (Table S1), we used DARC to dock the 
ligand back into its cognate receptor either with or without including the electrostatic complementarity 
term. In both cases, leave-one-out cross-validation was used to ensure the weights were not overfit to 
the training set. Each point represents a separate complex; points above the diagonal are those for 
which inclusion of electrostatics led to better pose recapitulation. 
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Given the electrostatic potential, we evaluate the electrostatic complementarity by summing over 
atomic partial charges in the traditional manner as follows: 
   Electrostatics score= qiφ i
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To determine the electrostatic potential (ϕi) at the location of a given ligand atom (i), we use 
trilinear interpolation of the closest gridpoints that encapsulate the center of the atom. Atomic partial 
charges (qi) for the ligand were determined using the “molcharge” program from OpenEye (see Methods). 
To ensure the ligand remained within the bounds of the protein surface pocket, we set the electrostatic 
potential to zero in the protein interior, and applied an unfavorable value of the electrostatic potential 
outside the defined binding site (+100 DARC units • C-1). 
We then used the strategy described above (Enhancement #2) to develop a new set of weights for 
DARC, this time including electrostatic complementarity as follows: 
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Critically, we note that the same reformulation that enabled the weight-fitting strategy described 
earlier (decoupling the energetic contributions from their weights) applies equally well here; this allowed 
us to use the same approach to derive a new set of weights that includes this electrostatic term. For the 
results presented below, we again used the same leave-one-out cross-validation described earlier. 
As we had done after each of the previous enhancements, we returned to the 25 complexes in our 
test set (Table S1), and used this latest iteration of DARC to dock multiple conformations of each ligand 
against its cognate protein partner (Figure 5b). Previously, on the basis of shape alone, we found that the 
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RMSD of the docked ligand relative to the crystal structure was less than 2 Å in 8 cases. Upon inclusion 
of electrostatics, 7 of these remain “correctly docked” while the RMSD in one case increases above 2 Å. 
Of the cases that were not previously docked to within 2 Å RMSD, however, five new complexes were 
now “correctly docked” upon inclusion of this electrostatics term (for a total of 12 such cases). Applying 
the Wilcoxon signed-rank test to compare the differences in RMSD associated with inclusion of 
electrostatics (see Methods), the improvement is detected but again does not reach statistical significance 
(p < 0.156) due to the modest size of our test set. 
Enhancement #5: improved implementation for GPU computing 
The fact that graphics processing units (GPUs) were originally designed to process multithreaded 
3D graphics through ray-tracing makes them extremely well-suited for the ray-casting that underlies 
DARC. Previously, we adapted DARC such that the ray-casting step would be carried out on the GPU; 
meanwhile, the central processing unit (CPU) would be responsible for updating the ligand coordinates 
and repeatedly passing these to the GPU. This GPU implementation proved extremely useful, because it 
led to a speedup of about 27-fold in typical-use cases, as compared to the time required to carry out the 
analogous calculations using the CPU alone (77). 
Upon more recent examination of the speedup observed when carrying out various calculations in 
DARC, we found that the size of the ligand and the number of particles both contributed to the bottleneck 
in the speedup that could be achieved. As noted earlier, DARC uses particle swarm minimization to 
optimize the ligand’s displacement and rotation (and now the “conformer index” as well, for on-the-fly 
sampling) relative to a saved “reference” position. While the ray-casting step was taking place on the 
GPU, applying the transformation to translate and rotate the ligand to its new coordinates was carried out 
on the CPU, and was required for every particle (at every step of the docking trajectory). Our 
observations of the scaling with respect to ligand size and number of particles led us to hypothesize that 
the performance bottleneck in the GPU-enabled calculation was either due to the time required for the 
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CPU to apply the appropriate transformation to every ligand atom of every particle, or because of the 
amount of data transferred from the CPU to the GPU. 
To address this bottleneck, we devised a new scheme for splitting control flow between the CPU 
and the GPU (Figure 6a). During setup, our new approach stores the “reference” position of each ligand 
conformer on the GPU. At each step of a docking trajectory, we previously passed from the CPU to the 
GPU a message obtained by “unpacking” the information in each particle (the coordinates of each ligand 
atom for that particle); now, we instead pass only the seven numbers stored in each particle: the 
conformer index (1 number), the displacement that must be applied to the ligand’s reference conformation 
(3 numbers), and the rotation that must be applied to the ligand’s reference conformation (3 numbers). In 
addition to reducing the amount of information transferred, this also allows the transformations of the 
ligand coordinates to be carried out on the GPU in a highly parallel fashion (instead of carrying out this 
step sequentially on the CPU). 
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To evaluate the speedup achieved by this new strategy we determined the time needed for 
docking each of the 25 complexes in our test set (Table S1), either using a CPU alone or using GPU-
enabled DARC (Figure 6b). Unsurprisingly, we find that the ratio of the runtimes (the “speedup factor”) 
differs for the complexes in our set: the size and shapes of the pockets differ (causing the number of rays 
to differ), and the ligand sizes differ. Nonetheless, on average we observe a 90-fold speedup when 
running on the GPU – about three times faster than our original GPU implementation. This result 
confirms our identification of the previous performance bottleneck, which has been successfully 
overcome through this new CPU/GPU control scheme. 
Our scheme also proved naturally amenable for using the GPU to calculate the electrostatic part 
of the DARC score as well (Figure 6a): at setup, we simply store the electrostatic potential grid on the 
GPU, and use the atomic positions of the ligand to compute the electrostatic score as described earlier 
(Equation 3). This part of the calculation also benefits tremendously from GPU parallelization: when 
electrostatic complementarity is included in the calculation, the average speedup of GPU-enabled DARC 
(relative to the analogous calculation on CPU alone) reaches 190-fold (Figure 6c). 
Figure 6: Updated GPU control flow. (A) Schematic illustration of CPU-GPU control flow in 
DARC 2.0. Previously, the ligand conformation was generated on the CPU and passed to the GPU; 
now, the conformer index / displacement / rotation (relative to a “reference” position) is instead 
passed, and the GPU is responsible for applying this transformation to the ligand’s atomic coordinates. 
The new electrostatic complementarity term is also computed entirely on the GPU. (B) For each 
protein-ligand complex in our set (Table S1), we timed DARC when docking the ligand back into its 
cognate receptor, using either GPU+CPU or CPU alone. We find an average speedup of 90-fold when 
using the GPU (red line), an improvement over the 27-fold speedup we achieved in our original GPU 
implementation of DARC. (C) The GPU led to an even greater speedup over the analogous calculation 
on the CPU when electrostatic complementarity was included in both calculations (190-fold speedup). 
 
 
91 
3.4 Discussion 
Here, we present a number of enhancements to the robustness, speed and accuracy of DARC; 
each enhancement builds upon the previous one. These include introduction of multiple origins from 
which rays can emanate, a new scheme for rapidly determining optimal weights in the scoring function, 
the ability to rapidly screen conformers “on-the-fly” during docking, inclusion of electrostatic 
complementarity in the scoring function, and improved control flow for GPU computing. As a result of 
the linear narrative by which we have describe these enhancements, however, the overall improvement 
from this collection of improvements is less apparent. In Figure 7, we therefore re-plot the results of our 
docking experiment such that we compare the results from this latest, fully-enhanced version of DARC – 
which we call “DARC 2.0” – against the iteration of DARC described in our previous work (186) 
(“DARC 1.0”) that marked the starting point for the current study. Whereas our starting version of DARC 
docked only one of the ligands in our test set to within 2 Å RMSD of its position in the crystal structure, 
“DARC 2.0” achieves this level of accuracy for 12 of the 25 complexes. The dramatic improvement in the 
RMSD of these docked complexes is reflected through the Wilcoxon signed-rank test, which confirms a 
statistically significant performance improvement from these collective enhancements (p < 0.001). 
 
The ability to achieve such a dramatic improvement in DARC 2.0 relative to DARC 1.0 is 
striking in part due to the success of DARC 1.0 for virtual screening. As noted earlier, our initial 
deployment of DARC in a screen against Mcl-1 allowed us to identify 6 new inhibitors with Ki values 
better than 35 µM (186); given that we tested 21 compounds suggested by DARC, this corresponded to a 
success rate of 29% at this potency cutoff. In retrospect, the unimpressive performance of DARC for pose 
recapitulation did not foretell poor performance in this seemingly more challenging arena, because in fact 
virtual screening is – in many ways – an easier task. 
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Figure 7: Summary of the collective effect of enhancements to DARC described here. For each 
protein-ligand complex in our set (Table S1), we used DARC to dock the ligand back into its cognate 
receptor. Here we compare performance of DARC before the enhancements described in this work 
(“DARC 1.0”), to its current performance (“DARC 2.0”). Each point represents a separate complex; 
points above the diagonal are those for which the use of multiple origins led to better pose 
recapitulation. Previously, only one ligand (of 25) was docked to within 2 Å RMSD of its position in 
the crystal structure; in contrast, “DARC 2.0” now achieves this level of accuracy in 12 cases. 
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In a virtual screening experiment, two types of errors can limit performance: false negatives 
(compounds that do not receive a high ranking, though they are in fact active) and false positives 
(compounds predicted to be active that are not actually active). In practice, as long as some hits are 
identified then a screening campaign is considered successful: missing out on additional active 
compounds in the library does not detract from this success. In other words, provided that the number of 
“true” hits in a library is not exceedingly small, false positives limit the perceived performance of virtual 
screening much more than false negatives. This is deceptive in some ways, however, since these 
additional hit compounds that were (incorrectly) excluded may have superior potency than the 
compounds that were ultimately prioritized for further characterization (i.e. in “wetlab” assays). 
In a pose recapitulation benchmark, such as the one used in this study, the ligand to be used for 
each testcase is pre-determined, and there is a single “right answer” (i.e. the bound pose from the crystal 
structure). This is a far more stringent test than a virtual screen; when screening, failing to correctly dock 
an individual (active) compound from the library would simply lead to exclusion of this compound from 
among the hits (a false negative), and would go unnoticed. 
In retrospect, DARC 1.0 exhibited impressive performance for virtual screening because a 
number of active compounds were identified – but many other compounds more potent than those we 
chose to characterize may have been present in our library. Because of the improved performance 
demonstrated by DARC 2.0 in pose recapitulation, we anticipate fewer false negatives in screening 
applications – leading, in turn, to improved potency of initial screening hits from DARC 2.0 relative to 
DARC 1.0. 
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3.5 Methods 
Implementation in Rosetta 
DARC is implemented as part of the Rosetta macromolecular modeling suite (60). Rosetta is 
freely available for academic use (www.rosettacommons.org), with the new features described here 
included in official releases 2015.05 and beyond. The Protocol Capture accompanying this manuscript 
(Dataset S1) contains all the commands required for running DARC, including sample input and output 
files. All results reported here were generated using git revision 011e012 of the master source code. 
Running DARC with Rosetta (no electrostatics) 
Running DARC within Rosetta is a two-step process: first generating the ray file, and second 
docking with DARC. 
In the first step we generate the protein surface pocket and map the shape of the pocket shell 
(points in direct contact with the protein) to a spherical coordinate file; we call this a “ray-file”. To 
generate this ray-file we need to input the protein (in PDB format), and specify one or more target 
residue(s). The command to run DARC is as follows: 
Rosetta/main/source/bin/make_ray_files.macosclangrelease -protein 
4ERF.pdb 
-central_relax_pdb_num 54,99 
 
To use multiple origins, we use: 
Rosetta/main/source/bin/make_ray_files.macosclangrelease -protein 
4ERF.pdb 
-central_relax_pdb_num 54,99 –multiple_origin 
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In the second step, we are actually running the docking calculations using the pre-generated 
ray-file. Here we give the input ligand(s) for screening against the ray-file, as follows: 
Rosetta/main/source/bin/DARC.macosclangrelease -protein 4ERF.pdb -ligand 0R3_0001.pdb 
-extra_res_fa 0R3.params -ray_file eggshell_rosetta_4ERF_54,99.txt 
 
To search conformers on-the-fly: 
Rosetta/main/source/bin/DARC.macosclangrelease -protein 4ERF.pdb -ligand 
0R3_0001.pdb 
-extra_res_fa 0R3.params -ray_file eggshell_rosetta_4ERF_54,99.txt 
–search_conformers true 
 
Rather than center the pocket grid at the target residue(s), we can instead center it using a bound 
ligand (primarily for benchmarking purposes): 
Rosetta/main/source/bin/make_ray_files.macosclangrelease -protein 
4ERF.pdb 
-central_relax_pdb_num 54,99 -bound_ligand 0R3_0001.pdb 
-extra_res_fa 0R3.params –lig_grid 
 
The output of the DARC run is a docked model of the protein-ligand complex; in this case it 
would be named “DARC_4ERF_0R3.pdb” 
Fullatom minimization in Rosetta 
Fullatom minimization of the DARC models can either be carried out separately in Rosetta, or 
immediately after completion of the DARC. To minimize the DARC models immediately after docking 
we add the flag “-minimize_output_complex” as follows: 
Rosetta/main/source/bin/DARC.macosclangrelease -protein 4ERF.pdb -ligand 
0R3_0001.pdb 
-extra_res_fa 0R3.params -ray_file eggshell_rosetta_4ERF_54,99.txt 
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–minimize_output_complex 
 
This gives an additional output file named “mini_4ERF_0R3.pdb”. 
 
Other optional flags to use when running DARC include: 
-origin_cutoff 9 -atom_radius_scale 0.9 -num_particles 100 -num_runs 100 
-missing_point_weight 13.3 -steric_weight 3.12 -extra_point_weight 8.13 
–esp_weight 0.03 –use_connolly_surface  
Multiple origin points 
Whether using a single origin or multiple origins, we begin by placing the first origin point (O1) 
at a distance 30 Å from the center of the pocket, and at a location centered “behind” the pocket. When 
using a single origin, we noted that the location of the origin is key for suitably defining the topography 
of the protein surface. The protein center of mass can work well for globular proteins, but can be “off-
center” for many proteins that are not nearly-spherical. Below we describe several ways to define O1: 
their applicability depends in part on the geometry of the pocket itself. We note, however, that the use of 
multiple origins provides more robust results with respect to the location of O1. 
As a first step, the user can choose whether O1 should simply be placed in the direction of the 
protein’s center of mass (this is default). If so, we place O1 30 Å away from the center of the pocket (P) 
along the P→Q direction, where Q is the center of the protein. If not, we offer three distinct methods to 
set O1: (1) We make use of the fact that pockets at protein-interaction sites are broad and flat, and thus we 
find the plane that best fits the pocket points (by minimizing the least-squares distance of points to the 
plane). We then place O1 along the normal to the plane passing through P, so that distance P–O1 = 30 Å, 
yielding two solutions (one “above” the plane of the pocket and one “below” the plane of the pocket). We 
then select the solution for which the O1–Q distance is less (i.e. the rays will emanate from within the 
protein rather than from far above the pocket). (2) Alternatively, for pockets that are deeper and narrower, 
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we define a series of vectors si, each of which defines the distance and direction from the ith surface point 
to P. We then carry out a vector summation of all these vectors si, such that we determine the direction of 
the pocket which most faces away from solvent. We place O1 in this direction at a distance of 30 Å. 
(3) Finally, we offer the user fine control over the location of the origin by placing O1 30 Å away from P 
along the P→R direction, where R is a user-specified residue. 
Once O1 is defined, four more origin points (O2–O5) are then defined. We add O2–O5 as follows: 
O2 and O3 are obtained by rotating O1 by ±45°  around vector w=u×v, where u is the vector from P to O1, 
v is the vector from P to a randomly chosen point, and × denotes vector product; O4 and O5 are obtained 
by rotating O1 by ±45°  around vector z=u×w. 
Electrostatic potential grid 
To prepare the protein, we begin by using Rosetta to fill in any missing atomic coordinates and 
add hydrogen atoms. We then use OpenEye’s “molcharge” program to add amber99 partial charges to 
each atom. 
To generate the electrostatic potential grid, we use OpenEye’s ZAP toolkit (201) (a finite 
difference Poisson-Boltzmann solver). We use 0.5 Å grid spacing, with 1.0 and 80.0 for the inner and 
outer dielectrics, and 2 Å distance as buffer between the molecule and the edge of the grid. Once we 
obtain the electrostatic potential grid that encompasses the whole protein, we extract from this a smaller 
grid that matches the dimensions of the “pocket grid” used for ray-casting (this also matches the bounds 
of the search space during the docking runs). To avoid extreme values that occur at certain grid points 
(i.e. very close to a charged atom) during docking, we set the maximum/minimum possible value of the 
electrostatic potential at each point to ±10 kT/e. 
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Running DARC with Rosetta (including electrostatics) 
To include electrostatics, we first resize the electrostatic potential grid (generated as described 
above) to match the size of the interface pocket grid. This step can be carried out while generating the ray 
file: 
Rosetta/main/source/bin/make_ray_files.macosclangrelease -protein 
4ERF.pdb 
-central_relax_pdb_num 54,99 -bound_ligand 0R3_0001.pdb 
-add_electrostatics –espGrid_file 4ERF.agd -extra_res_fa 
0R3.params 
 
The output from this command will be a ray-file named “eggshell_4ERF_54,99.txt” and an 
electrostatic potential grid file named “DARC_4ERF.agd” which we will use as input for running docking 
using DARC. 
Then we call DARC for running the docking calculations using the pre-generated ray-file and 
corresponding electrostatic potential grid as follows: 
Rosetta/main/source/bin/DARC.macosclangrelease -protein 4ERF.pdb -ligand 
0R3_0001.pdb 
-extra_res_fa 0R3.params -ray_file eggshell_rosetta_4ERF_54,99.txt 
 
To include electrostatics score: 
Rosetta/main/source/bin/DARC.macosclangrelease -protein 4ERF.pdb -ligand 
0R3_0001.pdb 
-extra_res_fa 0R3.params -ray_file eggshell_rosetta_4ERF_54,99.txt 
–add_electrostatics -espGrid_file DARC_4ERF.agd 
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Generating conformers 
For each ligand in our test set, we used the OMEGA software (44, 45, 187) to generate up to 300 
conformers, using default parameters. The number of conformers used for each ligand in our study is 
reported in Table S1 (these depend on the number of rotatable bonds and the ligand’s geometry). 
Statistical analysis 
The statistical significance of the comparisons presented here was evaluated using Wilcoxon 
signed-rank test, as implemented in the R statistical computing environment (202). 
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4.1 Abstract 
RNA-binding proteins (RBPs) are key regulators of post-transcriptional gene expression, and 
underlie many important biological processes. Here, we develop a strategy that entails extracting a 
“hotspot pharmacophore” from the structure of a protein-RNA complex, and using this as a template for 
designing small-molecule inhibitors. With this approach we first target Musashi-1, a stem-cell marker that 
is upregulated in many cancers. We design and synthesize novel inhibitors that are active in biochemical 
and cell-based assays against Musashi-1, and then demonstrate how these inhibitors can be used as tool 
compounds to probe the activity of close homolog Musashi-2. This study extends the paradigm of 
“hotspots” from protein-protein complexes to protein-RNA complexes, supports the “druggability” of 
RNA-binding protein surfaces, and represents the first rationally-designed inhibitors of non-enzymatic 
RNA-binding proteins. Owing to its simplicity and generality, we anticipate that this approach may also 
be used to develop inhibitors of many other RNA-binding proteins. 
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4.2 Introduction 
RNA-binding proteins (RBPs) play crucial roles in many diverse cellular processes. They 
regulate the life cycle of mRNAs by controlling splicing, polyadenylation, stability, localization and 
translation, and also modulate function of non-coding RNAs (8). Mammalian proteomes are thought to 
include upwards of 800 RBPs (203, 204), corresponding to both RNA-processing enzymes and non-
enzymatic RNA-binding proteins. In light of the broad range of functions carried out by RBPs, the goal of 
this study is to devise a general and robust strategy for designing chemical tools that will allow precise 
manipulation of the interactions between RBPs and their cognate RNAs. We expect that such tools will 
help unravel the mechanisms of important biological processes controlled by RBPs, and may also serve as 
a starting point to validate RBPs as targets for therapeutic intervention (205-207). 
To date, there exist few classes of compounds that target protein-RNA interactions. Inhibitors of 
certain RBPs have been identified via high throughput screening (208, 209), including one series from 
virtual screening that competes with double-stranded RNA for binding to toll-like receptor 3 (210), and a 
number of compounds have been reported that disrupt binding by interacting with the RNA rather than 
with the RBP (211, 212). Among rationally designed small-molecule inhibitors that target RBPs, 
however, all examples reported to date can be categorized into two general classes. The first class 
comprises nucleoside analogues (213-216), such as anti-HIV-1 NRTIs, that mimic the chemical structures 
of natural-occurring nucleosides and rely on enzymatic processing by their targets to form covalent 
adducts (10). While nucleoside analogues can be straightforward to design, the inability of these 
molecules to provide sufficient binding affinity or selectivity without covalent linkage has prevented this 
strategy from being extended to non-enzymatic RBPs. The second class of compounds comprises 
allosteric inhibitors (216, 217), such as anti-HIV-1 NNRTIs, that bind to secondary sites on the protein 
target and shift its conformation to an inactive state (218). In principle, allosteric inhibitors could be used 
to target both enzymatic and non-enzymatic RBPs; in practice, however, challenges associated with both 
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identifying allosteric sites and then finding small molecules to complement these sites has limited the 
general utility of this approach to all but a few cases. Collectively, the fact that these RNA-binding 
protein surfaces are not thought to have evolved to bind small molecules makes them a “non-traditional” 
class of drug target. Moreover, the relatively flat and polar nature of protein surfaces in this class typically 
leads to poor performance by structure-based virtual screening (docking) approaches (71), and given the 
lack of a known small-molecule binding partner it is even unclear a priori that such protein surfaces are 
suitable for inhibition by any small-molecule ligand at all (14). 
Here, we present a new approach for rationally designing small-molecule inhibitors of RBPs. We 
draw inspiration from a related class of “non-traditional” drug targets, protein-protein interfaces. In a 
protein-protein complex, each of the individual interfacial residues typically do not contribute equally to 
the energetics of binding; rather, the majority of the binding affinity derives from a small number of 
“hotspot” residues (219-221). This observation, in turn, motivated several groups to mimic these key 
interactions when designing small-molecule inhibitors (156, 222-224). In this study, we take the 
“hotspot” paradigm and extend it to protein-RNA interactions. 
Our approach entails identifying the chemical moieties of a given RNA that contribute critical 
interactions to a particular protein-RNA complex, and then identifying small molecules that recapitulate 
the precise geometrical arrangement of these moieties. Our underlying hypothesis is that compounds 
capable of mimicking the three-dimensional structure of the RNA “hotspot” will also mimic the 
energetically dominant interactions in the protein-RNA complex, using a much smaller chemical scaffold. 
By establishing a new method for reusing these protein-RNA interactions, we circumvent the challenging 
problem of needing to design interactions that target a flat, polar protein surface. 
4.3 Computational Approach 
Computational methods are implemented in the Rosetta software suite (60) unless otherwise 
indicated. Rosetta is freely available for academic use (www.rosettacommons.org), with the new features 
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described here included in the 3.6 release. Computational methods are summarized below, and presented 
in further detail in the Supporting Methods section. 
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Figure 1: The hotspot mimicry approach. We demonstrate this approach by applying it to the Msi1 / 
NUMB mRNA interaction. (A) The structure of the Msi1 / RNA complex. The RNA (yellow and 
orange sticks denoting the backbone and the bases, respectively) wraps around the protein (green and 
grey spheres). Two adjacent bases, A106 and G107 (magenta), are buried in a shallow pocket on the 
protein surface. (B) An interaction map is generated from the RNA in the complex, by collecting 
deeply buried bases (magenta) and atoms involved in intermolecular hydrogen bonds (acceptors 
shown in yellow, donors in green). (C) Components of the interaction map are clustered in space, and 
atoms that do not participate in hydrogen bonding are reverted to carbon atoms; this produces a 
“hotspot pharmacophore.” (D) The difference in binding free energy between an RNA harboring a 
single abasic site versus the wild-type NUMB mRNA, as determined through competition with a 
fluorescently-labeled RNA. Positive values indicate diminished binding when a given base is replaced 
with an abasic site, showing that A106 and G107 contribute more than the other nearby bases to Msi1 
/ NUMB mRNA binding affinity. (E) The hotspot pharmacophore serves as a template for ligand-
based screening. In this case we identified three classes of hit compound that mimic the three-
dimensional features of the pharmacophore, as exemplified by the representatives shown here. (F) 
Superposition of the hotspot pharmacophore back onto the protein structure illustrates the interactions 
that should be captured by an ideal ligand: stacking against three aromatic sidechains, and four 
intermolecular hydrogen bonds. (G) Superposition of R12 onto the protein structure shows that this 
compound is expected to preserve the aromatic stacking, and recapitulate three of the four hydrogen 
bonds. 
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Building “hotspot pharmacophores” 
While interfaces between RBPs and their cognate RNAs are mostly flat, complexes involving 
segments of single-stranded RNA often include a few interfacial nucleobases that are buried much more 
deeply than the others (Figure 1a); this uneven distribution is reminiscent of “hotspot” sidechains in 
protein-protein complexes (219, 220). The protein has evolved to interact with these buried nucleobases 
through precise intermolecular aromatic stacking interactions and hydrogen bonding. 
We have developed an automated framework that distills the structure of a protein-RNA complex 
to a “hotspot pharmacophore,” which in turn can serve as a template for ligand-based screening. Our 
framework first picks out those RNA aromatic moieties that are deeply buried in the protein-RNA 
complex, as well as any RNA atoms involved in intermolecular hydrogen bonds to the protein or ordered 
water molecules (Figure 1b). Any polar atoms on the nucleobases that do not participate in hydrogen 
bonds are then replaced with carbon atoms, since those polar groups need not be carried forward into 
inhibitor design. This gives a broad spatial map of the protein-RNA interaction, which typically cannot be 
spanned by a single drug-like small molecule; we therefore clustered neighboring moieties, and advanced 
each cluster separately. Through this approach, we reduce the structure of the protein-RNA complex to a 
minimal “hotspot pharmacophore” that encapsulates the key interactions to be recapitulated by a small 
molecule (Figure 1c). 
Identifying complementary ligands 
To identify such compounds, we used this hotspot pharmacophore as a template for carrying out 
ligand-based virtual screening. In order to facilitate rapid characterization of compounds emerging from 
our screen, we restricted our search to the ~7 million compounds in the ZINC database (43) that are both 
commercially available, and predicted to have drug-like physicochemical properties. We used OMEGA 
(OpenEye Scientific Software, Santa Fe, NM) (44-46) to build low-energy conformations of each 
compound, then ROCS (OpenEye Scientific Software, Santa Fe, NM) (88, 225) to align each 
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conformation to our hotspot pharmacophore. For each of the top-scoring hits emerging from ROCS, we 
then used the aligned orientation to position the compound relative to the protein, and evaluated the 
interaction energy of the protein-ligand complex using the fullatom Rosetta energy function (60). 
Musashi-1, an RRM-containing protein 
The approach described above can, in principle, be applied to the structure of any protein-RNA 
complex. As a first test, we selected a target from the most common and well-studied of RNA-binding 
modules, the RNA-recognition motif (RRM) domain. Hundreds of structures of RRMs have been 
deposited in the Protein Data Bank, including more than fifty in complex with RNA (226). Collectively 
these structures show that RRMs adopt a conserved fold that packs two α-helices against one face of a 
four-stranded β-sheet; in most cases the opposite face of this β-sheet is then used to bind a single-stranded 
segment of RNA. Recognition of cognate RNA is usually driven by a cluster of three outward-facing 
aromatic amino acids on this β-sheet, which often form stacking interactions with a pair of adjacent RNA 
bases (227). Accordingly, mutations to the protein that remove these aromatic sidechains have been 
shown to disrupt binding in representative RRMs (227, 228), as has introduction of non-canonical bases 
to the RNA that alter the pattern of hydrogen bonding groups (229-231). Despite these shared features, 
however, the precise geometry of the dinucleotide pair in its complex with the RRM can differ very 
drastically across members of this family (227). 
Mammalian Musashi-1 (Msi1) recognizes its cognate RNAs through a pair of RRMs, RBD1 and 
RBD2 (232). Together these two domains bind to the 3’ UTR region of specific target mRNAs, including 
the mRNA encoding NUMB, and impede initiation of their translation (233, 234). NUMB mRNA encodes 
an inhibitor of Notch, so translational inhibition by Msi1 triggers Notch signaling and thus promotes self-
renewal and cell survival (18, 234). Relative to its protein levels in normal tissue, Msi1 is over-expressed 
in many cancers including colon adenocarcinomas, medulloblastoma, glioma, astrocytoma, 
retinoblastoma, hepatoma, and endometrial, cervical, and breast carcinomas, and has particularly high 
 
 
108 
levels in later stages of cancer progression (235-241). Considering the role of Msi1 in stem cell 
maintenance and renewal, and its over-expression in a wide array of cancers, disrupting its RNA-binding 
ability may inhibit cancer stem cells that play a role in drug- and radio-resistance, and thus serve as an 
attractive potential anti-tumor strategy (242). 
4.4 Results 
Computational screening against Msi1 RBD1 
We applied our “hotspot mimicry” approach to the Musashi-1 RBD1 / NUMB mRNA complex 
(232), and found a single hotspot pharmacophore derived from an adjacent pair of buried nucleobases, 
Adenine106 and Guanine107 (Figure 1a). This pharmacophore captures both the aromatic stacking and 
the hydrogen bonding of the RNA hotspot through its inclusion of ring moieties and donor/acceptor 
positions, respectively (Figure 1c). To test whether these particular two bases indeed serve as a hotspot of 
the Msi1 RBD1 / RNA interaction, we used a fluorescence polarization competition assay (see Supporting 
Methods) to measure the binding affinity of NUMB mRNA variants that lacked individual bases. Using 
this assay, we found that introduction of an abasic site at either of these two positions led to a marked 
decrease in binding to Msi1 RBD1 (Figure 1d). In contrast, introduction of an abasic site at other nearby 
positions affecting binding much less. Confirmation that A106 and G107 serve as hotspot bases of this 
interaction thus provided experimental evidence supporting the pharmacophore selection from our 
computational approach. 
We then used this pharmacophore as a template for virtual screening, and found that the 12 top-
scoring hits could each be classified into one of three diverse chemotypes (Figure S1). While none of 
these scaffolds bear any obvious resemblance in chemical structure to a nucleobase pair, the overlap in 
three-dimensional shape and hydrogen bonding potential between the hotspot pharmacophore and the 
modeled conformation of each compound is immediately evident (Figure 1e). Despite this strong 
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similarity, none of the 12 hit compounds recapitulated all four of the polar groups included in the hotspot 
pharmacophore, and only three hit compounds matched to three of the polar groups: R12, its close analog 
R4, and R7. The lack of hits that simultaneously match all four polar groups reflects a limit of the 
chemical space spanned by our screening library; we will discuss this in detail later. 
As expected, superposition of the hit compounds back onto the hotspot pharmacophore in the 
context of the protein-RNA complex confirmed that these ligands might preserve the favorable 
interactions of the dinucleotide pair. In particular, the ring moieties in the pharmacophore represent the 
stacking of nucleobases against Phe23, Phe65 and Phe96 of Msi1, while the hydrogen bonding atoms 
indicate polar contacts with the sidechain of Lys21 and the backbones of Val94 and Phe96 of Msi1 
(Figure 1f). Mimicry of these interactions through the hotspot pharmacophore allows the hit compounds 
to recapitulate these interactions, as exemplified by R12 (Figure 1g). In this model R12 adopts a similar 
three-dimensional geometry as the hotspot pharmacophore, and thus recapitulates its aromatic stacking 
and polar interactions. 
Biochemical characterization of computational hits 
We purchased each of the compounds corresponding to these 12 top-scoring hits (Figure S1). We 
used surface plasmon resonance (SPR) to directly test for binding of each compound to Msi1, by 
immobilizing recombinant human Msi1 RBD1 onto an SPR chip and then passing each compound over 
the chip at a concentration of 50 µM (see Supporting Methods). The sensorgram for R12 showed a kinetic 
profile consistent with binding to Msi1 RBD1 (Figure 2a); none of the other compounds exhibited this 
behavior (Figure S2). 
As noted earlier, only R12 and two other compounds matched as many as three polar groups in 
the hotspot pharmacophore; the lack of binding observed for the other compounds (at this concentration) 
may be attributable to the fact that they do not sufficiently recapitulate the interactions of the hotspot 
pharmacophore. While R7 matched three polar groups, retrospective analysis of the structural model 
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revealed that the imperfect alignment of the rings to the pharmacophore may have led to a steric clash 
with the protein (Figure S3). 
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Interestingly, the R12 class included two compounds: R12 and R4. These compounds differ only 
in the position and identity of a single substituent: the R12 has a bromine atom at the 3- position of the 
pyridine moiety, while R4 instead harbors a methyl group at the 2- position. Comparison of these 
compounds in the context of the protein partner immediately reveals a potential source for their differing 
responses in the SPR experiment: in our model, this methyl group of R4 forms a steric clash with the side 
chain of Leu50 on Msi1 that we had not initially recognized (Figure 2b); in contrast, the shifted position 
of the R12 substituent avoids this steric clash. This initial (inadvertent) structure-activity experiment 
provides strong support for the structural model of R12 binding. 
Figure 2: Biochemical characterization and optimization of computational hit compounds. 
(A) Initial screening via surface plasmon resonance: representative sensorgrams for R12 and R4 are 
shown. The kinetic profile of R12 (red) is consistent with binding to Msi1, whereas that of its close 
analog R4 (blue) shows no evidence of binding. (B) Comparison between the predicted binding 
models of R12 and R4. The top scoring conformers of R12 (red) and R4 (blue) are transferred back to 
the protein by alignment to the hotspot pharmacophore. The model of R4 suggests its lack of binding 
may stem from a steric clash with Leu50, whereas R12 avoids this steric clash since this ring is 
substituted at a different position. (C) Chemical structures of R12 and one of its derivatives, R13. (D) 
Model of R13 bound to Msi1, by alignment to the hotspot pharmacophore. R13 preserves the 
interactions of R12, but reduces flexibility of the linker and removes potential electrostatic repulsion 
with Msi1. (E) R13 increases the Msi1 melting temperature in a concentration-dependent manner, 
providing evidence of their interaction in solution. (F) R13 competes with fluorescein-labeled RNA 
for Msi1 binding, as observed through a fluorescence polarization assay. 
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Figure 3: Computational prediction of potential off-target interactions. (A) We screened each 
conformer of a given ligand against the complete set of unique hotspot pharmacophores from other 
protein-RNA complexes in the PDB. Hits in this screen correspond to other proteins that recognize 
their cognate RNAs using interaction geometry that can be mimicked by the compound of interest. 
(B) Like Msi1, the RRM from Tra2-β1 binds to specific purine-rich RNAs. The distinct geometry with 
which the cognate RNA is recognized, however, produces a hotspot pharmacophore that is 
dramatically different from that of Msi1. (C) Application of this approach to a series of hypothetical 
compounds built by connecting adenine and guanine with various flexible linkers. The distribution of 
scores for the complete pharmacophore library is shown, with the score of the Msi1 (red arrow) and 
Tra2-β1 (grey arrow) pharmacophores indicated. These artificial compounds match the Msi1 and 
Tra2-β1 pharmacophores equally well, and they match many other pharmacophores better than they 
match these two. (D) Application of this approach to R12. Only one “off-target” pharmacophore from 
the library has a score comparable to that of Msi1 (PDB ID 2MF0); this match is accessed through the 
conformational flexibility of R12 (blue arrow/box). (E) Application of this approach to R13. No 
pharmacophores from the library have scores comparable to that of Msi1; the scores of the off-target 
matches to R12 are now significantly worse (blue arrow), since R13 can no longer access these 
alternate conformations. Neither R12 nor R13 provides a high-quality match to the Tra2-β1 hotspot 
pharmacophore (grey arrows/box). In all cases the red arrow indicates the score of the hotspot 
pharmacophore derived from the first model in the Msi1/RNA NMR ensemble, and the red bar 
indicates the range of scores spanned by pharmacophores extracted from the other members of this 
NMR ensemble. 
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Optimization of R12 
Guided by this model, we next set out to improve the potency of R12. The limited chemical space 
in our screening library led to two undesirable features of this compound. First, the carbonyl oxygen in 
the ester linker of R12 is positioned in close proximity to the Phe96 backbone carbonyl of Msi1 
(Figure 1f); beyond simply the lost opportunity for an intermolecular hydrogen bond, we expect 
electrostatic repulsion between these two negatively charged moieties. Second, the two ring systems of 
R12 are connected by a somewhat flexible linker; rigidifying this linker might reduce the conformational 
entropy lost upon binding. With these two motivations in mind, we designed and synthesized a panel of 
five new R12 derivatives, R13-R17 (Figure S4) (see Supporting Methods). 
Using our previous SPR assay, we found that all five derivatives exhibit kinetic profiles at 50 µM 
consistent with binding to Msi1 (Figure S5). Below we will present further biochemical characterization 
of R13, a compound that met our design goals by replacing R12’s ester with a piperidine ring and a 
secondary amine in the linker (Figure 2c). Upon building models for each of the five R12 derivatives in 
complex with Msi1 (see Supporting Methods), we find that the rigidified linker in each compound allows 
recapitulation of R12’s interactions while relieving the potential source of electrostatic repulsion; 
unfortunately however, none of the models include an additional hydrogen bond to Msi1 (Figure 2d, 
Figure S6). 
In order to confirm binding of R13 to Msi1 in an orthogonal assay, we used differential scanning 
fluorimetry (DSF / Thermofluor) to determine protein thermostability as a function of ligand 
concentration. We found that the melting temperature of Msi1 increased upon addition of R13 in a dose-
dependent manner (Figure 2f), up to a 3.7 ˚C increase in presence of 100 µM R13. 
Finally, we directly examined the ability of R13 to not simply bind Msi1, but also to inhibit its 
interaction with NUMB mRNA. We used a fluorescein-labeled RNA oligonucleotide corresponding to the 
Msi1 recognition sequence of NUMB, which exhibits an increase in polarization upon Msi1 binding 
(Figure S7). The subsequent addition of R13 is expected to lead to a decrease in polarization, if R13 
 
 
115 
competes with NUMB mRNA for Msi1 binding as designed. Indeed we observe this dose-dependent 
behavior, and using the apparent binding affinity of the labeled RNA for Msi1 we estimate Ki for the 
R13-Msi1 interaction to be 17 µM (Figure 2g). 
Predicting target selectivity 
Many RRM proteins recognize their target RNAs with high sequence specificity, through 
additional interactions outside the central RNA dinucleotide (227). Our mimicry of the Msi1 hotspot was 
predicated on recapitulating the interactions solely within this dinucleotide; we therefore sought to 
explore the target selectivity expected for these inhibitors by searching for potential off-target 
interactions. Starting from every example of protein-RNA complexes in the Protein Data Bank, we used 
our computational approach to extract the set of all available hotspot pharmacophores (see Supporting 
Methods). For a given compound of interest, we can then screen all conformers of this molecule against 
this “library” of 543 unique hotspot pharmacophores (Figure 3a). The top-scoring hits in this experiment 
represent proteins that recognize their cognate RNAs through interaction patterns that can be recapitulated 
by the compound of interest, making these candidate proteins for off-target binding. We note that this 
large-scale experiment does not explicitly account for protein flexibility, which may enable further 
off-target interactions. To demonstrate the variation in pharmacophore structure associated with typical 
protein fluctuations, we have included in our studies each member of the experimentally-derived Msi1-
RNA NMR ensemble (232). As a further point of comparison, we also highlight another protein domain 
that binds to a purine-rich segment of RNA, the RRM from Tra2-β1 (243, 244). Despite the shared 
domain architecture and similar recognition preference, this protein binds its cognate RNA via 
interactions that are quite distinct from those of Msi1 (Figure 3b); this, in turn, leads to a hotspot 
pharmacophore with little resemblance to that of Msi1. 
We applied this analysis first to a series of hypothetical compounds, each one comprised of 
guanine and adenine attached by flexible linkers of varying lengths (Figure 3c). We find that each of 
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these constructs can adopt a conformation that aligns well to the Msi1 hotspot pharmacophore, but they 
also undergo rearrangements that allow them to match many of the other hotspot pharmacophores in our 
library, including the one from Tra2-β1. This observation is unsurprising, since one would expect these 
artificial ligands to mimic many guanine-adenine dinucleotide pairs with little consideration of their 
three-dimensional arrangement. 
We next carried out the same analysis for R12 (Figure 3d) and each of the other hits from our 
initial computational screen (Figure S8a). Relative to the guanine-adenine pairs, R12 lacks certain polar 
groups (those that do not participate in the Msi1 pharmacophore). While this reduces R12’s potential for 
mimicking some of the off-target hotspot pharmacophores, we nonetheless find one alternate match with 
score comparable to that of Msi1: the pharmacophore is from a complex involving the bacterial RsmE 
protein (245). RsmE adopts a fold completely unlike an RRM domain, and no pharmacophores from other 
RRM domains had comparable scores to that of Msi1. Notably, the off-target hotspot pharmacophore 
from RsmE was identified not because it bears strong resemblance to the Msi1 pharmacophore, but rather 
because flexibility in the R12 linker allows it to match this alternate pharmacophore by adopting a 
drastically different conformation from that used in mimicking the Msi1 pharmacophore (Figure 3d, blue 
box). 
Finally, we applied this analysis to R13 (Figure 3e) and each of the other R12 derivatives 
(Figure S8b); we find that these match the Msi1 hotspot pharmacophore far better than any others 
extracted from the PDB. The conformation that allowed R12 to mimic the RsmE hotspot pharmacophore 
is not accessible to R13, leading to a diminished score for this comparison (blue arrow). R13 is also 
unsuitable for mimicking the alternate geometry of the purine-purine pair from the Tra2-β1 hotspot 
pharmacophore (grey arrow and grey box), and indeed superposition of R13 onto this RRM domain 
results in obvious steric clashes (Figure S9). While this experiment does not account for flexibility of any 
of the off-target proteins, we do note that R13 matches some of the other members of the Msi1 NMR 
ensemble better than the single structure that led to its design (red bar). This highlights the robustness of 
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hotspot pharmacophore matching to small changes in protein structure, and suggests that protein 
flexibility is unlikely to lead to alternate hotspot pharmacophores that are preferred by R13. While further 
experimental evidence will be necessary to explicitly determine whether these compounds engage in 
unanticipated interactions with other RBPs, these results suggest that the increased rigidity of the R13 
linker makes it unable to access the alternate conformations that might allow R12 to mimic certain off-
target pharmacophores. 
Collectively, these observations point to the uniqueness of the Msi1 hotspot pharmacophore with 
respect to the rest of the Protein Data Bank; while many other RBPs bind to guanine-adenine pairs, only 
Msi1 recognizes a guanine-adenine pair in precisely this geometry. Through the use of a rigid chemical 
scaffold that closely mimics the three-dimensional geometry of the hotspot pharmacophore, we expect to 
achieve target selectivity that would not be possible by direct mimicry of chemical structure (i.e. by using 
nucleoside analogues). 
Inhibition of cellular Msi1 activity 
Through the biochemical assays presented earlier, we confirmed that R12 and its derivatives 
R13-R17 bind to Msi1 in vitro. We next set out to explore whether these compounds inhibit RNA-binding 
of endogenous Msi1 in cells, by monitoring Msi1’s interaction with cognate mRNAs (234). The tumor 
suppressor APC is a target of Msi1, and we previously demonstrated that a firefly luciferase reporter 
containing the 3’ UTR from APC mRNA was responsive to Msi1 levels in HCT116-βw colon cancer cells 
(234). Since endogenous Msi1 inhibits translation through its interaction with the APC 3’ UTR, we 
expected compounds that inhibit endogenous Msi1 activity would relieve this translational inhibition, and 
thus result in increased luciferase activity. In each case we co-transfected with an expression construct 
harboring Renilla luciferase, and normalized the relative light output to the latter; by doing so we account 
for potential differences in transfection efficiency and monitor the possibility that loss of the firefly 
luciferase activity might derive from compound toxicity. We also tested the effect of each compound on 
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cells that express a firefly luciferase reporter lacking the APC 3’ UTR, to ensure that any observed 
differences were indeed Msi1-dependent. 
At a concentration of 20 µM, we find that several of the R12 derivatives lead to increased 
luciferase activity from the construct containing the APC 3’ UTR (Figure 4a). Given that Msi1 inhibits 
luciferase translation via the 3’ UTR of APC, the observed increase in luciferase activity is consistent 
with neutralization of this Msi1 inhibition by the R12 derivatives. This effect is most pronounced for 
compounds R13, R15, and R17; we see little effect from R14 or R16 in this assay. As a negative control, 
we also include R4 (which did not exhibit inhibition in our biochemical assays), and find no evidence of 
inhibition. In the case of R12 we observe increased luciferase activity in the construct lacking the APC 
3’ UTR, suggesting some off-target activity of this compound. None of the other compounds increased 
activity of this control construct, however, confirming that activity of these R12 derivatives is indeed 
through Msi1. 
While Msi1 does not bind the R12 derivatives as potently as it binds to its cognate RNA, the 
competition for Msi1 binding is driven not only by the relative binding affinities, but also by the relative 
concentrations of the competing species. By testing several concentrations of R13 we found that this 
effect is dose-dependent, and increases monotonically up to a concentration of 40 µM (Figure 4a). We 
also find that luciferase activity is diminished at a concentration of 60 µM, which may result either from 
off-target activity at this higher concentration or from negative feedback in response to inhibition of Msi1. 
NUMB mRNA also harbors a 3’ UTR that is recognized by Msi1, and was the first identified 
target of translational inhibition by Msi1 (246). The designed compounds are expected to relieve the 
interaction of endogenous Msi1 with the 3’ UTR from NUMB, which in turn should increase levels of 
Numb protein. Upon treatment of HCT116-βw cells with these compounds, we indeed observe this 
expected response (Figure 4b). Further, across this series of compounds R4 again had the least effect. 
These results demonstrate the ability of the designed compounds to rationally perturb endogenous 
signaling pathways in human cells. 
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Inhibition of cellular Musashi-2 activity 
While expression of Msi1 is tissue-restricted, its homolog Msi2 is ubiquitously expressed (247, 
248). Like Msi1, Msi2 includes two RRM domains; the first of these shares 80% sequence identity with 
Msi1 RBD1. Sequence alignment of Msi1 and Msi2 reveals that with the exception of L50M, all but one 
of the residues that differ correspond to surface exposed positions far from the hotspot pharmacophore 
Figure 4: Inhibition of Musashi’s RNA-binding activity in cells. (A) The luciferase reporter 
construct contains the APC 3’ UTR, and therefore responds to translation inhibition by endogenous 
Msi1. Luciferase activity increased after addition of R12 derivatives (each at 20 µM), consistent with 
Msi1 inhibition. Control indicates a construct lacking the APC 3’ UTR. All values were normalized to 
Renilla luciferase activity and represent the average from 6 independent experiments. The response to 
compound R13 was also tested at increasing doses. Error bars in all cases represent SEM, and 
* indicates a statistically significant increase in luciferase activity relative to the construct lacking the 
APC 3’ UTR (p < 0.05). (B) NUMB mRNA is a well-characterized target of translational inhibition by 
Msi1. As a second readout of endogenous Msi1 activity, levels of Numb protein were assessed via 
Western blot in lysates from cells treated with R12 derivatives. Normalized Numb band intensity from 
4 independent experiments is presented (images of the Western blots, with quantification, are included 
as Figure S10). Error bars in all cases represent SEM, and * indicates a statistically significant 
increase relative to cells treated with R4 (p < 0.05). (C) Msi2 downregulates cJun in K562 cells, as 
demonstrated by the fact that anti-MSI2 shRNA leads to increased cJun protein. Treating these cells 
with R12 derivatives (R13, R15, R17) leads to increased levels of cJun (as detected in an anti-cJun 
Western blot). In contrast, the inactive analog R4 has levels of cJun that are comparable to vehicle 
alone (DMSO). Treatment with DMSO does not affect the level of cJun relative to untreated cells 
(Figure S12). 
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(Figure S11); based on this model, we anticipated that the R12 derivatives would also show activity 
against Msi2’s RBD1. 
Msi2 plays a key role in hematopoietic stem cell proliferation and differentiation (247, 249) as 
well as in aggressive myeloid leukemia (247, 248), where it has generated extreme interest as a potential 
target for therapeutic intervention (250). Through polysome profiling we defined translational targets of 
Msi2 in K562 myelogenous leukemia cells, and identified transcription factor cJun as a potential 
downstream target of Msi2. This was confirmed using shRNA knock-down of Msi2 in K562 cell lines by 
immunoblotting (Figure 4c), providing evidence supporting Msi2’s regulation of cJun but not indicating 
the mechanism by which Msi2 exerts this effect. 
To test the hypothesis that Msi2 modulates cJun protein levels through its RNA-binding activity, 
we treated K562 cells with those R12 derivatives that were most active in our luciferase reporter assay. At 
a concentration of 20 µM, we found that all three of these compounds induce increased cJun protein 
levels (Figure 4c). In contrast, we did not observe any increase in cJun upon treatment with R4 even up 
to a concentration of 40 µM. 
Leukemia cells lines, including K562, have negligible expression of Msi1 (247): this strongly 
suggests that indeed these R12 derivatives are active not only against Msi1, but against Msi2 as well. 
These observations are further consistent with the intended model of inhibition of Msi1, in which the 
designed compounds interact with the surface of Musashi’s RBD1 that is most conserved between Msi1 
and Msi2 (Figure S11). 
4.5 Discussion 
The ability to rationally design selective inhibitors of RNA-binding proteins in a robust and 
general way will enable development of new tool compounds to help elucidate cellular processes 
mediated by these interactions. Naturally-occurring examples have shown that proteins can mimic certain 
structural features of RNAs (251, 252); here, we instead encode a key RNA epitope on a small-molecule 
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scaffold. We demonstrate the application of our approach using Musashi-1, leading to a novel class of 
inhibitors that disrupt the RNA-binding activity of this tumor-promoting protein. By using the hotspot 
pharmacophore as a template for ligand-based screening, our approach circumvents the challenge of 
explicitly designing de novo interactions against a relatively flat and polar protein surface. 
The major advantages of this mimicry approach are its generality and simplicity. In this first 
application of the RNA mimicry approach, we elected to restrict our initial screening to commercially 
available compounds. Though convenient, none of the resulting hit compounds provided complete 
recapitulation of the desired hotspot interactions. Of three compounds that each matched three of the 
pharmacophore’s polar groups, only one compound (R12) complemented the protein surface without 
steric clashes. In light of the fact that this compound provided a starting point for new inhibitors of Msi1, 
and thus validated the computational method, in future it will be worthwhile to explore chemical space 
more extensively in search of hits that more effectively mimic the desired hotspot pharmacophore. A 
computational screening platform was recently described (155) that uses multi-component reaction 
chemistry (253) to build a virtual library containing tens of millions of novel compounds that can be 
readily accessed through proven “one-step, one-pot” reactions. While this strategy was originally used to 
construct a library of compounds that resemble collections of amino acid sidechains, it can be adapted to 
include privileged moieties that mimic patterns of hydrogen bond donors and acceptors in protein-RNA 
complexes, connected with rigid chemical linkers. By expanding the space of available compounds 
through this combinatorial strategy, and integrating computational screening with chemical synthesis, we 
envision discovery of compounds that more accurately match the target hotspot pharmacophores and thus 
exhibit improved potency prior to optimization. 
The design of R12-derived compounds active against the Msi1 / NUMB mRNA interaction 
highlights the simplicity and robustness of the “hotspot mimicry” method, and also validates the 
“druggability” of this protein surface. We expect that the generality of this design strategy will allow it to 
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be applied broadly in future, to develop inhibitors of RNA-binding proteins as novel chemical probes and 
also as potential starting points for new therapeutics. 
 
4.6 Methods 
Detailed descriptions of computational and experimental methods are provided in the Supporting 
Methods section. 
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CONCLUSIONS 
What structural properties define inhibitory complexes of non-traditional drug targets? 
Over the past few decades, it has become generally believed that identifying small-molecule 
inhibitors for non-traditional targets such as protein-protein interactions was an impossible task (254). 
However, the recent discovery of several small-molecule inhibitors for protein-protein interactions 
demonstrated that non-traditional drug targets are in fact druggable. With these available examples, I have 
examined structural properties that define inhibitory complexes of non-traditional drug targets. From the 
results of this quantitative analysis, it is evident that small molecules binding at protein interaction sites 
retain more exposed surface area in comparison to small molecules bound to traditional targets. Also, the 
deep pockets present on traditional drug targets are typically absent at protein interaction sites. The results 
from the virtual screening experiment described in Chapter 1 demonstrates that these protein 
conformations present relatively flat surface pockets, and hence can harbor only a relatively exposed 
ligand. In order to address protein interaction sites with small-molecule inhibitors, we may need to 
carefully select proteins that are amenable for complexes with less exposed surface area, target allosteric 
sites that can accommodate extensively buried ligands, or develop new approaches to improve the 
delivery and oral accessibility for compounds outside rule-of-five chemical space. The results from this 
experiment further demonstrates that modern virtual screening methods typically are less suited for 
identifying inhibitors of protein interactions than for identifying inhibitors of traditional drug targets.  
 
DARC: Matching pocket topography to a complementary small molecule 
Next, I have presented DARC, a new approach to docking that matches the topography of a 
surface pocket “observed” from within the protein to the topography “observed” when viewing a potential 
ligand from the same vantage point. By matching the topography of the protein surface to the buried face 
of the ligand, DARC can outperform popular docking programs (DOCK and AutoDock) when screening 
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for inhibitors of protein-protein interactions. In the virtual screen carried out against the human anti-
apoptotic protein Mcl-1 using DARC, 6 of the top scoring 21 compounds showed clear inhibition in a 
biochemical assay. The results from this virtual screen demonstrate the utility of DARC for identifying 
novel inhibitors of protein-protein interactions. 
I have also presented several key enhancement to the DARC method; the starting version of 
DARC docked only one of the ligands in my test set to within 2 Å RMSD of its position in the crystal 
structure, whereas “DARC 2.0” achieved this level of accuracy for 12 of the 25 complexes. I anticipate 
these enhancements will help reduce the number of false negatives when we use DARC for real screening 
applications, thus allowing us to successfully identify more initial compounds with activity against the 
intended target. 
 
Further potential applications of DARC: 
In future, I anticipate that DARC can also be used for several other tasks related to non-traditional 
targets: 
Focused chemical libraries: 
There is great interest in designing “focused” chemical libraries: collections of compounds with 
enhanced hit rates against a given protein class. I believe that DARC might be used to address this 
challenge: by using DARC to screen against many diverse protein surfaces and compiling those 
compounds which are identified for these targets, one could build a collection of small-molecules that 
may be enriched in protein interface inhibitors. 
One could also build a further target-specific library of small-molecules, for example a “Bcl-2 
family focused compound library” by compiling together DARC hits for each of the Bcl-2 proteins. 
Target-specific, focused chemical libraries can not only increase the chances of identifying hit compounds 
in biochemical screens, but can also decrease the time and resources required for carrying out the screen. 
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Predicting binding specificity for the ligands: 
Discriminating between family-nonspecific ligands and family-selective ligands is an important 
step in the advanced stages of the drug discovery pipeline. This is particularly important for families of 
proteins that perform opposing functions, like the Bcl-2 protein family . With the improved performance 
demonstrated by DARC 2.0 in pose recapitulation, I am enthusiastic to find out whether DARC can be 
used to predict which Bcl-2 family members will be inhibited by a given inhibitor. 
 
Small molecules that mimic hotspot pharmacophores in protein-RNA complexes: 
For rationally designing small-molecule inhibitors that target protein-RNA interactions, I have 
presented a new "pharmacophore mimicry" approach. I have demonstrated the application of this 
approach by identifying compounds that match the hotspot pharmacophore from the Msi1 / RNA 
complex, enabling development of novel inhibitors of the Musashi-1 / NUMB mRNA interaction; these 
inhibitors are active in both biochemical and cell-based assays. 
 
Further potential applications of the hotspot mimicry approach: 
The major advantages of this mimicry approach is its generality; accordingly, I expect that this 
design strategy will allow it to be applied broadly in future to develop inhibitors for other RNA-binding 
proteins. 
Pharmacophores from dynamic protein-RNA complexes: 
 In this initial study targeting Msi-1, I considered only a single member of the NMR 
ensemble for this protein-RNA complex. However, considering hotspot pharmacophores from other 
members of this NMR ensemble may lead to identification of slightly different inhibitors. Moving 
forward, more studies will be required in order to reach general conclusions about how the dynamic 
nature of protein-RNA complexes can best be incorporated into this method. 
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Pharmacophores from homology models of protein-RNA complexes: 
This initial application of the “hotspot mimicry” approach made use of an experimentally-derived 
structure of the protein-RNA complex. In principle, however, this approach might be extended to 
homology model complexes as well. With the increasing number of experimentally-derived structures of 
protein–RNA complexes, it may soon be possible to reliably model high quality protein-RNA complexes. 
Application of the hotspot mimicry approach to homology models of protein-RNA complexes will 
certainly prove challenging, and will require very accurate modeling in order to reliably recapitulate 
details of the pharmacophore. Nonetheless, if successful, this may provide new targets for structure-based 
drug discovery that would otherwise not be accessible by other methods. 
 
Summary: 
Collectively, the methods I have described in this thesis offer new ways to go about identifying 
small molecule inhibitors of non-traditional protein targets. This, in turn, may help make these exciting 
targets more accessible to drug discovery. 
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APPENDIX A.1: Supporting Information for Chapter 1 
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1.1 Supplemental Tables 
Protein target 
PDB 
id 
Inhibitor 
molecular 
weight (Da) 
Potency 
(µM) 
Ligand efficiency 
(kcal/mol per 
heavy atom) θlig 
βII tryptase 2bm2 402 0.015 0.35 0.56 
penicillin G acylase 1gm8 350 16 0.27 0.46 
urokinase 1owe 291 0.63 0.38 0.41 
ADAM33 1r55 331 0.16 0.40 0.39 
β-lactamase 1l2s 318 26 0.33 0.39 
factor Xa 1lpz 467 0.025 0.32 0.38 
Chk1 2br1 391 15.4 0.23 0.38 
NS5B polymerase 1yvf 438 0.1 0.34 0.38 
factor VIIa 1ygc 548 0.00035 0.34 0.37 
vascular endothelial growth 
factor receptor 2 1y6b 479 0.038 0.30 0.37 
tRNA-guanine transglycosylase 1n2v 208 83 0.37 0.36 
tryptophan synthase 1k3u 290 -NR- -NR- 0.36 
cyclin-dependent kinase 2 1ke5 329 0.56 0.37 0.35 
thymidine kinase 1of1 252 4.1 0.41 0.34 
thyroid hormone receptor α1 1nav 355 0.025 0.45 0.34 
neuraminidase B 1vcj 351 26 0.25 0.34 
thymidine phosphorylase 1uou 245 0.02 0.65 0.34 
neuraminidase A 1l7f 330 0.0008 0.54 0.33 
c-Abl tyrosine kinase 1opk 427 0.00015 0.46 0.33 
protein kinase 5 1v0p 433 0.13 0.31 0.33 
progesterone receptor 1sqn 298 0.0004 0.58 0.33 
p38 kinase 1ywr 475 0.032 0.29 0.33 
androgen receptor 1z95 430 0.076 0.33 0.33 
thyroid hormone receptor β1 1n46 367 0.00003 0.53 0.32 
purine nucleoside phosphorylase 1v48 337 0.0069 0.50 0.32 
estrogen receptor α 1sj0 466 0.0008 0.37 0.32 
thymidylate kinase  1w2g 242 27 0.37 0.32 
c-Jun terminal kinase 3 1pmn 487 0.007 0.34 0.32 
glucokinase 1v4s 349 1000 0.18 0.32 
phosphodiesterase 5A 1xoz 389 0.0012 0.42 0.31 
myosin II 1yv3 292 4.9 0.33 0.31 
c-kit tyrosine kinase 1t46 496 0.413 0.23 0.30 
heat shock protein 90 2bsm 388 0.14 0.34 0.30 
thrombin 1oyt 408 0.057 0.33 0.30 
cyclin-dependent kinase 5 1unl 354 0.2 0.35 0.30 
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glucocorticoid receptor 1m2z 392 0.06 0.35 0.29 
glutamate receptor 6 1tt1 215 64.6 0.38 0.29 
vitamin D nuclear receptor 1s19 413 0.0017 0.40 0.28 
glycogen synthase kinase 3β 1q41 277 0.022 0.50 0.28 
activated Cdc42 kinase 1 1u4d 245 -NR- -NR- 0.28 
transthyretin 1tz8 268 -NR- -NR- 0.27 
adipocyte fatty acid-
binding protein 1tow 253 0.57 0.45 0.27 
dihydrofolate reductase 1s3v 375 0.038 0.37 0.27 
acetylcholinesterase 1gpk 244 4.3 0.41 0.27 
HIV-1 reverse transcriptase 1jla 364 -NR- -NR- 0.26 
HIV-1 protease 1kzk 576 0.00004 0.34 0.24 
 
 
Table S1: Inhibitors bound to traditional targets, a subset of the Astex set. Potency is taken from 
reported Kd or Ki values where available; if unavailable, IC50 values were used instead. In several cases 
(“-NR-”), no measure of potency has been reported. θlig indicates the fraction of ligand SASA exposed in 
the complex, as defined in Equation 1. 
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1.2 Supplemental Figures 
 
 
 
Figure S1 (complements Figure 1)  The distribution of the extent of inhibitor solvent exposure (θlig) is 
similar across a number of drug-like sets: Astex (35) (blue), DOCK (255) (magenta), DUD-E (37) 
(brown), and SB2010 (38) (green). 
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Figure S2 (complements Figure 2)  The distribution of molecular weights for the inhibitors in each set 
underlies the observed difference in ligand efficiencies. Inhibitors binding at protein interaction sites (red, 
median value 475 Da) are typically larger than their drug-like counterparts (blue, median value 355 Da), 
and the difference in the means is statistically significant (p < 10-4). 
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Figure S3 (complements Figure 2)  The relationship between θlig and ligand efficiency for both the PPI 
set and the Astex set. While there is a statistically significant negative correlation between these 
properties for the PPI set (as noted in Figure 2c), no statistically significant correlation exists for the 
Astex set (p = 0.27). 
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Figure S4 (complements Figure 2)  The relationship between θlig and potency for both the PPI set and 
the Astex set. No statistically significant correlation exists between these properties for either set (p = 
0.33 for the PPI set, p = 0.50 for the Astex set). 
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Figure S5 (complements Figure 3)  A known inhibitor was embedded in a custom set of 50 “decoy” 
compounds selected by the DUD-E server to match the physical properties of the known inhibitor. FRED 
exhibits superior ability to identify the known drug-like inhibitors from the decoy compounds (blue), 
relative to inhibitors that bind at protein interaction sites (red), and the difference in the means is 
statistically significant (p < 0.002). 
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Figure S6 (complements Figure 3)  The observation that virtual screening at protein interaction sites 
performs less well than for drug-like compounds holds for other docking software as well. DOCK 6.6 was 
used to identify a known inhibitor embedded in a custom set of 50 “decoy” compounds selected by the 
DUD-E server to match the physical properties of the known inhibitor. DOCK 6.6 exhibits superior 
ability to identify the known drug-like inhibitors from the decoy compounds (blue), relative to inhibitors 
that bind at protein interaction sites (red), though this difference is not statistically significant (p = 0.11). 
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2.1 Supplementary Results 
Characterization of the M0/Mcl-1 interaction 
To determine whether binding of M0 to Mcl-1 is reversible, we monitored their interaction via 
surface plasmon resonance (SPR). We immobilized Mcl-1 to the sensor surface, and then passed M0 over 
this surface at several different concentrations (see Supplementary Methods). While the resulting 
sensorgrams showed a kinetic profile consistent with reversible binding to Mcl-1 (Figure S7), the data 
deviate very slightly from a 1:1 Langmuir binding model. Although these data are insufficient to 
confidently allow quantitative comparison to the inhibition constant determined in the fluorescence 
polarization competition assay, these results nonetheless confirm that M0 binds reversibly to Mcl-1. 
To further confirm binding of M0 to Mcl-1, we next produced isotopically-labeled Mcl-1 and 
collected 1H-15N-HSQC spectra in the presence and absence of M0 (Figure S8a). In light of concerns 
regarding M0 solubility, the concentration of M0 used in this experiment (100 µM) was less than the 
Mcl-1 concentration (300 µM): this is unfortunately expected to reduce differences in the spectra resulting 
from addition of M0. Nonetheless, even under these conditions we observe chemical shift differences in 
several peaks, providing further evidence for the interaction of M0 with Mcl-1. Further, the fact that 
chemical shift differences are limited to a small number of peaks suggests that residues distant from the 
M0 binding site are unaffected, and implies that binding does not induce a large-scale conformational 
change that might be expected of an allosteric inhibitor. Analogous experiments using Mcl-1’s cognate 
peptide Bak show changes in a similarly limited subset of peaks (256), consistent with our model of 
binding in which M0 utilizes a very similar Mcl-1 conformation. Unfortunately, the fact that our Mcl-1 
construct differs from the one used in the Bak spectra precludes direct comparison of whether the same 
peaks are shifted in each of these experiments. 
After we collected our spectra, however, a newly assigned spectrum of unbound human Mcl-1 
was made available (125); this newer spectrum corresponds much more closely to the construct used in 
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our studies. While this spectrum does not perfectly match our spectrum of unbound Mcl-1 (there are still 
slight differences between the constructs and buffer conditions), we are nonetheless able to confidently 
transfer assignments of several of the most disperse peaks (Figure S8b). While almost all of these 
unambiguously matched peaks do not shift upon addition of M0, two of the peaks that can be assigned do 
respond to addition of M0: Gly61 and Ser76 (Figure S8c). Mapping the location of these two residues to 
the structure of Mcl-1 reveals that they are located on opposing sites of the binding site in our model of 
the M0 complex, but are not in contact with the portion of the binding groove utilized by Bcl-xL 
inhibitors such as ABT-737 and WEHI-539 (Figure S8d). 
In vitro cellular assay 
We tested compound D2 using an in vitro cellular assay, by probing its effect of D2 on viability 
of DU-145 cells (a human prostate cancer cell line that produces high levels of Mcl-1, but little Bcl-xL 
and almost no Bcl-2 (257)). Despite this, compound D2 did not exhibit reduced viability at concentrations 
close to the 5 µM Ki observed in the FP assay (Figure S11a). 
To explore whether this could be attributable to residual Bcl-xL and/or Bcl-2 activity rescuing 
cells from D2, we treating cells simultaneously with both D2 and ABT-263. The latter is an inhibitor of 
Bcl-xL and Bcl-2 that has been shown not to inhibit Mcl-1 (258, 259). Given these cells reliance on Mcl-1 
for survival, ABT-263 does not begin to affect viability of DU-145 cells until concentrations of about 
10 µM (Figure S11b); this is much higher than the concentrations needed for cells reliant on Bcl-xL or 
Bcl-2 for survival, or for DU-145 cells in which Mcl-1 has been knocked down via siRNA (results not 
shown). 
If compound D2 failed to affect cell viability due to residual Bcl-xL and/or Bcl-2 activity, then 
treatment with ABT-263 should sensitize cells to D2. However, we find that ABT-263 does not affect cell 
survival in response to D2 (Figure S11c). This suggests that D2’s lack of biological activity is not due to 
residual Bcl-xL and/or Bcl-2 activity, but rather failure of D2 to inhibit Mcl-1 in these cells. 
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2.2 Supplementary Methods 
Implementation in Rosetta 
Computational methods are implemented in the Rosetta software suite (60). Calculations were 
carried out using svn revision 52964 of the developer trunk source code. The new features described here 
are included in the Rosetta 3.6 release. Rosetta is freely available for academic use 
(www.rosettacommons.org). 
Identifying surface pockets 
As described in our earlier work (75), we have implemented into the Rosetta software suite a 
variation of the LIGSITE algorithm (76) for identifying potential small molecule binding sites on protein 
surfaces. To define pockets used in the benchmark experiments (Figures 2, 3, S1-5), we used a 10 Å grid 
around Val141 of Bcl-xL or Leu307 of XIAP. The structures used for Bcl-xL were 2yxj (inhibitor-bound) 
and 1r2d (unbound); the structures used for XIAP were 2jk7 (inhibitor-bound) and 1f9x (unbound). In our 
screen against Mcl-1, we used as a starting point the peptide-bound structure 2pqk (since no unbound 
structure was available at the time (125)), and defined the pocket using Phe270. 
Pocket optimization 
In our earlier work we developed the “pocket optimization” method for preferentially sampling 
protein fluctuations that contain a surface pocket (75). This method incorporates a term in the Rosetta 
energy function that favors pocket formation, and operates alongside the canonical energetic determinants 
of protein structure such as packing, hydrogen bonding, and solvation. Using this method we previously 
generated 1000 pocket-containing output structures starting from the unbound structures of both Bcl-xL 
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and XIAP (75), or the peptide-bound structure or Mcl-1. In the studies described here, we used the single 
lowest-energy conformation from each ensemble (energies were evaluated without the pocket-biasing 
term). 
Choosing origin point for ray-casting 
Determining where to place the “origin” (from which rays emanate) can contribute to the success 
of the ray-casting approach. Ideally, the rays should span the lower surface of the pocket uniformly, and 
should not intersect the protein again once they enter the pocket (i.e. the pocket should be purely concave, 
as viewed from a suitable origin). For globular proteins that are nearly spherical, it natural to choose the 
protein center of mass as the origin; however for proteins that are very non-spherical, an origin placed at 
the protein center of mass leads to rays that cover the pocket very non-uniformly. 
To overcome this problem, we use an origin point directly “below” the pocket. We identify such a 
point by first determining the pocket center, and then identifying the two orthogonal vectors that account 
for the most variation around this point (the “width” of the pocket). We take a direction normal to these 
two vectors (corresponding to the “depth” of the pocket), and extend this vector 30 Å in the direction 
towards the center of mass of the protein (i.e. we place the origin “on the protein side” of the pocket, not 
“on the exposed side” of the pocket). While the origin identified in this manner is not necessarily located 
within the protein, the origin nonetheless is located at a vantage point that allows rays to span the pocket 
fairly uniformly. 
DARC parameter optimization 
The DARC score entails summing contributions for individual rays with one of four weights 
applied, depending on the intersections encountered by the ray (Equation 1). Since scaling all weights 
equally would not change the relative ranking of compounds / poses, there are effectively three free 
parameters. We fixed c1=1.0, and optimized the values of the other three weights (c2/c3/c4) as described 
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below. Through ad hoc testing of many variations of the values assigned to these weights, we find that the 
results of our benchmark experiments (Figures 2 and 3) are very robust to the particular weights used. 
We compiled a training set comprised of seven different protein-protein interaction systems for 
which a structure had been solved in complex with a known small-molecule inhibitor (Table S1); none of 
the members of the training set are related to our test systems, Bcl-xL and XIAP (Figures 2 and 3), or to 
Mcl-1 (Figures 4 and 5). Starting with all four weights set to 1.0, we used simplex optimization 
(implemented via the GSL multidimensional minimization tools in C++, http://www.gnu.org/s/gsl/) to 
optimize the values of c2/c3/c4. At every step of the optimization, DARC was used to dock each inhibitor 
to the corresponding protein pocket with the current set of weights, and the sum of the ligand RMSDs 
from all seven complexes was used as the objective function. Upon completion of this optimization, we 
reached a set of weights that gave an average ligand RMSD of 1.2 Å when docking the seven compounds 
in our training set to their cognate target proteins; the value of these weights was c1=1.00 (fixed during 
optimization), c2=3.12, c3=13.32, and c4=8.13. We used these weights in carrying out all benchmark 
experiments (Figures 2 and 3) and also for the virtual screen against Mcl-1 (Figures 4 and 5). 
Running DARC with Rosetta 
Running DARC within Rosetta is a two-step process: first generating the ray-file from the protein 
surface, and second docking with DARC. 
In the first step we generate the pocket at the interface and map the shape of the pocket shell into 
a spherical coordinate file, which is called the ray-file. To generate this ray-file we read the protein 
coordinates in PDB format and specify a target residue at the interface. If the protein has a bound ligand 
we can use the ligand to center the grid. The command to run DARC is as follows: 
make_ray_files.macosgccrelease -protein 2YXJ.pdb -central_relax_pdb_num 141 
-bound_ligand N3C.pdb -extra_res_fa N3C.params 
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The output from this command will be a ray-file named “ray_2YXJ_141.txt” which we use as 
input for running docking using DARC. 
In the second step, we run the docking calculations using the pre-generated ray-file. Here we give 
the input ligands for screening against the ray-file, as follows: 
DARC.macosgccrelease -protein 2YXJ.pdb –ray_file ray_2YXJ_141.txt 
-ligand N3C.pdb -extra_res_fa N3C.params 
 
The output for this command is a docked model of the protein-ligand complex named 
“DARC_2YXJ_N3C.pdb”. 
Other optional flags to use when running DARC include: 
-origin_cutoff 9 -atom_radius_scale 0.9 -num_particles 100 -num_runs 
100 -missing_point_weight 13.3 -steric_weight 3.12 -extra_point_weight 
8.13 -search_conformers false 
 
Full documentation for these additional flags is distributed with the Rosetta source code. 
Fullatom minimization in Rosetta 
Fullatom minimization of the resulting DARC models can be carried out separately in Rosetta or 
as an additional option when invoking DARC. To minimize the DARC models immediately after docking 
we add the flag “-minimize_output_complex”: 
DARC.macosgccrelease -protein 2YXJ.pdb –ray_file ray_2YXJ_141.txt  
-ligand N3C.pdb -extra_res_fa N3C.params –minimize_output_complex 
 
This gives an additional output file named “mini_2YXJ_N3C.pdb”. 
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DOCK6 usage 
For both Bcl-xL and XIAP, a surface was generated using the UCSF Chimera package (260). 
Spheres to define the binding pocket were selected within 10 Å of the bound ligand conformation. The 
same ligand conformers used to run DARC (those generated using OMEGA (44-46)) were also used to 
run DOCK, with charges added using QuacPac (59). The grid score based on a non-bonded molecular 
mechanics force field was used as the primary and secondary scoring function (to score and rank the 
compounds). All other DOCK parameters were set to values described elsewhere (255). 
AutoDock usage 
AutoDock4.2 (85) implements a Lamarckian genetic algorithm for virtual searching, by 
optimizing a semi-empirical energy function. For Bcl-xL, a grid box size of 40*80*60 Å with 0.375 Å 
spacing covering the hydrophobic groove at the interface was used. For XIAP, a grid box size of 
50*50*50 Å with 0.375 Å spacing was used. Docking calculations were performed using the Lamarckian 
genetic algorithm with a mutation rate of 0.02 and a crossover rate of 0.8. For each ligand, 200 runs of 
docking were carried out with maximum 2.5 million energy evaluations and maximum 27,000 
generations, to obtain 200 docked conformations. The final docked conformation was taken to be the one 
with the lowest energy, and this energy was used in ranking the compounds. 
rDock usage 
rDock version 2013.1 is a docking method that sequentially uses a genetic algorithm then 
minimization to generate low-energy ligand poses, using a pre-defined cavity at the binding site of the 
target protein (86). Docking sites at the protein interface were defined using the ligand-bound crystal 
structures (2YXJ for Bcl-xL, 2JK7 for XIAP) as input for the reference ligand method in the cavity 
mapping program “rbcavity”, with a radius of 10 Å. Docking calculations were carried out with the 
standard 50 runs for each ligand. All other rDock parameters were set to their default values. The final 
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docked conformation was taken to be the one with the lowest score, and this score was used in ranking the 
compounds. 
PLANTS usage 
PLANTS (Protein-Ligand ANT System) version1.2 is a stochastic docking method based on ant 
colony optimization (87). Docking sites at the protein interface were defined using the ligand-bound 
crystal structures (2YXJ for Bcl-xL, 2JK7 for XIAP), with a radius of 10 Å. Docking calculations were 
carried out using the “rigid_all” flag, to carry out multiconformer docking for each ligand. The same 
ligand conformers used to run DARC (those generated using OMEGA (44-46)) were also used to run 
PLANTS. CHEMPLP was used as the scoring function, and all other PLANTS parameters were set to 
their default values. The final docked conformation was taken to be the one with the lowest score, and this 
score was used in ranking the compounds. 
ROCS usage 
ROCS (88-90) ligand-based screening uses Gaussian overlap to evaluate 3-dimensional similarity 
of a given ligand to a template, in terms of both shape and “color” (overlap of chemical features such as 
rings and polar groups). In this case we used the bound co-crystallized ligands in the holo structures 
(2YXJ for Bcl-xL, 2JK7 for XIAP) as the templates. The same ligand conformers used to run DARC 
(those generated using OMEGA (44-46)) were also used to run ROCS. The TanimotoCombo score was 
used to score and rank the compounds. All other ROCS parameters were set to their default values. 
Compound library for Mcl-1 screen 
Starting from the ZINC database (43), we first downloaded the “drugs now” subset of 
compounds: this subset contains about 6 million compounds with molecular weight between 150 and 
500 Da, xlogP ≤ 5, no more than 5 Hbond donors, no more than 10 Hbond acceptors, and at least one 
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commercial vendor that offers the compound for immediate delivery. We then filtered this library for 
diversity, by removing any compound with chemical similarity to any other compound in the library 
(2D Fingerprint Tanimoto score (80) > 0.7). Upon completion of this filtering step, 62,442 compounds 
remained. 
Finally, we built conformers for each of these compounds using OMEGA (44-46), with a 
maximum of 300 conformers per compound and all other options set to default. 
Expression and purification of Mcl-1 
A gene encoding residues 172-327 of human Mcl-1 (this segment lacks the PEST and 
transmembrane regions) was incorporated into a pSV282 vector as a construct containing N-terminal 
TEV-cleavable hexahistidine and maltose binding protein (MBP) fusion tags. The protein was 
transformed into E. coli Rosetta2(2DE3) pLysS cells and grown in LB media (Fisher Scientific) with 
100 µg/mL ampicillin at 37°C to an OD600 of 0.8. Expression was then induced with 1 mM IPTG for 
20 hours at 15°C. The cells were pelleted by centrifugation then resuspended in lysis buffer (20 mM 
HEPES pH 7.55, 300 mM NaCl) and lysed by sonication. The protein was purified by nickel affinity 
chromatography, then the fusion tags were removed using hexahistidine-tagged tobacco etch virus 
protease (TEV) (provided by Dr. Philip Gao, University of Kansas) at a 1:10 (m/m) ratio. The digestion 
mixture was incubated at room temperature overnight in dialysis tubing against reaction buffer (20 mM 
HEPES pH 8.0, 300 mM NaCl). The His-tagged TEV protease and His-tagged MBP were then removed 
by repassaging the reaction mixture over a Ni-column and collecting the flow-through fraction 
(corresponding to untagged Mcl-1). The untagged Mcl-1 was further purified using gel filtration on 
HiLoad 16/60 Superdex 75 prep grade column in 20 mM HEPES buffer, pH 7.55, 1 mM DTT, directly 
followed by ion exchange chromatography on HiTrap SP FF column (GE Healthcare). Final samples 
were buffer-exchanged into 20 mM HEPES buffer, pH 7.55, 1 mM DTT. Mcl-1 produced in this manner 
was used for all assays described here, including pilot fluorescence polarization studies. For the final 
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fluorescence polarization experiments described in this study, we used an Mcl-1 construct that contained 
17 additional residues at the N-terminus and 14 additional residues at the C-terminus. 
15N-labeled Mcl-1 was expressed via auto-induction in media supplemented with 15NH4Cl as 
described elsewhere (261), then purified as described above. 
TEV protease used above was also produced in E. coli Rosetta2(2DE3) pLysS cells, using the 
same expression protocol. The (His-tagged) protein was purified by nickel affinity chromatography then 
stored in 50% (v/v) glycerol, 50 mM Tris buffer, pH 8.0, 300 mM NaCl, 500 mM imidazole at -20 oC. 
Fluorescence polarization competition assay 
All fluorescence polarization experiments used a carboxyfluorescein-labeled 26-mer Noxa 
peptide (FITC-GTMENLSRRLKVTGDLFDIMSGQTDV-CONH2) in 96-well black polystyrene flat 
bottom plates (Whatman), and were carried out using a Synergy Neo plate reader (Biotek). Mcl-1 samples 
were centrifuged prior to the assay, to remove any aggregated protein; the protein concentration in the 
supernatant was then estimated via Bradford assay, and this supernatant was used for fluorescence 
polarization experiments. All assays were carried out in 20 mM HEPES (pH 7.55), 1 mM DTT, 5% 
DMSO (v/v), and 0.1% CHAPS (w/v). In all cases plates were incubated at 26°C for 1 hour prior to 
reading. All measurements were carried out in triplicate. 
To measure the apparent binding affinity of the labeled Noxa peptide with Mcl-1, a fixed 
concentration of Noxa peptide (50 nM) was incubated with increasing concentrations of purified Mcl-1 
(from 0.05 nM to 25 µM) (Figure S6a). Fluorescence polarization as a function of Mcl-1 concentration 
was fit using GraphPad Prism, with the Hill coefficient fixed at 1, leading to a Kd estimate of 79 nM. The 
fluorescence polarization at the observed endpoints of this titration (i.e. peptide alone and peptide with 
saturating Mcl-1) were taken as 100% and 0% inhibition in the competition experiments below. 
Candidate inhibitors from the DARC screen (compounds M0-M20) and M0 analogs (compounds 
D1-D27) were tested by mixing the compound with a pre-incubated mixture of Noxa peptide (50 nM) and 
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Mcl-1 (150 nM) at room temperature, at fifteen different compound concentrations ranging from 15 nM 
to 250 µM. Data were fit to a single-site competition model to determine IC50 using GraphPad Prism, 
fixing the Hill coefficient at 1 and the top and bottom values were fixed at 0 and 100% inhibition (leaving 
a single free parameter in each fit). Given the known experimental conditions and the binding affinity 
described above for the labeled Noxa peptide, the Ki was then computed from the IC50 using the method 
of Nikolovska-Coleska et al (262). 
Bio-layer interferometry 
All bio-layer interferometry (BLI) experiments were carried out using the Octet RED96 system 
(ForteBIO). 
The human Mcl-1 construct containing N-terminal hexahistidine and maltose binding protein 
(MBP) fusion tags (described above) was loaded onto Ni-NTA sensor tips. The loading step was carried 
out using 1 µM protein in 50 mM Tris, 1 mM DTT, 0.5 mM EDTA pH 7.55, and was allowed to continue 
until the BLI signal was shifted by 2 nm relative to the baseline. As a negative control, we used TEV 
protease to first remove Mcl-1 from this construct, then loaded the resulting His-tagged MBP construct. 
To generate “blank” data, the program described below was also carried out using empty sensor tips and 
the resulting blank data were subtracted from the data collected with each protein of interest. 
After loading the protein of interest, we reset the baseline in “analysis buffer” (50 mM Tris, 0.5 
mM EDTA pH 7.55). The sensor tips were then introduced into wells containing the compound of interest 
at a concentration of 50 µM in the same “analysis buffer” (with 0.5% DMSO), and separate tips were also 
introduced into wells that lacked the compound. Association-phase data were collected for 300 sec, then 
the tips were then transferred to wells containing “analysis buffer” (with no compound), and dissociation-
phase data were collected for 300 sec. All sample volumes were 250 µL, in black 96-well plates, with a 
shake speed of 1000 rpm. Data were collected every 0.2 seconds. 
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After collecting data, the sensor tips were washed with 50 mM Tris buffer, then regenerated with 
10 mM Glycine at pH 1.7, then washed with ForteBIO “kinetic buffer” then activated with 10 mM NiCl2. 
Data were collected using the ForteBIO “Data Acquisition” software (version 8.2), and analyzed 
using the ForteBIO “Data Analysis” software (version 8.2). All data were analyzed by double referencing 
(by subtracting data from sensor tips with and without protein, and subtracting data from wells with and 
without the compound of interest. 
Surface plasmon resonance 
Human Mcl-1 was coupled to CM5 sensor chip (Biacore) at approximately 9,700 response units, 
with one flow cell left uncoupled as a reference cell. Mcl-1 (in 1 mM DTT, 20 mM HEPES pH 7.55) was 
diluted into immobilization buffer (10 mM sodium acetate pH 5.0) for this step. 
Samples of M0 were prepared by carefully matching to the sample/running buffer (1 mM DTT, 
20 mM HEPES pH 7.55, 5% DMSO (v/v), 0.3% TritonX-100 (v/v)). Careful matching of buffer 
conditions mitigated potential bulk solvent effects upon analyte injection. Data were collected using a 
Biacore 3000, using a flow rate of 50 µL/min, and all sample injections (250 µL) were preceded and 
followed by buffer carry over injections (25 µL). Data points were collected at a frequency of 1 Hz. 
NMR studies 
NMR studies were carried out using 300 µM of 15N-labeled Mcl-1 in 20 mM Na2HPO4 pH 7, with 
10 mM deuterated TCEP, in 90%(H2O)/10%(D2O). Compound M0 was added as a 10 mM deuterated 
stock in 100% DMSO-d6, in three sequential additions. This led to a final concentration of 100 µM M0 
and 1.2% DMSO-d6. 
All 2D-1H-15N-HSQC spectra were acquired on a BRUKER AVANCE III 600 MHz NMR 
instrument with z-gradient, at 25°C. Spectra were recorded with 1024 complex points in the 
1H (t2, acquisition) dimension and 200 complex points in the 15N (t1, indirect) dimension with sweep 
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widths of 9615.39 Hz and 1944.90 Hz in the 1H and 15N dimensions. 48 scans were used per t1 increment. 
NMR spectra were processed using NMRPipe (263). 
MTT-based cytotoxicity assay 
DU-145 cell viability was determined by the MTT-based assay using WST-8 (GenScript, 
Piscataway, NJ). All experiments were carried out in triplicate. DU-145 cells (3500 cells/well) were 
plated in 96-well culture plates, and diluted compound D2 and/or ABT-263 then were added. Four days 
later, when control wells with no compound present reached confluence, WST-8 was added to each well 
and incubated for 2 hours at 37°C. Absorbance was measured with Synergy H4 plate reader (Biotek, 
Winooski, VT) at 450 nm. The results are expressed as the percentage of absorbance of treated wells 
versus that of the control in which no compound was added. 
Synthesis of M0 derivatives : overview 
All air and moisture-sensitive reactions were carried out in flame- or oven-dried glassware under 
argon atmosphere using standard gastight syringes, cannula, and septa. Stirring was achieved with oven-
dried magnetic stir bars. Flash column chromatography was performed with SiO2 from Sorbent 
Technology (30930M-25, Silica Gel 60 A, 40-63 mm) or by using an automated chromatography 
instrument with an appropriately sized column. Thin layer chromatography was performed on silica gel 
w/UV254 plates (1624126, sorbent technologies). 1H and 13C NMR spectra were recorded on instruments 
operating at 400 or 500 MHz and 100 or 126 MHz respectively. High-resolution mass spectrometry 
(HRMS) spectra were obtained on an ESI-TOF mass spectrometer. The analytical method utilized a 
Waters Acquity BEH C18 column (2.1 x 50 mm, 1.7 mm) eluting with a linear gradient of 95% water 
(modified to pH 9.8 through addition of NH4OH) to 100% CH3CN at 0.6 mL min-1 flow rate where purity 
was determined using UV peak area at 214 nm. 
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Synthesis of M0 derivatives : chalcone formation 
To a round-bottomed flask equipped with a stir bar was added an aldehyde (0.819 mmol), 
absolute ethanol (10 mL) and a ketone (0.819 mmol). To the reaction mixture was added an aqueous 
solution of potassium hydroxide (20%, 10 mL), and the reaction was allowed to stir overnight at room 
temperature. The reaction mixture was then poured into water (100 mL), and after neutralization with 
hydrochloric acid (5%) to precipitate the chalcone. The product was filtered, washed with cool water. The 
product was either recrystallized from ethanol, or purified via normal phase (methanol/dichloromethane) 
and/or reverse phase (water, acetonitrile) chromatography. The generalized reaction scheme is shown in 
Figure S9a. 
Synthesis of M0 derivatives : flavone formation 
To a round-bottomed flask equipped with a stir bar was added the corresponding 
2’-hydroxychalcone (numbering as in Table 1) (1 mmol) in DMSO (10 mL), and then I2 (0.01 mmol) at 
room temperature. The reaction mixture was then refluxed for 2 h. The reaction mixture was cooled to 
room temperature, and then water was added. The product was extracted with ethyl acetate three times 
from the aqueous phase. The combined organic layers were washed twice with 5% NaHSO4 aqueous 
solution, twice with water, once with brine, dried over sodium sulfate and then concentrated en vacuo. 
The crude product was purified via normal phase (methanol/dichloromethane, ethyl acetate/hexanes) 
and/or reverse phase (water, acetonitrile) chromatography. The generalized reaction scheme is shown in 
Figure S9b. 
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Synthesis of M0 derivatives : specific compounds 
 
D1: (E)-3-(3-chloro-4-hydroxy-5-methoxyphenyl)-1-(2,3,4-trimethoxyphenyl)prop-2-en-1-one. 1H NMR 
(500 MHz, DMSO-d6) δ 10.23 – 9.93 (m, 1H), 7.47 – 7.29 (m, 5H), 6.93 (d, J = 8.8 Hz, 1H), 3.89 (s, 3H), 
3.87 (s, 3H), 3.83 (s, 3H), 3.79 (s, 3H). 13C NMR (126 MHz, DMSO) δ 190.4, 156.3, 152.5, 148.5, 145.0, 
142.3, 141.6, 126.5, 126.2, 125.1, 124.8, 122.8, 120.1, 109.9, 107.7, 61.6, 60.2, 56.3, 56.0. HRMS 
calculated for C19H20ClO6 [M+H]+: 378.0870, found 379.0955. Internal barcode: SCAP108855. 
 
 
D2: (E)-3-(3-chloro-5-fluoro-4-hydroxyphenyl)-1-(2,3,4-trimethoxyphenyl)prop-2-en-1-one. 1H NMR 
(500 MHz, DMSO-d6) δ 7.68 (d, J = 8.8 Hz, 3H), 7.36 (d, J = 8.8 Hz, 2H), 6.93 (d, J = 8.8 Hz, 2H), 3.88 
(s, 3H), 3.82 (s, 3H), 3.79 (s, 3H). 13C NMR (126 MHz, DMSO) δ 185.1, 180.1, 165.2, 156.5, 135.6, 
134.7, 127.7, 126.1, 125.0, 119.2, 114.2, 112.4, 107.7, 101.8, 96.7, 61.7, 60.5, 56.1. HRMS calculated for 
C18H17ClFO5 [M+H]+: 366.0670, found 367.0748. Internal barcode: SCAP108958. 
 
 
D3: (E)-3-(3-chloro-5-fluoro-4-hydroxyphenyl)-1-(4-methoxyphenyl)prop-2-en-1-one. 1H NMR (500 
MHz, DMSO-d6) δ 8.19 (d, J = 8.9 Hz, 2H), 8.01 – 7.78 (m, 3H), 7.60 (d, J = 15.4 Hz, 1H), 7.09 (d, J = 
8.9 Hz, 2H), 3.87 (s, 3H). 13C NMR (126 MHz, DMSO) δ 187.0, 163.2, 152.8, 150.9, 143.4, 141.1, 130.9, 
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130.4, 126.3, 122.3, 121.4, 114.9, 113.9, 55.5. HRMS calculated for C16H13ClO3 [M+H]+: 306.0459, 
found 307.0529. Internal barcode: SCAP108760. 
 
 
D4: (E)-3-(3-chloro-4-hydroxy-5-methoxyphenyl)-1-(4-methoxyphenyl)prop-2-en-1-one. 1H NMR (500 
MHz, DMSO-d6) δ 10.04 (s, 1H), 8.19 (d, J = 8.9 Hz, 2H), 8.01 – 7.92 (m, 1H), 7.87 (d, J = 15.5 Hz, 1H), 
7.62 (d, J = 15.5 Hz, 1H), 7.58 (d, J = 1.8 Hz, 1H), 7.50 (d, J = 1.9 Hz, 1H), 7.09 (d, J = 8.9 Hz, 1H), 7.05 
(d, J = 8.9 Hz, 2H), 3.93 (s, 3H), 3.88 (s, 3H). 13C NMR (126 MHz, DMSO) δ 197.9, 187.1, 163.1, 162.3, 
148.7, 145.0, 142.6, 130.9, 126.5, 123.1, 120.2, 113.9, 110.5, 56.4, 55.5. HRMS calculated for 
C17H16ClO4 [M+H]+: 318.0659, found 319.0733. Internal barcode: SCAP108835. 
 
 
D5: (E)-3-(3-fluoro-4-hydroxyphenyl)-1-(2,3,4-trimethoxyphenyl)prop-2-en-1-one. 1H NMR (400 MHz, 
DMSO-d6) δ 10.51 (s, 1H), 7.63 (dd, J = 12.5, 2.1 Hz, 1H), 7.46 (d, J = 15.7 Hz, 1H), 7.43 – 7.39 (m, 
1H), 7.38 – 7.25 (m, 2H), 7.00 (dd, J = 9.1, 8.3 Hz, 1H), 6.94 (d, J = 8.8 Hz, 1H), 3.88 (s, 3H), 3.84 (s, 
3H), 3.79 (s, 3H). 13C NMR (126 MHz, DMSO) δ 190.1, 160.0, 156.3, 152.6, 147.4, 143.3, 141.6, 130.8, 
126.8, 126.7, 124.9, 123.2, 118.7, 115.9, 107.8, 61.7, 60.8, 56.1. HRMS calculated for C18H18FO5 
[M+H]+: 332.1060, found 333.1142. Internal barcode: SCAP108889. 
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D6: (E)-3-(3-fluoro-2-hydroxyphenyl)-1-(4-methoxyphenyl)prop-2-en-1-one. 1H NMR (500 MHz, 
DMSO-d6) δ 8.14 (d, J = 8.9 Hz, 1H), 7.86 – 7.51 (m, 4H), 7.45 – 7.35 (m, 1H), 7.07 (d, J = 8.9 Hz, 2H), 
6.85 (t, J = 8.8 Hz, 1H), 3.87 (s, 3H). 13C NMR (126 MHz, DMSO) δ 186.8, 162.8, 162.3, 145.7, 143.3, 
130.9, 130.6, 127.4, 125.2, 118.4, 115.3, 115.2, 113.8, 55.5. HRMS calculated for C16H14FO3 [M+H]+: 
272.0849, found 273.0921. Internal barcode: SCAP108974. 
 
 
D7: (E)-1-(2-hydroxy-3,4,5-trimethoxyphenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one. 1H NMR (500 
MHz, DMSO-d6) δ 12.41 (s, 1H), 10.12 (s, 1H), 7.62 – 7.55 (m, 3H), 7.42 (d, J = 15.7 Hz, 1H), 6.84 (d, J 
= 8.6 Hz, 2H), 6.38 (s, 1H), 3.84 (s, 3H), 3.83 (s, 3H), 3.70 (s, 3H). 13C NMR (126 MHz, DMSO) δ 
192.4, 160.1, 158.1, 158.0, 153.2, 144.1, 134.6, 130.6, 125.6, 123.4, 116.0, 110.1, 96.4, 61.5, 60.6, 56.0. 
HRMS calculated for C18H19O6 [M+H]+: 330.1103, found 331.1180. Internal barcode: SCAP108798. 
 
 
D8: (E)-3-(3-chloro-5-fluoro-4-hydroxyphenyl)-1-(pyridin-4-yl)prop-2-en-1-one. 1H NMR (500 MHz, 
DMSO-d6) δ 11.22 (s, 1H), 8.90 – 8.81 (m, 2H), 8.06 – 7.97 (m, 2H), 7.87 (s, 2H), 7.84 – 7.65 (m, 2H). 
13C NMR (126 MHz, DMSO) δ 188.4, 153.0, 151.1, 150.7, 144.0, 143.6, 128.3, 127.2, 122.5, 122.5, 
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121.6, 119.9, 115.2. HRMS calculated for C14H10FNO2 [M+H]+: 277.0306, found 278.0380. Internal 
barcode: SCAP108810. 
 
 
D9: (E)-1-(6-hydroxy-2,3,4-trimethoxyphenyl)-3-(4-(trifluoromethyl)phenyl)prop-2-en-1-one. 1H NMR 
(500 MHz, DMSO-d6) δ 12.06 (s, 1H), 7.96 (d, J = 8.0 Hz, 2H), 7.81 (d, J = 8.1 Hz, 2H), 7.66 (d, J = 4.1 
Hz, 2H), 6.41 (s, 1H), 3.85 (d, J = 4.0 Hz, 6H), 3.71 (s, 3H). 13C NMR (126 MHz, DMSO) δ 179.8, 162.0, 
159.0, 157.8, 153.2, 147.3, 140.5, 129.9, 128.9, 125.8, 122.9, 120.4, 105.9, 96.3, 61.5, 60.6, 56.0. HRMS 
calculated for C19H18F3O5 [M+H]+: 382.1028, found 383.1108. Internal barcode: SKCM104238. 
 
 
D10: (E)-1-(6-hydroxy-2,3,4-trimethoxyphenyl)-3-(4-nitrophenyl)prop-2-en-1-one. 1H NMR (400 MHz, 
DMSO-d6) δ 12.07 (s, 1H), 8.28 (d, J = 8.8 Hz, 1H), 8.02 (d, J = 8.8 Hz, 1H), 7.70 (d, J = 8.0 Hz, 2H), 
6.42 (s, 2H), 3.86 (d, J = 1.6 Hz, 6H), 3.72 (s, 3H). 13C NMR (101 MHz, DMSO) δ 192.1, 158.5, 157.9, 
153.2, 147.7, 140.9, 139.5, 134.9, 131.2, 129.2, 123.8, 110.1, 96.2, 61.6, 60.7, 56.1. HRMS calculated for 
C18H18NO7 [M+H]+: 359.1005, found 360.1078. Internal barcode: SKCM104164. 
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D11: (E)-1-(6-hydroxy-2,3,4-trimethoxyphenyl)-3-(2-nitrophenyl)prop-2-en-1-one. 1H NMR (500 MHz, 
DMSO-d6) δ 12.01 (s, 1H), 8.10 (dd, J = 8.2, 1.2 Hz, 1H), 7.96 (dd, J = 7.9, 1.3 Hz, 1H), 7.89 – 7.79 (m, 
2H), 7.70 (ddd, J = 8.5, 7.4, 1.4 Hz, 1H), 7.52 (d, J = 15.6 Hz, 1H), 6.41 (s, 1H), 3.85 (d, J = 0.8 Hz, 6H), 
3.70 (s, 3H). 13C NMR (126 MHz, DMSO) δ 192.1, 158.6, 158.0, 153.2, 148.5, 137.2, 134.6, 134.0, 
131.4, 130.9, 129.8, 129.0, 124.8, 110.1, 96.3, 61.6, 60.7, 56.1. HRMS calculated for C18H18NO7 [M+H]+: 
359.1005, found 360.1087. Internal barcode: SKCM101933. 
 
 
D12: (E)-1-(2-hydroxy-3,4,5-trimethoxyphenyl)-3-(4-methoxyphenyl)prop-2-en-1-one. 1H NMR (500 
MHz, DMSO-d6) δ 12.32 (s, 1H), 7.72 (d, J = 8.7 Hz, 2H), 7.67 – 7.41 (m, 2H), 7.04 (d, J = 8.9 Hz, 2H), 
6.40 (s, 1H), 3.89 – 3.81 (m, 10H), 3.72 (s, 3H). 13C NMR (126 MHz, DMSO) δ 192.4, 161.3, 158.0, 
153.2, 143.4, 134.6, 130.4, 127.7, 127.2, 124.5, 114.6, 110.2, 96.4, 61.5, 60.6, 56.0, 55.4. HRMS 
calculated for C19H21O6 [M+H]+: 344.1259, found 345.1336. Internal barcode: SCAP108811. 
 
 
D13: (E)-1-(2-hydroxy-3,4,5-trimethoxyphenyl)-3-(4-(trifluoromethyl)phenyl)prop-2-en-1-one. 1H NMR 
(500 MHz, DMSO-d6) δ 12.08 (s, 1H), 7.96 (d, J = 7.9 Hz, 2H), 7.80 (d, J = 8.3 Hz, 2H), 7.72 – 7.59 (m, 
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2H), 6.41 (s, 1H), 3.85 (d, J = 3.7 Hz, 6H), 3.71 (s, 3H). 13C NMR (126 MHz, DMSO) δ 192.4, 158.4, 
157.9, 153.2, 140.5, 138.7, 134.6, 129.9, 129.0, 125.8, 125.1, 122.9, 110.3, 96.4, 61.6, 60.6, 56.1. HRMS 
calculated for C19H18F3O5 [M+H]+: 382.1028, found 383.1111. Internal barcode: SCAP108799. 
 
 
D14: (E)-1-(2-hydroxy-3,4,5-trimethoxyphenyl)-3-(4-nitrophenyl)prop-2-en-1-one. 1H NMR (500 MHz, 
DMSO-d6) δ 12.02 (s, 1H), 8.10 (dd, J = 8.2, 1.2 Hz, 1H), 7.96 (dd, J = 7.9, 1.3 Hz, 1H), 7.90 – 7.78 (m, 
2H), 7.70 (ddd, J = 8.5, 7.5, 1.4 Hz, 1H), 7.53 (d, J = 15.6 Hz, 1H), 6.41 (s, 1H), 3.86 (d, J = 1.1 Hz, 6H), 
3.70 (s, 3H). 13C NMR (126 MHz, DMSO) δ 192.1, 158.6, 153.2, 148.5, 137.2, 134.6, 134.0, 131.4, 
130.9, 129.8, 124.8, 110.1, 96.3, 61.6, 60.7, 56.1. HRMS calculated for C18H18NO7 [M+H]+: 359.1005, 
found 360.1086. Internal barcode: SCAP108785. 
 
 
D15: (E)-3-(4-hydroxyphenyl)-1-(4-methoxyphenyl)prop-2-en-1-one. 1H NMR (500 MHz, DMSO-d6) δ 
10.07 (s, 1H), 8.14 (d, J = 8.9 Hz, 2H), 7.84 – 7.53 (m, 4H), 7.08 (d, J = 8.9 Hz, 2H), 6.84 (d, J = 8.6 Hz, 
2H), 3.87 (s, 3H). 13C NMR (126 MHz, DMSO) δ 187.2, 162.9, 162.3, 159.9, 143.6, 130.8, 130.7, 125.9, 
118.4, 115.7, 113.9, 55.5. HRMS calculated for C16H15O3 [M+H]+: 254.0943, found 255.1014. Internal 
barcode: SCAP108837. 
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D16: (E)-1-(4-hydroxyphenyl)-3-(pyridin-4-yl)prop-2-en-1-one. 1H NMR (500 MHz, DMSO-d6) δ 10.21 
(s, 1H), 8.98 – 8.70 (m, 2H), 8.11 – 7.94 (m, 2H), 7.87 – 7.55 (m, 6H), 6.85 (d, J = 8.6 Hz, 2H). 13C NMR 
(126 MHz, DMSO) δ 150.7, 146.2, 142.9, 131.4, 121.5, 117.9, 115.9, 104.6, 102.0, 99.5. HRMS 
calculated for C14H12ON2 [M+H]+: 225.0789, found 226.0853. Internal barcode: SCAP108817. 
 
 
D17: (E)-3-(2-hydroxy-4-methoxyphenyl)-1-(4-hydroxyphenyl)prop-2-en-1-one. 1H NMR (500 MHz, 
DMSO-d6) δ 13.67 (s, 1H), 10.21 (s, 1H), 8.83 (d, J = 5.4 Hz, 2H), 7.97 (d, J = 5.4 Hz, 1H), 7.78 (dt, J = 
8.6, 4.6 Hz, 4H), 6.90 – 6.80 (m, 2H), 3.85 (s, 3H). 13C NMR (126 MHz, DMSO) δ 184.3, 156.2, 150.9, 
147.9, 145.6, 138.6, 135.2, 131.9, 120.0, 118.1, 115.9, 100.4, 99.5, 58.0. HRMS calculated for C16H15O4 
[M+H]+: 270.0892, found 271.0963. Internal barcode: SCAP108814. 
 
 
D18: (E)-1-(4-hydroxyphenyl)-3-(4-methoxyphenyl)prop-2-en-1-one. 1H NMR (500 MHz, DMSO-d6) δ 
10.07 (s, 1H), 8.14 (d, J = 8.9 Hz, 2H), 7.81 – 7.55 (m, 4H), 7.21 – 6.99 (m, 2H), 6.93 – 6.57 (m, 2H), 
3.87 (s, 3H). 13C NMR (126 MHz, DMSO) δ 187.2, 162.9, 159.9, 143.6, 130.8, 130.7, 130.6, 125.9, 
118.4, 115.7, 113.9, 55.5. HRMS calculated for C16H15O3 [M+H]+: 254.0942, found 255.1007. Internal 
barcode: SCAP108927. 
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D19: (E)-1-(2-hydroxy-4-methoxyphenyl)-3-(pyridin-4-yl)prop-2-en-1-one. 1H NMR (500 MHz, DMSO-
d6) δ 13.20 (s, 1H), 8.84 – 8.47 (m, 2H), 7.73 (d, J = 9.4 Hz, 1H), 7.56 (ddd, J = 4.5, 1.7, 0.7 Hz, 2H), 
6.93 – 6.58 (m, 3H), 5.75 (dd, J = 12.4, 3.2 Hz, 1H), 3.84 (s, 3H). 13C NMR (126 MHz, DMSO) δ 189.3, 
165.7, 162.6, 149.9, 147.6, 128.0, 122.6, 121.0, 114.4, 110.2, 107.7, 101.1, 55.9. HRMS calculated for 
C15H14NO3 [M+H]+: 255.0895, found 256.0969. Internal barcode: SCAP109011. 
 
 
D20: (E)-1-(2,3-dihydrobenzofuran-5-yl)-3-(4-hydroxyphenyl)prop-2-en-1-one. 1H NMR (500 MHz, 
DMSO-d6) δ 10.05 (s, 1H), 8.07 (q, J = 1.3 Hz, 1H), 8.04 – 7.92 (m, 1H), 7.82 – 7.57 (m, 4H), 6.90 (d, J 
= 8.4 Hz, 1H), 6.83 (d, J = 8.6 Hz, 2H), 4.66 (t, J = 8.7 Hz, 2H), 3.27 (dd, J = 9.3, 8.2 Hz, 2H). 13C NMR 
(126 MHz, DMSO) δ 187.0, 163.7, 159.8, 143.3, 131.0, 130.8, 130.1, 128.2, 125.9, 125.8, 118.5, 115.7, 
108.8, 72.1, 40.4. HRMS calculated for C17H15O3 [M+H]+: 266.0943, found 267.1014. Internal barcode: 
SCAP108842. 
 
 
D21: (E)-3-(3,5-difluoro-4-hydroxyphenyl)-1-(2,3-dihydrobenzofuran-5-yl)prop-2-en-1-one. 1H NMR 
(500 MHz, DMSO-d6) δ 10.82 (s, 1H), 8.11 (q, J = 1.3 Hz, 1H), 8.04 (dd, J = 8.5, 2.0 Hz, 1H), 7.88 (d, J 
= 15.5 Hz, 1H), 7.69 (dd, J = 8.3, 1.7 Hz, 2H), 7.58 (d, J = 15.4 Hz, 1H), 6.91 (d, J = 8.4 Hz, 1H), 4.67 (t, 
J = 8.7 Hz, 2H), 3.31 – 3.25 (m, 2H). 13C NMR (126 MHz, DMSO) δ 186.7, 164.0, 162.3, 153.1, 151.2, 
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141.2, 141.2, 130.7, 130.4, 128.3, 126.0, 121.5, 112.4, 112.2, 108.8, 72.2, 28.3. HRMS calculated for 
C17H13F2O3 [M+H]+: 302.0755, found 303.0828. Internal barcode: SKCM101972. 
 
 
D22: (E)-1-(2,3-dihydrobenzofuran-5-yl)-3-(3-fluoro-4-hydroxyphenyl)prop-2-en-1-one. 1H NMR (500 
MHz, DMSO-d6) δ 10.49 (s, 1H), 8.09 (q, J = 1.3 Hz, 1H), 8.03 (dd, J = 8.4, 1.9 Hz, 1H), 7.85 (dd, J = 
12.7, 2.1 Hz, 1H), 7.80 (d, J = 15.4 Hz, 1H), 7.64 – 7.57 (m, 1H), 7.51 – 7.44 (m, 1H), 6.99 (dd, J = 9.1, 
8.3 Hz, 1H), 6.90 (d, J = 8.4 Hz, 1H), 4.66 (t, J = 8.7 Hz, 2H), 3.31 – 3.22 (m, 2H). 13C NMR (126 MHz, 
DMSO) δ 186.9, 163.9, 162.3, 152.1, 150.2, 147.2, 142.2,130.9, 130.3, 128.2, 126.8, 120.1, 117.7, 115.6, 
108.8, 72.1, 28.4. HRMS calculated for C17H14FO3 [M+H]+: 284.0849, found 285.0921. Internal barcode: 
SKCM104208. 
 
 
D23: (E)-3-(benzo[d][1,3]dioxol-5-yl)-1-(2-hydroxy-3,4,5-trimethoxyphenyl)prop-2-en-1-one. 1H NMR 
(500 MHz, DMSO-d6) δ 12.13 (s, 1H), 7.54 (d, J = 15.7 Hz, 1H), 7.43 (s, 1H), 7.37 (d, J = 1.7 Hz, 1H), 
7.24 (dd, J = 8.3, 1.7 Hz, 1H), 6.99 (d, J = 8.0 Hz, 1H), 6.38 (s, 1H), 6.11 (s, 2H), 3.84 (s, 3H), 3.83 (s, 
3H), 3.70 (s, 3H). 13C NMR (126 MHz, DMSO) δ 193.3, 157.9, 155.5, 153.1, 144.9, 130.7, 125.2, 121.0, 
117.0, 113.6, 110.4, 108.7, 106.8, 106.0, 101.7, 81.8, 61.5, 60.6, 56.0. HRMS calculated for C19H19O7 
[M+H]+: 358.1053, found 359.1132. Internal barcode: SCAP108867. 
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D24: 2-(4-aminophenyl)-5,6,7-trimethoxy-4H-chromen-4-one. 1H NMR (500 MHz, DMSO-d6) δ 7.74 (d, 
J = 8.7 Hz, 2H), 7.16 (s, 1H), 6.66 (d, J = 8.8 Hz, 2H), 6.49 (s, 1H), 5.95 (s, 2H), 3.94 (s, 3H), 3.79 (s, 
3H), 3.76 (s, 3H). 13C NMR (126 MHz, DMSO) δ 195.1, 171.0, 158.9, 152.2, 131.2, 127.5, 123.1, 119.3, 
113.4, 111.9, 105.9, 103.6, 102.6, 99.5, 97.2, 61.8, 60.9, 56.4. HRMS calculated for C18H18NO5 [M+H]+: 
327.1107, found 328.1186. Internal barcode: SKCM101975. 
 
 
D25: 5,6,7-trimethoxy-2-(4-(trifluoromethyl)phenyl)-4H-chromen-4-one. 1H NMR (500 MHz, DMSO-d6) 
δ 7.62 (dd, J = 12.4, 2.1 Hz, 1H), 7.34 (d, J = 8.7 Hz, 1H), 7.28 (d, J = 15.8 Hz, 1H), 6.99 (dd, J = 9.1, 8.3 
Hz, 1H), 6.93 (d, J = 8.8 Hz, 1H), 3.87 (s, 3H), 3.83 (s, 3H), 3.79 (s, 3H). 13C NMR (126 MHz, DMSO) δ 
190.1, 156.4, 152.7, 152.0, 150.1, 147.3, 142.0, 141.6, 126.4, 126.0, 124.9, 124.6, 117.9, 115.8, 115.7, 
107.8, 61.7, 60.5, 56.0. HRMS calculated for C19H16F3O5 [M+H]+: 380.0872, found 381.0952. Internal 
barcode: SKCM102002. 
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D26: 5,6,7-trimethoxy-2-(2-nitrophenyl)-4H-chromen-4-one. 1H NMR (500 MHz, DMSO-d6) δ 8.22 (dt, 
J = 8.1, 0.8 Hz, 1H), 7.95 – 7.92 (m, 1H), 7.89 – 7.86 (m, 1H), 6.91 (s, 1H), 6.54 (s, 1H), 3.90 (s, 3H), 
3.83 (s, 3H), 3.78 (s, 3H). 13C NMR (126 MHz, DMSO) δ 175.2, 159.5, 157.9, 151.7, 144.8, 141.6, 140.0, 
134.1, 132.6, 132.4, 131.5, 125.4, 124.9, 111.5, 96.8, 61.9, 61.0, 56.5. HRMS calculated for C18H16NO7 
[M+H]+: 357.0849, found 358.0930. Internal barcode: SKCM104161. 
 
 
D27: 2-(2-aminophenyl)-5,6,7-trimethoxy-4H-chromen-4-one. 1H NMR (500 MHz, DMSO-d6) δ 
7.39 (dd, J = 7.8, 1.6 Hz, 1H), 7.20 (ddd, J = 8.6, 7.2, 1.6 Hz, 1H), 7.14 (s, 1H), 6.82 (dd, J = 8.3, 1.1 Hz, 
1H), 6.65 (ddd, J = 8.0, 7.2, 1.1 Hz, 1H), 6.33 (s, 1H), 5.61 (s, 2H), 3.93 (s, 3H), 3.81 (s, 3H), 3.77 (s, 
3H). 13C NMR (126 MHz, DMSO) δ 192.9, 162.3, 157.3, 154.2, 151.5, 150.9, 147.0, 145.5, 140.9, 137.5, 
131.6, 129.2, 116.5, 110.2, 97.5, 61.8, 61.0, 56.4. HRMS calculated for C18H18NO5 [M+H]+: 327.1107, 
found 328.1185. Internal barcode: SKCM104166. 
 
 
 
 
 
O
O
O O
O
NO2
O
O
O O
O
NH2
 
 
163 
2.3 Supplementary Tables 
 
Protein Inhibitor-bound PDB Ligand RMSD after DARC docking (Å) 
Clathrin 2XZG 1.35 
IL-2 1PW6 2.05 
gp41 peptide 2KP8 1.42 
FKBP12 1J4I 0.65 
ZipA 1S1S 0.56 
TNFα 2AZ5 1.95 
HIV-1 integrase 3LPU 0.32 
 
Table S1: Protein-ligand complexes used in DARC parameter optimization (c1/c2/c3/c4). This 
training set was assembled from complexes included in the 2P2I (56) and TIMBAL (78) databases. 
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Compound ZINC ID Chemical structure 
M0 04252579 
 
M1 02098378 
 
M2 12790730 
 
M3 04823201 
 
M4 08783173 
 
M5 03954116 
 
M6 02411771 
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M7 18258326 
 
M8 08856242 
 
M9 12547109 
 
M10 72151170 
 
M11 20325906 
 
M12 49735096 
 
M13 18197321 
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M14 18195186 
 
M15 57351782 
 
M16 08771601 
 
M17 12323480 
 
M18 04058299 
 
M19 03656394 
 
M20 05445823 
 
 
Table S2: Initial DARC screening hits tested for Mcl-1 inhibition. The chemical structures and 
ZINC IDs are presented for each of the initial DARC hits that were purchased and characterized. 
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2.4 Supplementary Figures 
 
Figure S1: This receiver operating characteristic (ROC) plot compares the performance of various 
methods (DARC, DOCK, AutoDock, rDock, PLANTS, and ROCS) in a similar benchmark experiment to 
that described in Figure 2. Here, the same active compounds were included but decoy compounds were 
drawn from the TIMBAL set (78, 79) instead of from the Astex diverse set (35). This allowed the use of 
328 decoy compounds in the Bcl-xL screen, and 425 decoy compounds in the XIAP screen. The results 
are presented on a semi-log plot to highlight the “early” performance of the methods; the grey curve 
indicates the random retrieval of compounds (i.e. a random predictor). 
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Figure S2: This receiver operating characteristic (ROC) plot compares the performance of various 
methods (DARC, DOCK, AutoDock, rDock, PLANTS, and ROCS) in a similar benchmark experiment to 
that described in Figure 2. Here, the same active compounds were included but decoy compounds were 
generated by the DUD-E server (81) to carefully match the physicochemical properties of the active 
compounds. There were 1350 decoy compounds in the Bcl-xL screen, and 700 decoy compounds in the 
XIAP screen. 
 
 
Figure S3: This receiver operating characteristic (ROC) plot examines the sensitivity of DARC’s 
performance to the location of the “origin point” from which rays emanate. The benchmark is analogous 
to that described in Figure 2, with decoys drawn from the Astex diverse set (35). In this experiment, four 
different methods were used to separately determine the location of the origin point; in each case the 
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origin was positioned exactly 30 Å from the center of the surface pocket. For Origin 1, the origin was 
positioned by following the direction towards the protein center of mass. Origin 2 corresponds taking a 
vector orthogonal to the maximal variation of the pocket points (this is the default method, as described in 
Supplementary Methods). Origin 3 is calculated by first summing the vectors connecting each pocket 
point with the pocket center; for a concave pocket, this vector sum yields a vector that points “out” of the 
pocket. The sign of this vector is inverted, then its magnitude is scaled to give the location of the origin. 
Finally, Origin 4 is determined by manually selecting an arbitrary residue in the binding site (Ser4 for 
Bcl-xL, and Glu282 for XIAP), then extending the vector connecting the pocket center to the center of 
mass of this residue to give the location of the origin. Each of these approaches gives a distinct – but 
reasonable – location of the origin point. For these two target proteins, the overall performance of DARC 
is remarkably robust to this variation of the location of the origin point. 
 
 
Figure S4: This benchmark experiment involves discrimination of the same active versus “decoy” 
compounds as in Figure S1 (decoy compounds from the TIMBAL set (78, 79)). This time, however, 
compounds were screened against a protein conformation generated via “pocket optimization” 
simulations (instead of against an inhibitor-bound crystal structure). The protein conformation used for 
Bcl-xL and XIAP in this experiment was also used in carrying out the benchmark experiment shown 
Figure 3. 
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Figure S5: This benchmark experiment involves discrimination of the same active versus “decoy” 
compounds as in Figure S2 (custom decoy compounds generated using the DUD-E server (81)). This 
time, however, compounds were screened against a protein conformation generated via “pocket 
optimization” simulations (instead of against an inhibitor-bound crystal structure). The protein 
conformation used for Bcl-xL and XIAP in this experiment was also used in carrying out the benchmark 
experiment shown Figure 3. 
 
 
Figure S6: (A) Direct monitoring of the interaction between a FITC-labeled Noxa peptide and 
recombinant human Mcl-1 (at concentrations of 0.05 nM to 25 µM). Their interaction leads to an increase 
in fluorescence polarization (black points), which is well-described by a curve with Hill coefficient fixed 
at 1 (red curve); the estimated dissociation constant (Kd) for this interaction is 79 nM. (B) As a positive 
control for this assay, we tested for inhibition of Mcl-1 by AT-101 (i.e. R-(-)-gossypol), a known Mcl-1 
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inhibitor (129). Experimental conditions for this fluorescence polarization competition assay and fitting of 
the resulting data were carried out as described in Figure 4 and in Supplementary Results. 
 
 
Figure S7: Surface plasmon resonance (SPR) confirms the M0/Mcl-1 interaction. Recombinant human 
Mcl-1 was immobilized on the surface of the chip, and increasing concentrations of M0 were flowed 
across the surface (concentrations of 25/50/100/150 µM are shown, each in duplicate). 
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Figure S8: (A) HSQC spectra are superposed for 300 µM recombinant human Mcl-1 alone (blue), and in 
the presence of 100 µM M0 (red). Despite the fact that Mcl-1 remains in excess, several peaks exhibit 
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chemical shift differences. In separate experiments, we have confirmed that the addition of DMSO-d6 was 
not responsible for these observed chemical shift differences. (B) Superposition of these two (unassigned) 
spectra with the assigned spectrum of human Mcl-1 (125) (black). Despite the use of slightly different 
constructs and buffer conditions, assignment of some peaks can be unambiguously transferred. 
(C) Among peaks that exhibit chemical shift differences upon addition of M0, assignments can be 
unambiguously transferred for only two of these: Ser76 and Gly61. (D) Mapping the location of these two 
residues to the DARC model of the M0/Mcl-1 complex reveals that they are located at the edge of the 
expected binding site, providing support for this model of M0 binding. 
 
 
Figure S9: Generalized reaction schemes for (A) chalcone synthesis (compounds D1-D23) and 
(B) flavone synthesis (compounds D24-D27). 
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Figure S10: Inhibition of Mcl-1 by the most potent M0 derivatives, D1 and D2. Experimental conditions 
for this fluorescence polarization competition assay and fitting of the resulting data were carried out as 
described in Figure 4. 
 
 
 
 
Figure S11: (A) Incubation of cells with compound D2 reduces viability of DU-145 cells only at very 
high concentrations. (B) An inhibitor of Bcl-xL and Bcl-2, ABT-263, reduces viability of DU-145 cells at 
concentrations above 10 µM. (C) Addition of ABT-263 does not sentitize cells to D2, suggesting lack of 
synergy between these compounds. Lines are drawn between adjacent points to guide the eye. 
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APPENDIX A.3: Supporting Information for Chapter 3 
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3.1 Supplementary Tables 
 
Protein Ligand-bound PDB Ligand conformers used 
Calpain 1ALW 8 
calmodulin 1CTR 30 
IL-2 1PW6 300 
HPV E2 1R6N 50 
XIAP-BIR3 1TFT 175 
ZipA 1Y2F 300 
Bcl-xL 1YSI 300 
TNFα 2AZ5 300 
HIV-gp41 2KP8 42 
integrin 2VC2 300 
BRD4 2YEL 250 
S100B 3GK1 198 
Grb2-SH2 3IN7 300 
SHANK PDZ 3O5N 3 
WDR5 3UR4 300 
PCNA 3VKX 62 
VHL 3ZRC 300 
Plasminogen 4CIK 36 
HIV integrase 4E1N 1 
Mdm2 4ERF 10 
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clathrin 4G55 300 
Menin 4GQ4 175 
Cytohesin-2 4JMO 7 
keap1 4L7D 59 
RPA1 4LUZ 264 
 
 
Table S1: Small-molecule inhibitors bound to protein interaction sites. We compiled a set of 25 
unique protein interaction sites for which a crystal structure has been solved in complex with a small-
molecule inhibitor. This set is based upon our previous set of 21 complexes that were available at the time 
(drawn in part from the 2P2I (56) and TIMBAL (78) databases) (71), and we now add 4 additional 
examples have since become available. We did not include complexes with small molecule stabilizers, or 
complexes with small fragments or large peptide-like compounds. We only included one representative 
complex from each protein family; in cases where more than one suitable inhibitor-bound structure had 
been solved from a given family, we retained only the structure in complex with the most potent ligand. 
We also report here the number of conformers for each ligand used in these studies; conformers were 
generated using OMEGA (see Methods), and an average of 163 were used for the ligands in this set. 
 
3.2 Supplementary Data 
 
Dataset S1. Protocol Capture. The protocol capture contains all the example input and output files, and 
representative command-lines and flags required for running DARC. The dataset was uploaded to the 
Rosetta demos revision control (Rosetta/demos/public/DARC/). 
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APPENDIX A.4 Supporting Information for Chapter 4 
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4.1 Supporting Methods 
PDB structures used in calculations 
The calculations that led to selection of R1-R12 were carried out using model 1 of the NMR 
structure of Musashi-1 bound to RNA (PDB ID 2RS2). 
Building hotspot pharmacophores 
Hotspot pharmacophores were built using a dedicated protocol implemented in the Rosetta 
software suite (60), and is freely available for academic use (www.rosettacommons.org).  
To select deeply buried RNA bases, the solvent accessible surface area (SASA) of each base in 
the RNA was calculated in the presence and absence of the protein. A base was carried forward if the 
change in SASA upon complexation was greater than a preset cutoff value (46.81 Å2 for adenine, 
31.09 Å2 for cytosine, 45.06 Å2 for guanine and 52.66 Å2 for uracil); these values correspond to the 
median values of 344 non-redundant protein-RNA complexes retrieved from the Protein-RNA Interface 
Database (PRIDB) (264) in March 2013 (http://pridb.gdcb.iastate.edu/download/RB344.txt). 
Polar groups from the RNA that participate in intermolecular hydrogen bonding (as defined using 
the Rosetta energy function) are also included. 
The Rosetta command line used to carry out this step is as follows: 
get_rna_pharmacophore_with_water.macosgccrelease -input_rna xxx_rna.pdb -input_protein 
xxx_protein.pdb 
 
The resulting interaction maps are then clustered using a modified version of Kruskal’s minimum 
spanning tree algorithm. We first build a complete graph, in which vertices are the ring moieties, and the 
edge weights are the Euclidean distances between vertices. Then we take edges in ascending order and 
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cluster the end vertices of that edge if no cycle would be caused. We halt the clustering when the distance 
is greater than a user-specified cutoff value (default 5.0 Å). The donor/acceptor atoms are then assigned to 
the closest ring moieties if the distance is less than another user-specified value (default 5.0 Å). Finally, 
we output the pharmacophore templates if the cluster contains at least two ring moieties. The Kruskal 
clustering code is also implemented in Rosetta, and is carried out as follows: 
cluster_pharmacophore.macosgccrelease –input xxx_rna.pdb –ring_cutoff xxx –da_cutoff 
xxx 
Identifying complementary ligands 
We used ROCS to screen large libraries for compounds that match the hotspot pharmacophore. 
We downloaded the standard ‘drugs-now’ subset of ~7 million molecules from ZINC database for 
screening (43). We generated up to 100 conformers for each molecule in the database using OMEGA (44-
46). We screened the database using the hotspot pharmacophore (using default ROCS parameters), and 
carried forward the top 500 compounds ranked by 'TanimotoCombo' score. We then aligned these back to 
the protein using the hotspot pharmacophore, then carried out a gradient-based fullatom minimization of 
the complex using the Rosetta energy function (60). The top-scoring compounds were visually inspected 
and selected for experimental validation based on cost and availability. 
Predicting target selectivity 
The complete set of 1792 protein-RNA complexes were retrieved from the PDB in June 2014. 
Hotspot pharmacophores were extracted from each complex, and non-unique pharmacophores were 
removed (those with ROCS shape_tanimoto > 0.94 and color_tanimoto > 0.74). This left 543 unique 
pharmacophores that were comprised of at least two rings, derived from 362 different protein-RNA 
complexes. 
Conformers for each compound were generated by OMEGA using the following command line: 
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omega2 -in xxx.pdb -strictatomtyping false -strictstereo false -strictfrags false -
searchff mmff94s -buildff mmff94s -maxconfs 500 
For a given compound, we then used ROCS to screen conformers of this molecule against the 
library of hotspot pharmacophores using the following command line: 
rocs -dbase conformer_ensemble.pdb -query hotspot.pdb -oformat pdb –rankby 
FitTverskyCombo  
Synthesis of R12 derivatives : overview 
All air- and moisture-sensitive reactions were carried out in flame- or oven-dried glassware under 
argon atmosphere using standard gastight syringes, cannula, and septa. Stirring was achieved with oven-
dried magnetic stir bars. Flash column chromatography was performed with SiO2 from Sorbent 
Technology (30930M-25, Silica Gel 60A, 40−63 µm) or by using an automated chromatography 
instrument with an appropriately sized column. Thin layer chromatography was performed on silica gel 
w/UV254 plates (1624126, Sorbent Technologies). 1H and 13C NMR spectra were recorded on 
instruments operating at 400 or 500 MHz and 100 or 126 MHz, respectively. High-resolution mass 
spectrometry (HRMS) spectra were obtained on an ESITOF mass spectrometer. The analytical method 
utilized a Waters Aquity BEH C18 column (2.1 × 50 mm, 1.7 µm) eluting with a linear gradient of 95% 
water (modified to pH 9.8 through addition of NH4OH) to 100% CH3CN at 0.6 mL/min flow rate where 
purity was determined using UV peak area at 214 nm. 
Synthesis of specific intermediates / derivatives is described in detail in the following sections, 
and summarized in Figure S4. 
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Synthesis of R12 derivatives : general procedure #1 
 
Following a modified procedure outlined by Do et al. (265), a mixture of tert-butyl 4-
aminopiperidine-1-carboxylate (0.85 g, 4.22 mmol), 3,5-dibromopyridine (1.0 g, 4.22 mmol) 
tris(dibenzylideneacetone)dipalladium(0) (0.077 g, 0.084 mmol), (±)-2,2'-bis(diphenylphosphino)-1,1'-
binaphthalene (0.11 g, 0.17 mmol) and sodium-t-butoxide (0.61 g, 6.33 mmol) in toluene (30.2 mL) was 
heated to 80 °C for 16 h, then the reaction mixture was allowed to cool to ambient temperature, diluted 
with ether (100 mL) and washed with brine (3×30 mL). The organic layer was dried over MgSO4, filtered 
and concentrated under vacuum. The residue was purified by silica gel chromatography (50% EtOAc in 
hexanes, Rf = 0.5) to afford the title compound tert-butyl 4-((5-bromopyridin-3-yl)amino)piperidine-1-
carboxylate (879.8 mg, 2.47 mmol, 59% yield) as a white solid. 1H NMR (400 MHz, CDCl3) δ 8.22 (d, J 
= 2.6 Hz, 1H), 8.11 (d, J = 1.9 Hz, 1H), 7.31 (dd, J = 2.6, 1.9 Hz, 1H), 4.55 (s, br. 1H), 3.70 – 3.60 (m, 
3H), 2.97 – 2.90 (m, 2H), 2.14 – 2.03 (m, 2H), 1.60 – 1.49 (m, 2H), 1.47 (s, 9H). 13C NMR (101 MHz, 
CDCl3) δ 155.10, 147.64, 140.51, 136.65, 124.72, 120.81, 47.51, 47.42, 31.88, 28.40. 
Synthesis of R12 derivatives : general procedure #2 
 
To a solution of tert-butyl 4-((5-bromopyridin-3-yl)amino)piperidine-1-carboxylate (433.5 mg, 
1.22 mmol) in dichloromethane (9 mL), was added hydrogen chloride in dioxane (15.2 mL, 60.8 mmol). 
The reaction was stirred at rt for 16 h. Solvents were removed to give a white solid. Yield: 445.0 mg, 
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100%. 1H NMR (400 MHz, MeOD) δ 8.53 (d, J = 2.4 Hz, 1H), 8.38 – 8.31 (m, 2H), 4.19 – 4.10 (m, 2H), 
3.83 – 3.58 (m, 3H), 3.53 – 3.47 (m, 1H), 3.26 – 3.14 (m, 2H), 2.26 – 2.17 (m, 2H), 1.84 – 1.73 (m, 2H). 
13C NMR (101 MHz, MeOD) δ 150.00, 132.59, 131.09, 127.98, 123.69, 73.59, 72.48, 62.23, 46.60, 
43.84. 
Synthesis of R12 derivatives : general procedure #3 
 
To a solution of 5-bromo-N-(piperidin-4-yl)pyridin-3-amine dihydrochloride (200.0 mg, 0.55 
mmol) in methanol (4 mL), was added sodium carbonate (174.0 mg, 1.64 mmol). Solvent was removed 
and residue was extracted with DCM. DCM was dried over MgSO4 and evaporated to dryness to give a 
light-yellow oil. Yield: 81.0 mg, 58%. 1H NMR (400 MHz, CDCl3) δ 8.20 (d, J = 2.6 Hz, 1H), 8.06 (d, J 
= 1.9 Hz, 1H), 7.28 (dd, J = 2.6, 1.9 Hz, 1H), 3.82 – 3.56 (m, 3H), 2.93 – 2.79 (m, 3H), 1.97 – 1.86 (m, 
2H), 1.50 – 1.43 (m, 3H). 13C NMR (101 MHz, CDCl3) δ 147.78, 140.25, 136.61, 124.48, 120.80, 48.22, 
47.37, 35.15. HRMS (m/z): calcd for C10H14BrN3 (neutral M+H) 255.0371; found 255.0379. 
Synthesis of R12 derivatives : general procedure #4 
 
To a solution of 2-chloroquinazolin-4-amine (28.4 mg, 0.16 mmol) and 5-bromo-N-(piperidin-4-
yl)pyridin-3-amine (81.0 mg, 0.32 mmol) in acetonitrile (2 mL) was heated at 180 °C for 1 h under 
microwave irradiation. The material was purified via reverse phase combiflash first, followed by further 
purification via silica gel chromatography (DCM/MeOH = 10:1, Rf = 0.3) to give 2-(4-((5-bromopyridin-
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3-yl)amino)piperidin-1-yl)quinazolin-4-amine (36.4 mg, 0.091 mmol, 58% yield) as a white solid. 1H 
NMR (400 MHz, CDCl3) δ 8.24 (d, J = 2.6 Hz, 1H), 8.12 (d, J = 1.9 Hz, 1H), 7.65 – 7.56 (m, 2H), 7.51 – 
7.48 (m, 1H), 7.33 (t, J = 2.3 Hz, 1H), 7.16 – 7.12 (m, 1H), 5.57 (s, br. 2H), 5.01 (s, br. 1H), 4.23 – 4.14 
(m, 1H), 3.72 – 3.62 (m, 2H), 3.07 – 3.00 (m, 2H), 2.25 – 2.20 (m, 2H), 1.71 – 1.56 (m, 2H). 13C NMR 
(101 MHz, CDCl3) δ 162.1, 158.5, 152.3, 147.8, 140.4, 136.7, 133.4, 125.6, 124.6, 121.9, 121.5, 120.8, 
110.4, 47.5, 47.3, 31.9. HRMS (m/z): calcd for C18H20BrN6 (neutral M+H) 399.0933; found 399.0900. 
Synthesis of R12 derivatives : specific compounds 
 
Synthesized by using general procedures #1, #2 and then #3. 1H NMR (400 MHz, DMSO-d6) δ 
8.35 (d, J = 2.6 Hz, 1H), 8.15 – 8.02 (m, 4H), 7.72 (t, J = 2.2 Hz, 1H), 3.92 (d, J = 13.5 Hz, 2H), 3.25 (d, 
J = 12.5 Hz, 1H), 2.97 – 2.84 (m, 2H), 1.95 (d, J = 10.8 Hz, 2H), 1.57 (qd, J = 12.2, 4.1 Hz, 2H). HRMS 
(m/z): calcd for C10H14BrN3 (neutral M+H) 255.0371; found 255.0366. 
 
Synthesized using general procedure 4 by reacting 2-chloroquinazolin-4-amine (0.036 g, 0.203 
mmol) and 5-bromo-N-(piperidin-4-yl)pyridin-3-amine (.078 g, 0.305 mmol) to give 2-(4-((5-
bromopyridin-3-yl)amino)piperidin-1-yl)quinazolin-4-amine (.062 g, 0.155 mmol, 76 % yield) 1H NMR 
(400 MHz, Acetone-d6) δ 7.97 (d, J = 2.5 Hz, 1H), 7.88 (dd, J = 8.1, 1.4 Hz, 1H), 7.78 (d, J = 1.9 Hz, 
1H), 7.47 (ddd, J = 8.4, 6.8, 1.4 Hz, 1H), 7.30 (dd, J = 8.5, 1.3 Hz, 1H), 7.17 (t, J = 2.2 Hz, 1H), 7.00 
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(ddd, J = 8.2, 6.8, 1.2 Hz, 1H), 5.38 (d, J = 8.1 Hz, 1H), 4.83 – 4.66 (m, 2H), 3.63 (tdd, J = 6.5, 4.2, 2.4 
Hz, 1H), 3.08 (ddd, J = 13.8, 11.5, 2.7 Hz, 2H), 1.45 – 1.30 (m, 2H). 13C NMR (101 MHz, Acetone) δ 
206.12, 163.36, 159.98, 153.94, 146.20, 138.11, 135.70, 133.34, 126.43, 123.77, 121.26, 120.48, 111.01, 
54.95, 50.64, 43.27, 32.60, 30.41, 30.22, 30.03, 29.83, 29.64, 29.45, 29.26. HRMS (m/z): calcd for 
C18H20BrN6 (neutral M+H) 399.0871; found 399.0855. 
 
Synthesized using general procedure 4 by reacting 2-chloroquinazolin-4-amine (0.045 g, 
0.248mmol) and 1-(5-bromopyridin-3-yl)-1,4-diazepane (266) (0.127 g, 0.496 mmol) to give 2-(4-(5-
bromopyridin-3-yl)-1,4-diazepan-1-yl)quinazolin-4-amine (0.067g, 0.168 mmol, 68% yield) 1H NMR 
(400 MHz, Chloroform-d) δ 8.05 (d, J = 2.7 Hz, 1H), 7.92 (d, J = 1.7 Hz, 1H), 7.57 – 7.45 (m, 3H), 7.13 – 
7.01 (m, 2H), 4.10 – 4.00 (m, 2H), 3.72 (t, J = 6.2 Hz, 2H), 3.64 (t, J = 5.3 Hz, 2H), 3.49 (t, J = 6.2 Hz, 
2H), 2.10 (t, J = 6.2 Hz, 2H). 13C NMR (101 MHz, CDCl3) δ 161.72, 158.08, 144.71, 137.58, 133.16, 
132.56, 125.72, 121.87, 121.24, 121.14, 120.16, 109.69, 77.36, 77.04, 76.72, 53.75, 49.89, 47.84, 46.61, 
46.22, 24.37. HRMS (m/z): calcd for C18H20BrN6 (neutral M+H) 399.0864; found 399.0855. 
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Synthesized using general procedure 4 by reacting 2-chloroquinazolin-4-amine (0.022 g, 0.124 
mmol) and 1-(5-bromopyridin-3-yl)piperazine (266) (.03 g, 0.124 mmol) to give 2-(4-(5-bromopyridin-3-
yl)piperazin-1-yl)quinazolin-4-amine (.031 g, 0.080 mmol, 64.9 % yield). 1H NMR (400 MHz, 
Chloroform-d) δ 8.26 (d, J = 2.6 Hz, 1H), 8.14 (d, J = 1.9 Hz, 1H), 7.63 – 7.48 (m, 3H), 7.34 (dd, J = 2.6, 
1.9 Hz, 1H), 7.13 (ddd, J = 8.1, 6.8, 1.3 Hz, 1H), 4.42 – 3.94 (m, 4H), 3.58 – 3.11 (m, 4H). 13C NMR (126 
MHz, CDCl3) δ 161.68, 158.76, 152.60, 147.97, 141.01, 136.62, 133.35, 126.08, 124.64, 121.76, 121.62, 
120.86, 109.91, 48.26, 43.48. HRMS (m/z): calcd for C17H17BrN6 (neutral M+H) 384.0698; found 
384.0709. 
 
5-bromopyridin-3-amine (0.3 g, 1.734 mmol) was dissolved in acetonitrile and the reaction 
mixture was cooled to 0 °C. N,N'-Diisopropylethylamine (0.636 ml, 3.65 mmol) was added dropwise. 
Then, 1-chloro-2-isocyanatoethane (0.156 ml, 1.825 mmol) was added dropwise. The reaction was 
allowed to stir for 16 hours. The reaction was quenched with water, washed with brine, dried with sodium 
sulfate and then concentrated en vacuo and then purified via normal phase chromatography (ethyl 
acetate/hexanes) to give 1-(5-bromopyridin-3-yl)-3-(2-chloroethyl)urea (.49 g, 1.759 mmol, 96 % 
yield)1H NMR (400 MHz, DMSO-d6) δ 9.09 (s, 1H), 8.44 (d, J = 2.2 Hz, 1H), 8.27 (t, J = 2.2 Hz, 1H), 
8.23 (d, J = 2.1 Hz, 1H), 6.67 (t, J = 5.9 Hz, 1H), 3.67 (t, J = 6.1 Hz, 2H), 3.43 (q, J = 6.1 Hz, 2H). 13C 
NMR (101 MHz, DMSO) δ 149.09, 142.29, 137.94, 130.73, 126.34, 114.38, 44.06, 41.27. HRMS (m/z): 
calcd for C8H9BrClN3O (neutral M+H) 276.9609; found 276.9618. 
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In a round bottomed flask, 1-(5-bromopyridin-3-yl)-3-(2-chloroethyl)urea (.3 g, 1.077 mmol) was 
dissolved in THF, a stir bar was added and the reaction mixture was cooled to 0 °C. To the reaction 
mixture sodium hydride (0.078 g, 3.23 mmol) was added slowly. The reaction was allowed to slowly 
warm to room temperature and allowed to continue stirring for 16 hours. The reaction was cooled to 0 °C 
and then quenched with the dropwise addition of water. More water was added, then extracted three times 
with ethyl acetate, washed twice with water, twice with brine and then dried with sodium sulfate and 
concentrated en vacuo. The crude residue was then purified via normal phase chromatography 
(Methanol/DCM) to give 1-(5-bromopyridin-3-yl)imidazolidin-2-one (.217 g, 0.896 mmol, 83 % yield). 
1H NMR (400 MHz, DMSO-d6) δ 8.72 – 8.64 (m, 1H), 8.34 (t, J = 2.2 Hz, 1H), 8.32 – 8.24 (m, 1H), 7.32 
(s, 1H), 3.96 – 3.86 (m, 2H), 3.45 (ddd, J = 8.9, 6.8, 1.1 Hz, 2H). 13C NMR (101 MHz, DMSO) δ 158.78, 
142.26, 136.70, 125.52, 119.66, 43.90, 36.92. HRMS (m/z): calcd for C8H8BrN3O (neutral M+H) 
240.9885; found 240.9851. 
 
To a dried round bottomed flask was added 1-(5-bromopyridin-3-yl)imidazolidin-2-one (.1 g, 
0.413 mmol), THF and a stir bar. The mixture was cooled to 0 °C. Then, sodium hydride (0.030 g, 1.239 
mmol) was added slowly. The mixture was allowed to stir for 30 minutes. Then, 2-chloroquinazolin-4-
amine (0.074 g, 0.413 mmol) was added. The reaction was allowed to warm to room temperature slowly 
and then continue stirring for 12 hours. The reaction was quenched with water, extracted three times with 
ethyl acetate, washed with brine, dried with sodium sulfate and then concentrated en vacuo. The crude 
residue was purified via normal phase chromatography (Methanol/dichloromethane) and tehn reverse 
phase chromatography (water pH = 9, acetonitrile) to yield 1-(4-aminoquinazolin-2-yl)-3-(5-
bromopyridin-3-yl)imidazolidin-2-one (.11 g, 0.286 mmol, 69.1 % yield). 1H NMR (400 MHz, DMSO-
d6) δ 8.83 (d, J = 2.3 Hz, 0H), 8.50 – 8.38 (m, 1H), 8.23 – 8.13 (m, 0H), 7.82 (s, 1H), 7.70 (ddd, J = 8.4, 
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6.9, 1.4 Hz, 0H), 7.57 – 7.51 (m, 0H), 7.34 (ddd, J = 8.3, 7.0, 1.3 Hz, 0H), 4.15 (dd, J = 9.2, 6.6 Hz, 1H), 
4.04 – 3.92 (m, 1H). 13C NMR (101 MHz, DMSO) δ 162.52, 154.72, 152.23, 150.58, 143.31, 137.97, 
137.47, 133.05, 126.49, 126.33, 123.56, 119.65, 111.96, 102.47, 41.66, 40.64. HRMS (m/z): calcd for 
C16H13BrN6O (neutral M+H) 384.0334; found 384.0340. 
Model building of R12 derivatives 
Conformers of R13-R17 were generated using OMEGA. For each compound, we aimed to 
generate sample likely conformers that optimally matched the ring geometry in the hotspot 
pharmacophore. To achieve this, we used the CHARMM software (267) to carry out a biased energy 
minimization of the compound (in the absence of the protein). We implemented the bias using a harmonic 
constraint applied to the Cartesian coordinates of certain atoms, centered at the position of the 
corresponding atom of the hotspot pharmacophore (C4,C5,N7,C8 and N9 on Adenine106 and N1, C2, 
N3, C4, C5, C6, N6, N7, C8 and N9 on Guanine107) and with a scale factor of 100 (this scale factor is 
related to the force constant in a way that depends on the mass of individual atoms). The residue topology 
file and parameter file for the compounds required by CHARMM minimization were obtained from 
CHARMM-GUI (268). 
Through this minimization of OMEGA conformers, we generated models of the R12 derivatives 
that maintain the ring geometry in the hotspot pharmacophore but contain a variety of geometries in the 
linker region. Since the resulting conformers match the hotspot pharmacophore, they are already aligned 
to the structure of the Msi1-RNA complex. We concluded by selecting the best model on the basis of 
protein-ligand interaction energy using the fullatom Rosetta energy function (60). 
Expression and purification of Msi1 
A gene encoding human Msi1 RBD1 domain was subcloned as a fusion protein with an 
N-terminal 6xHis-tagged streptococcal GB1 domain and a tobacco etch virus (TEV) protease site. The 
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expression plasmid was transformed into Escherichia coli BL21(DE3) pLysS, then a 5 mL overnight 
starter culture was used to inoculate a 1 L culture of Luria-Bertani (LB) media. Cells were grown at 37 ºC 
to an OD600 of 0.6–0.8 and were induced with 1 mM IPTG overnight at 15 ºC. The induced cells were 
resuspended in lysis buffer (50 mM Tris, 150 mM NaCl, 5 mM imidazole pH 8.0) and sonicated for 10 
minutes (Fisher Scientific Sonic Dismembrator Model 100). The cell lysates were then centrifuged at 
15,000g for 30 min. The GB1-RBD1 remained in the supernatant, which was purified by HPLC affinity 
chromatography with Ni-chelated Sepharose Fast Flow Resin (GE Healthcare), followed by a HiLoad 
16/60 Superdex 75 gel filtration column (GE Healthcare). GB1 tag was digested with TEV protease (1 
OD280 of TEV per 5 OD280 of fusion protein) in reaction buffer (50 mM Tris-HCl, 0.5 mM EDTA and 
1mM DTT pH 8.0). All protein concentrations were determined with reference to bovine albumin 
standards using Bradford assays. 
Fluorescence polarization competition assays 
RNA oligonucleotides were ordered from Integrated DNA Technologies (Coralville, IA) and 
dissolved in TE buffer (10 mM Tris-HCl, 1 mM EDTA pH 8.0): sequences are included in Table S1. To 
measure the dissociation constant of Msi1 RBD1 and RNA binding, a fixed concentration (2 nM) of 
fluorescein-labeled RNA (FC-NUMB, Table S1) and increasing concentrations of Msi1 RBD1 (1 nM to 
1000 nM) were mixed in binding assay buffer (20 mM HEPES, 150 mM NaCl, 0.05% F-68 pH 7.4). 
Fluorescence intensities were measured in replicate on the BioTek Synergy 2 plate reader (Winooski, VT) 
and the fluorescence polarization value (FP) was calculated by the following equation: 
𝐹𝑃 =
𝐼∥   −   𝐼!
𝐼∥ +   𝐼!
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The dissociation constant (KD) was fit using Prism (v 6.0e, GraphPad Software, Inc., La Jolla, 
CA), with the Hill coefficient fixed at n=1 as follows: 
𝑌 = 𝐵𝑜𝑡𝑡𝑜𝑚 +
𝑇𝑜𝑝 − 𝐵𝑜𝑡𝑡𝑜𝑚
1 + 𝐾!/𝐿
 
 
To test the contribution to binding affinity of each base in the NUMB RNA sequence, we 
purchased five oligos that each harbor an abasic site at a different position, as well as the corresponding 
wild-type (aNUMB0-5, Table S1). Ki values were then determined from a competition experiment in 
which serial dilution of unlabeled aNUMB oligos (5 nM – 5000 nM) were added to compete against a 
fixed concentration (2 nM) of fluorescein-labeled RNA (FC-NUMB) for binding to a fixed concentration 
of Msi1 RBD1 (75 nM). The Ki value was determined by fitting with Prism to the “Binding – 
Competitive – One site – Fit Ki” model (269). 
To examine the displacement of FC-NUMB by R13, we performed the same competition assay 
using R13 as a competitor. The Ki value was determined as described above. 
Surface plasmon resonance 
Binding between Msi1 RBD1 and each compound were analyzed by SPR using a Biacore 3000 
optical biosensor (GE Healthcare). GB1-tagged Msi1 RBD1 was covalently immobilized by amine-
coupling on a carboxymethylated dextran sensor chip (CM-5, GE Healthcare). Amine-coupling reactions 
for immobilization of proteins were performed at approximately 5 µg⁄mL in 10 mM sodium acetate buffer 
pH 5.5 injected at 5 µL⁄ min until 8400 response units (RU) were immobilized. An unmodified flow cell 
was used as reference. An unrelated protein, human Mcl-1, was immobilized on another flow cell and 
used to subtract out the response from unspecific binding. 
All SPR runs were performed at 25 ºC using a flow rate of 50 µL/min in running buffer (HEPES 
buffered saline with 0.05% Tween-20 pH 7.4). Compounds were injected over sample and reference flow 
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cells at a concentration of 50 µM in running buffer, for 250 s. Following each injection, flow cells were 
regenerated with a 20 s injection of 1 M NaCl. 
SPR titration data were analyzed by using Scrubber 2 software (Biologic) to zero, crop, align and 
subtract responses from the unmodified surface and average blank injections. Response from the Mcl-1 
flow cell was also subtracted to remove the response from unspecific binding. 
Differential scanning fluorimetry (Thermofluor) 
Differential scanning fluorimetry (DSF) experiments were carried out using a standard protocol 
described by others (270). All experiments were carried out in a reaction volume of 25 µL, with 25 mM 
Tris-Cl pH 8.0, 120 mM NaCl, 2% DMSO, and 100x-diluted Sypro Orange dye (Invitrogen). Multiple 
concentrations of GB1-tagged Msi1 RBD1 (ranging from 1 µM to 15 µM) were tested to identify the 
lowest concentration necessary to generate a smooth melting curve. For subsequent experiments, we used 
a concentration of 7.5 µM. 
This concentration of protein was incubated with varying concentrations of R13 (ranging from 
0.1 µM to 100 µM). Testing tubes were incubated in StepOnePlus™ Real-Time PCR System (Applied 
Biosystems) and samples were heated from 25 ºC to 65 ºC gradually with 0.5% increase. The 
fluorescence emission was measured using filter for ROX (610 nm). 
The melting temperature (Tm) values were determined by taking the maximum of the first 
derivative of the raw fluorescence intensity with respect to temperature (270), using GraphPad Prism 5. 
Msi1 reporter assay 
HCT-116βW cells, a generous gift from Bert Vogelstein, were cultured as previously described 
(271). APC 3’ UTR-luciferase reporter was utilized to assay Msi1 activity in cell culture as previously 
described (234). Briefly, GeneExpresso (Lab Supply Mall, Gaithersburg, MD) was used to co-transfect 
cells at 30-40% confluency with APC 3’ UTR-luciferase reporter (900 ng) or pGVP2 vector (900 ng) and 
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Renilla luciferase expression construct (100 ng) in 24-well plates. 24 hours after transfection the cells 
were treated with R12 derivatives at 20 µM for 24 hrs. The cells were lysed using 60 µl of 1X passive 
lysis buffer (Promega) for 10 min. Lysates were assayed using the Dual-Luciferase Assay System 
(Promega) and a LMAXII384 microplate reader (Molecular Devices, Sunnyvale, CA) per manufacturer’s 
instructions. 
Firefly luciferase data were normalized to Renilla luciferase. Fold change of the normalized 
firefly luciferase from each compound was calculated relative to the normalized firefly luciferase from 
DMSO. Data were collected from six independent experiments. Statistical significance was evaluated 
using the one-tailed Wilcoxon rank-sum test. 
Msi1 Numb assay 
HCT-116βw (mut ko, β-cat w/-) cells were maintained in McCoy’s 5A media (Iwakata & Grace 
Modifications) with L-glutamine containing 10% fetal bovine serum at 37 °C with 5% CO2. Cells were 
treated with R12 derivatives or vehicle to a final concentration of 20 µM. Twenty-four hours after 
treatment proteins from cell extracts were resolved by electrophoresis on a 4-20% SDS-PAGE gel. The 
proteins were then transferred to a nitrocellulose membrane (Protran BA79) and blocked in 5% 
milk/TBST overnight at 4 °C. Membranes were incubated with primary antibodies (Rabbit anti-Numb 
mAb, 1:3000, Cell Signaling Technologies C29G11; Mouse anti-β-actin mAb, 1:5000, Sigma A2228) in 
1% milk/TBST overnight at 4 °C followed by incubation with horseradish peroxidase conjugated 
secondary antibodies in 1% milk/TBST (Goat anti-Rabbit IgG (H+L) HRP conjugate, 1:10,000, Bio-Rad 
172-1019; HRP-Goat anti-mouse IgG (H+L), 1:10,000, Invitrogen 626520). The blots were developed 
using SuperSignal West Femto Maxiumum Sensitivity Substrate (Themo Scientific 34096) for Numb or 
SuperSignal West Pico Chemiluminescent Substrate (Pierce 34080) for β-actin. Blot images were 
captured and net band intensities quantified using the IS4000R Image Station (Kodak). Graph represents 
average net band intensities collected from four independent experiments, with Numb values normalized 
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to β-actin loading control. Statistical significance was evaluated using the one-tailed t-test (since four 
replicates were insufficient for the Wilcoxon rank-sum test). 
Msi2 cJun assay 
K562 cells were originally obtained from American Type Culture Collection (ATCC, Manassas, 
VA) and maintained in RPMI1640 media supplemented with 10% Fetal Bovine Serum (FBS). 
K562-Msi2 knock-down cells and controls were made by lentiviral shRNA vectors using the TRC 1.5 
vectors available through Sigma-Aldrich through standard transduction, puromycin selection and single 
cell cloning by plating on methylcellulose. Clones were analyzed for Msi2 expression by immunoblot 
with anti-Msi2 rabbit monoclonal antibody (EMD Millipore, Billerica, MA). cJun immunoblots on K562 
cells were performed with anti-JUN rabbit monoclonal antibody (Cell Signaling, Dovers, MA). β-actin 
antibody conjugated to horse-radish peroxidase (HRP, Genscript, Piscataway, NJ) was used as loading 
control. To determine effect of R12 derivatives, K562 cells were plated at 1x106 cells per 6-well plate and 
treated with compounds at concentrations of 10, 20 or 40 µM for 48 hours along with controls (DMSO 
only, inactive analog R4, or no treatment). Cells were harvested at 48 hours and analysed for cJun and 
β-actin expression.  
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4.2 Supporting Tables 
 
Name Sequence 
FC-NUMB 5’- F-GUAGU -3’ 
NUMB 5’- GUAGU -3’ 
NUMBa0 (WT) 5’- UGUAGUU -3’ 
NUMBa1 (G104x) 5’- UxUAGUU -3’ 
NUMBa2 (U105x) 5’- UGxAGUU -3’ 
NUMBa3 (A106x) 5’- UGUxGUU -3’ 
NUMBa4 (G107x) 5’- UGUAxUU -3’ 
NUMBa5 (U108x) 5’- UGUAUxU -3’ 
 
Table S1: Sequences of RNA oligonucleotides used in this study. “F” refers to the fluorescein label, 
and “x” refers to an abasic site (i.e. internal RNA spacer site). After validation to ensure binding to Msi1 
RBD1 (Figure S8), the FC-NUMB construct was used in fluorescence competition assays (Figure 1d, 
Figure 2g). 
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4.3 Supporting Figures 
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Figure S1: The 12 initial hit compounds. The chemical structure is shown for each compound, as well 
as a three-dimensional model of each compound (cyan) superposed with the Msi1 RBD1 hotspot 
pharmacophore (magenta). 
 
 
Figure S2: Initial SPR screening. Surface plasmon resonance was used to test for binding of all 12 
compounds, with immobilized Msi1 RBD1. At a concentration of 50 µM, none of the compounds except 
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for R12 showed a kinetic profile consistent with reversible binding. All sensorgrams shown have been 
reference-subtracted using a flow cell with an unrelated protein immobilized (human Mcl-1). 
 
 
Figure S3: An inadvertent steric clash may explain the lack of binding by R7. (A) The rings in the 
model of R12 (yellow) are well-superposed with those of the hotspot pharmacophore (magenta), allowing 
for aromatic stacking with Msi1. (B) The relative positioning of the rings in the R7 (cyan) do not quite 
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align with the hotspot pharmacophore (right side of this perspective). (C) This difference in the 
positioning of the ring leads to a steric clash with Phe23 (orange). 
 
 
Figure S4: Synthesis of R12 derivatives. (A) Chemical structures of all derivatives R13-R17. (B) 
Scheme leading to synthesis of all derivatives R13-R17 except R15. Reagents and conditions: 
(i) Pd2(dba)3, t-BuONa, BINAP, 80 ºC, toluene, BocCOREH, 59-91%. (ii) Dioxane, HCl, >95% yield. 
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(iii) Aqueous NaCO3, CH2Cl2, >95%. (iv) CH3CN, 2-chloroquinazolin-4-amine, 180 ºC, MW, 58-71%. 
(C) Scheme leading to synthesis of R15. Reagents and conditions: (v) DIEA, CH3CN, 96%. (vi) NaH, 
THF, 83%. (viii) NaH, THF, 69.1%. 
 
 
Figure S5: SPR screening of R12 analogs. Surface plasmon resonance was used to test for binding of all 
five R12 analogs, with immobilized Msi1 RBD1. At a concentration of 50 µM, all five showed a kinetic 
profile consistent with reversible binding. All sensorgrams shown have been reference-subtracted using a 
flow cell with an unrelated protein immobilized (human Mcl-1). 
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Figure S6: Models of R12 analogs in complex with Msi1. Structures were generated by building 
conformations of each compound that closely superpose with the rings of R12, then aligning this 
conformation to the hotspot pharmacophore. 
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Figure S7: Binding of fluorescein-labeled RNA to Msi1. The polarization from the fluorescein tag 
increases upon addition of Msi1 RBD1, implying that the protein binds to the RNA. The analogous 
polarization change is not observed when Msi1 RBD1 is added to a mixture of fluorescein-labeled RNAs 
with random sequences (Table S1). 
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Figure S8: Computational prediction of potential off-target interactions. We screened each 
conformer of a given ligand against a large set of hotspot pharmacophores derived from other protein-
RNA complexes, as described in Figure 3. (A) Compounds from our initial computational screen. 
(B) Derivatives of R12. 
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Figure S9: Superposition of R13 onto the hotspot pharmacophore from Tra2-β1. The RRM domain 
of Tra2-β1 recognizes a purine-purine pair in a dramatically different geometry from that used by Msi1. 
Superposition of R13 (cyan) onto the Tra2-β1 hotspot pharmacophore (white and green) highlights the 
poor match, and R13 cannot be accommodated on the surface of Tra2-β1 without obvious steric clashes. 
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Figure S10: Quantification of Numb protein levels. Levels of Numb protein were quantified from the 
four Western blots shown. Values in Figure 4b represent the average net band intensities collected from 
four independent experiments, with each Numb value normalized to the corresponding β-actin loading 
control. Numb has 4 different isoforms (all made from mRNAs with the same 3’ UTR) that resolve into 2 
bands on the gels used here. 
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Figure S11: Comparison of Msi1 and Msi2. (A) Sequence alignment comparing RBD1 from Msi1 to 
RBD1 from Msi2. Over these 90 residues, only 17 positions differ (81% sequence identity) and only 9 
correspond to non-conservative mutations (90% sequence similarity). This alignment was rendered using 
ESPript (272, 273). (B) The structure of Msi1 RBD1 is shown (grey cartoons), with the hotspot 
pharmacophore derived from its cognate RNA (magenta and blue spheres). Residues at which the 
sequence differs in Msi2 RBD1 are highlighted (orange sticks); with the exception of Leu50 (Met in 
Msi2), each of the residues that differ are surface exposed and located far from the hotspot 
pharmacophore. 
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Figure S12: Effect of DMSO on cJun levels. Protein levels of cJun as determined via Western blot (as 
in Figure 4c) are unaffected by the DMSO vehicle used, relative to untreated cells. 
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